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RESUMO 
Introdução: O parto prematuro é uma das principais causas de morbidade e 
mortalidade perinatal e neonatal. Identificar quais são as mulheres de maior risco 
e desenvolver modelos de predição é ainda um grande desafio, potencialmente 
impactando na eficácia de medidas preventivas. Objetivo: Desenvolver uma 
abordagem ampla aos fatores clínicos e epidemiológicos associados ao parto 
prematuro, seus preditores metabolômicos e respectivos desfechos perinatais. 
Métodos: Duas análises secundárias de um estudo multicêntrico de corte 
transversal avaliando a associação do índice de massa corpórea (IMC), o ganho 
de peso gestacional e fenótipos maternos com a ocorrência de prematuridade e 
desfechos maternos e perinatais; uma revisão narrativa sobre ciência ômica 
aplicada na área de saúde materna e perinatal, com enfoque na metabolômica; 
protocolo de revisão sistemática sobre a performance da metabolômica em 
predizer parto prematuro espontâneo (PPE) em mulheres assintomáticas; dois 
artigos abordando o desenvolvimento do método e dos procedimentos técnicos 
para um estudo multicêntrico prospectivo para investigar parto prematuro; um 
estudo caso-controle aninhado a uma coorte multicêntrica internacional para 
identificar preditores clínicos e metabolômicos para PPE; dois artigos originais 
abordando a incidência, fatores de risco e os desfechos maternos e perinatais 
associados ao parto prematuro em uma coorte multicêntrica no Brasil com 
gestantes nulíparas de baixo risco. Resultados: Nas análises secundárias do 
EMIP, observou-se que independente do IMC inicial, quanto maior o ganho de 
peso materno, maior a probabilidade para todos os subtipos de prematuridade, 
exceto para PPE em mulheres com IMC normal ou sobrepeso. Foram identificados 
três clusters de mulheres com parto prematuro, sendo um caracterizado 
principalmente por mulheres sem nenhuma das condições de risco, o segundo por 
mulheres com várias condições e o terceiro por mulheres que tiveram pré-
eclâmpsia, eclâmpsia, síndrome HELLP e/ou restrição de crescimento fetal. A 
metabolômica, uma das ciências ômicas, é uma abordagem factível e promissora 
para investigar a fisiopatologia e identificar biomarcadores de doenças complexas 
como o PPE. A técnica de metabolômica usando cromatografia gasosa acoplada 
a espectrômetro de massa identificou mais de 140 metabólitos nas amostras de 
soro de gestantes nulíparas; três destes foram significativamente associados com 
 
 
parto prematuro espontâneo nas amostras de Cork, Irlanda. O modelo preditor 
usando marcadores clínicos e metabolômicos mostrou uma área sob a curva ROC 
de 0,73 para PPE. Na coorte multicêntrica com mulheres Brasileira e nulíparas, a 
incidência de parto prematuro espontâneo foi de 6,7% e os fatores 
significativamente associados à sua ocorrência foram uso de álcool durante a 
primeira metade da gestação e medida do colo uterino. Os desfechos perinatais 
adversos foram muito mais frequentes nos casos de parto prematuro, 
especialmente parto prematuro terapêutico, quando comparados com os partos a 
termo. Conclusão: O ganho de peso gestacional é um fator modificável associado 
com a probabilidade de parto prematuro. Um número considerável de mulheres 
não possui nenhuma condição potencialmente associada ao parto prematuro. A 
ciência Ômica parece ser uma abordagem adequada para a identificação da 
etiologia e de marcadores para predição de complicações maternas e perinatais, 
embora ainda necessitem de sucessivas validações e evidência de 
reprodutibilidade. O desenvolvimento, implementação e coordenação de um 
estudo multicêntrico para estudar preditores e fatores associados ao parto 
prematuro requer recursos humanos qualificados, infraestrutura para pesquisa 
adequada, comprometimento institucional e envolvimento de agências de fomento 
e desenvolvimento de pesquisa. O modelo preditor para parto prematuro 
espontâneo em mulheres nulíparas mostra resultados de boa performance, 
embora requeira futuras validações. A medida do colo demonstra-se um marcador 
importante e que deve ser melhor explorado, assim como intervenções 
preventivas para reduzir os desfechos perinatais adversos relacionados a PPE. A 
resolução baseada em evidência é essencial nos casos de prematuridade 
terapêutica. 
Palavras-chave: trabalho de parto prematuro, ruptura prematura de membranas 
fetais, fatores de risco, programas de rastreamento, cuidado pré-natal, 
perinatologia, metabolômica. 
 
 
ABSTRACT 
Introduction: Preterm birth is the leading cause of perinatal and neonatal 
morbidity and mortality. Identifying women at higher risk and developing prediction 
models remains a great challenge, potentially affecting preventive interventions. 
Objectives: To develop a comprehensive approach investigate risk factors 
associated with preterm birth, its metabolomics predictors and respective perinatal 
outcomes. Methods: Two secondary analysis of a multicentre cross-sectional with 
a nested case-control study addressing the association of maternal body mass 
index (BMI), gestational weight gain per week and phenotypes with the occurrence 
of preterm birth and maternal and perinatal outcomes; an integrative review about 
omics sciences applied to maternal and perinatal health, focusing on 
metabolomics; a systematic review and respective protocol investigating the 
performance of metabolomics to predict spontaneous preterm birth (sPTB) in 
asymptomatic women; two articles describing the methods, clinical protocol,  
technical procedures for the development and implementation of a multicentre 
prospective cohort study to investigate preterm birth and other maternal and 
perinatal complications; a nested case-control from a multicentre international 
cohort to identify clinical and metabolomics predictors for sPTB; two articles 
addressing incidence, clinical and epidemiological risk factors and maternal and 
perinatal outcomes associated with sPTB in a Brazilian multicentre cohort of low-
risk nulliparous pregnant women. Results: According to the EMIP secondary 
analyses, the greater the rate of weight gain, the higher the predicted probability 
for all preterm birth subtypes regardless the initial BMI, except in normal BMI or 
overweight women and sPTB. Three clusters of women with preterm birth were 
identified; cluster one of women without any pre-defined conditions, cluster two 
with mixed conditions and cluster three with women who had preeclampsia, 
eclampsia, HELLP syndrome and/or fetal growth restriction. Maternal and perinatal 
outcomes did not differ between clusters. Metabolomics is an achievable and 
promising technique to investigate the pathophysiology and to identify biomarkers 
of complex disease such as sPTB. Metabolomics using gas chromatography-mass 
spectrometry identified more than 140 metabolites in serum samples of nulliparous 
pregnant women and three of them were significantly associated with sPTB in 
samples from Cork, Ireland. A predictive model associating metabolites and clinical 
 
 
markers showed an area under ROC curve of 0.73 for sPTB. The incidence of 
sPTB was 6.7% in the Brazilian multicentre cohort study of nulliparous women and 
use of alcohol and cervical length were the factors significantly associated with its 
occurrence. Perinatal adverse outcomes were much more frequent in preterm birth 
cases, especially pi-PTB, than term birth cases. Conclusion: Gestational weight 
gain is a modifiable factor associated with the predicted probability for preterm 
birth. A substantial number of women does not present conditions potentially 
associated with preterm birth. Omics science studies might be a reasonable 
approach to investigate the aetiology and predictive markers for maternal and 
perinatal complications. Metabolomic studies addressing the prediction for sPTB, 
preeclampsia, gestational diabetes mellitus and fetal growth restriction show 
promising findings, although they still require repeated validations and 
reproducibility. The development of a multicenter study to investigate sPTB 
requires qualified human resources, adequate infrastructure, institutional 
commitment and the involvement of funding and research agencies. The predictive 
model for sPTB in nulliparous women showed a good performance, although 
further validation is required. The cervical length remains a remarkable clinical 
marker to be better explored in our population, as related preventative interventions 
to reduce the increased perinatal adverse outcomes associated with sPTB. 
Evidence-based resolution of pregnancy is essential in pi-PTB cases. 
Key words: premature obstetric labor, premature rupture fetal membranes, risk 
factors, mass screening, prenatal care, perinatology, metabolomics. 
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1. INTRODUÇÃO 
A introdução dessa tese foi transformada em uma revisão narrativa 
introdutória sobre o tema e foi submetida a publicação na revista The Scientific 
World Journal, e cujo texto aparece a seguir. 
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Abstract  
Preterm birth is a major maternal complication implicating in a great burden for perinatal, 
neonatal, infant and adult health. Lack of knowledge regarding its aetiology and development is 
known, resulting in poor screening, prediction and preventive methods. This current integrative 
review discuss the current knowledge regarding some risk factors for preterm birth, the 
differences between screening and predicting methods, the limitations of some current 
preventive interventions, the importance of applying standardized concepts for exposures and 
outcomes and why it is important to develop  more accurate and reproducible methods for 
predicting preterm birth. In addition, it introduces the concept of metabolomics technology and 
how it has become a promising approach for identifying biomarkers for spontaneous preterm 
birth.  
 
  
20 
 
1. Definition and impact of prematurity 
“[…] I went into premature labor at 24 weeks 6 days. I had been really 
uncomfortable the night before and thought I needed to go to the bathroom.  Well 
the next day it was still bad so I called the doctor on call. She told me I probably 
just needed to have a BM but if it would make me feel better, I could come in. My 
husband and I went in just to get checked out. They never actually checked me 
until I started bleeding (the doctor was in a c-section when I got to the 
hospital).  They gave me the steroid shots and magnesium to stop the 
contractions. It didn’t work and I was 10cm just a couple hours later.  She was still 
breach so they did an emergency c-section. Our beautiful daughter, Charlie, was 
born on April 14, 2018 weighing 1lb 9.4oz and 12.21” long. She was intubated due 
to her lungs being underdeveloped, but the team said everything else looked good. 
She was doing great, but on her 4th day here she suddenly took a turn for the 
worse. Basically, her heart gave out and they were not able to resuscitate her.  We 
had her for 4 days and then the Lord called her home. She is my first biological 
child and now I fear to try again.  After seeing a specialist, we were told I have an 
incompetent cervix and that is why I went into labor and displayed so quickly. I 
also have a bicornuate uterus.  The doctor said if we decide to try again, I would 
have a cerclage and the shots. She gave us a 50-70% chance of making it to 36 
weeks. They would do a cesarean at 36 weeks due to the way they cut me inside 
during the emergency. […]” [1] 
The birth of a preterm baby may have diverse negative consequences for the baby, 
(his or her) neonatal life, childhood or adult life, family, healthcare system/service, and 
the entire society. The experience of a mother describing how she accompanied her 
daughter progress with complications and death due to prematurity, led us to address 
topics related to preterm birth. The focus of such approach will be factors associated with 
preterm birth, perinatal outcomes and ways to predict this outcome. This is supported by 
the hypothesis that it is possible to better understand and predict the preterm birth 
process, creating opportunities for increased effectiveness in preventing the condition. 
It took several decades to consolidate the definition of preterm birth. At the 
beginning of the 20th century, newborn infants weighing less than 2.500g at birth were 
considered preterm, based primarily on neonatal behavior and progression to neonatal 
mortality, intracranial hemorrhage and other morbid conditions [2]. In 1950, a group of 
experts of the World Health Organization (WHO) published a technical report defining 
preterm newborns as those weighing less than 2.500g at birth or those born at less than 
37 weeks of gestation [3]. In this document, the WHO had already established two 
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priorities for the promotion of research and specific programs aimed at minimizing the 
consequences of preterm birth: prevention and preterm infant care. 
Preterm birth may be classified according to clinical presentation or motivator: 
spontaneous, when due to spontaneous preterm labor (contractions, cervical effacement 
and dilatation) or preterm rupture of membranes; and therapeutic, when theoretically 
there is a maternal and/or fetal condition that poses risk to the mother or fetus, 
generating sufficient motivation for resolution at a preterm gestational age [4]. 
Furthermore, iatrogenic preterm birth is defined as birth due to therapeutic intervention 
without the existence of sufficient risks to justify any intervention, i.e., due to 
convenience, maternal desire or simply without scientific evidence for premature 
resolution [5]. For each of the three subtypes of preterm births (spontaneous preterm 
labor, preterm premature rupture of membranes - P-PROM - or therapeutic) there are 
different risk factors and associated maternal and perinatal outcomes [6–8].  
Therefore, at least the distinction between spontaneous and therapeutic preterm 
birth is highly recommended when studying the determinants and consequences of 
preterm birth. The recognition that not every preterm birth occurs because of the same 
determinants was an early step in studying causes and developing preventive strategies. 
Preterm birth is also categorized according to gestational age at birth, and is divided into: 
late preterm (between 34 weeks + 0 days and 36 weeks + 6 days), moderately preterm 
(32+0 weeks – 33+6 weeks), very preterm (28+0 weeks – 31+6 weeks) and extremely 
preterm (<28weeks) [5,9]. 
Pregnancy of a singleton or multiple fetuses (twins) confers great differences not 
only in terms of the incidence of preterm birth, but also concerning its associated factors 
and maternal and perinatal outcomes [10]. A study evaluating offical data of the 
Information System of Live Births (SINASC) from 2011 to 2014 in Brazil, shows that about 
53% of twin pregnancies progress to preterm deliveries [11]. Furthermore, there is an 
increase in complications, such as maternal near-miss events, maternal mortality, 
perinatal mortality, preeclampsia, postpartum hemorrhage [10–12]. The increased 
incidence of complications due to multiple pregnancies associated with a higher rate of 
twin pregnancies in the last decades denote the importance of this type of pregnancy in 
preterm birth and maternal and perinatal health [10,13]. Twin pregnancy is not the focus 
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of this review, since an adequately designed and appropriate approach would be required 
for this type of pregnancy to evaluate its associated factors, preventive and predictive 
methods for preterm birth and respective perinatal outcomes [10]. 
A study by the World Health Organization (WHO) estimated that around 15 million 
preterm births occur annually worldwide [4,14], representing a rate of 10.3% of all 
deliveries. International data from 1990 to 2010 in 65 countries of Europe, Australasia, 
and the Americas showed that the absolute number of preterm births and preterm infant 
rates increased during this period [4]. Countries from North Africa, Sub-Saharan Africa and 
Asia represent little more than 70% of deliveries and 80% of preterm births across the 
world. Furthermore, only five countries -India, China, Nigeria, Bangladesh, and Indonesia 
– account for almost half of preterm births worldwide [14]. Around 17% of preterm births 
occur in the Americas (North America, Latin America and Caribbean), Europe and Oceania. 
However, these regions have the highest proportion of extreme preterm births [14]. 
Preterm birth represents a huge public health issue in all contexts and countries, either in 
low-income or high-income countries [15,16].  
Complications due to preterm births account for more than one-third of neonatal 
deaths worldwide, representing over 1 million newborn infants who died in the first 
month of life in 2010. The impact of complications due to preterm birth still has 
repercussions for childhood health indicators. It is the second cause of death until age 5 
years globally, and the first cause of death in mid-income and high-income countries [4]. 
Since the 1950s many advances have been made in the number of options and 
level of scientific evidence-based preventive measures for neonatal complications due to 
preterm birth. Examples include measures of tertiary prevention such as the use of 
tocolytics and corticotherapy for the prevention of hyaline membrane, intraventricular 
hemorrhage and necrotizing enterocolitis; magnesium sulfate for the prevention of 
cerebral palsy in cases of imminent preterm delivery; and antibiotic therapy for the 
prevention of neonatal sepsis and for prolonging the latent phase in cases of P-PROM [17–
21]. Although these measures have a short- and long-term impact on perinatal morbidity 
and mortality, they are usually only adopted when preterm birth has already begun and 
its occurrence is imminent.  Earlier identification of these cases while still in the 
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asymptomatic phase, could theoretically increase the window of opportunity for 
preventive interventions and bring better perinatal outcomes [22,23]. 
There were also advances in the identification and institution of early therapies for 
neonatal complications such as neonatal sepsis, hypothermia, visual, cerebral (intra and 
periventricular hemorrhage), auditory and/or neuropsychomotor impairment, providing 
the newborn infant with the possibility of earlier neonatal follow-up and better long-term 
results [24,25]. The advent of CPAP, for example, which is the English abbreviation for 
continuous positive airway pressure, mechanical ventilation, use of exogenous surfactant 
in the 70s and refinement of oxygen saturation targets in neonatal oxygen therapy in the 
last decade, resulted in significant improvement in neonatal survival, especially for 
extremely preterm infants [24]. When estimating the potential “years of life lost” due to 
premature death - YLL, in Brazil, neonatal complications arising from preterm birth fell to 
second place in 1990, to sixth in 2005, then dropped to tenth place in 2015, reducing 
approximately 50 and 40% of years lost in the respective periods [26]. Advances in tertiary 
and quaternary prevention, which correspond to a decrease in complications or adverse 
events after the emergence of disease or its sequelae, do not seem to be equally 
accompanied by primary or secondary intervention. Difficulty lies, in part, in the lack of 
knowledge of the pathophysiology of preterm birth and its risk factors, limiting the 
development of preventive measures and effective prediction models.  
 
 
2. Risk factors for preterm birth and prediction 
Risk factor is a term used to designate conditions, characteristics, habits or 
markers that, when present, increase the probability or likelihood of a determined injury. 
Risk, therefore, is related to the appearance of a condition [27,28]. Fixed risk factors are 
gender, ethnicity or age. Modifiable risk factors are weight, body mass index (BMI), 
smoking, alcoholism or use of a condom, for example [27]. They may have different 
strengths of association with the risk for a determined condition, depending on the 
combination of other factors, time of exposure or even the population studied [28,29].  
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An example of a combination of factors is BMI and gestational weight gain. The 
Institute of Medicine (IOM) categorized BMI into low weight (BMI <18.5 kg/m2), normal 
(BMI 18.5-24.9 kg/m2), overweight (BMI 25.00-29.9 kg/m2) and obesity (BMI ≥30.0 kg/m2) 
[30]. A study evaluating data from a prospective cohort with more than 45 thousand 
North-American pregnant women showed that BMI and gestational weight gain seem to 
have different impacts on risk for different subtypes of preterm births, depending on the 
category of initial BMI and respective weight gain [31]. Nevertheless, in this study 
gestational weight gain was calculated by subtracting the initial weight from the last 
weight before childbirth. This method does not consider that women with preterm 
delivery had less weeks of gestation to gain weight, mainly in the third trimester, period 
of highest rate of weight gain according to the IOM [30]. This results in a biased 
comparison of weight gain, for example, between a woman delivering at 28 weeks and 
another woman delivering at 41 weeks.  In this case, the use of weight gain rate per week, 
would be highly recommended. A systematic review evaluating 39 studies including data 
of almost one million and 800 thousand women highlights the lack of homogeneity in 
categorizing initial BMI and defining outcome according to subtypes of prematurity and 
estimate of gestational age [32]. Studies on circumventing these limitations are still 
scarce, although necessary to better understand the role of BMI and gestational weight 
gain in the risk for different subtypes of prematurity. 
Didactically, risk factors for preterm delivery may be classified as clinical, 
semiological, microbiological, ultrasonographic and biochemical [33]. Enviromental, social 
and genetical factos are also included [30]. According to some systematic reviews, the 
main clinical risk factors for preterm birth, i.e., those that have a higher independent 
association with preterm delivery, are history of previous preterm delivery, smoking and 
multiple pregnancy [4,8,34]. A history of previous preterm birth is the most important risk 
factor for preterm birth. A previous preterm delivery increases 3-fold to 4-fold the risk of 
having a new preterm delivery [8,35–37]. Availability of information is relatively 
accessible, since it is collected from basic obstetric clinical history, preferentially detailing 
how and at which gestational age the preterm birth occurred [35–37]. The earlier the 
preterm delivery, the higher the risk for a new case of preterm delivery; the number of 
recurrences was also associated with a 5-fold to 6-fold increase in the chance of having a 
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new preterm delivery [37]. However, a limitation of this risk marker is that it cannot be 
applied to nulliparous women.  
Smoking is a modifiable risk factor. It is associated with an incidence of preterm 
birth that is 3-fold to 4-fold higher in smokers than in non-smokers [34,38]. Risk seems to 
be dose-dependent, i.e., the higher the number of cigarettes, the higher the risk. In 
addition, it is also associated with passive smokers, i.e., women living in areas of exposure 
to cigarette smoke [39,40]. 
It is important to emphasize that a condition that is associated with an outcome may 
not always be considered a risk factor for the condition. Exposure prior to the appearance 
of disease, its removal or reduction is a characteristic associated with a lower incidence 
of disease. Dose-dependence and measure of exposure need to be considered in risk 
relation. These characteristics are preponderant in the application of risk factors as 
predictors. Flecther and cols [28] described (p.54): 
“[...] cumulative doses of exposure to the sun constitute a risk factor for non-
melanoma skin cancer, while episodes of severe solar burns are the best predictors 
for melanoma. The choice of the appropriate measure of exposure to a risk factor 
is based on all that is known about the clinical and biological effects from exposure, 
on pathophysiology of the disease and any epidemiologival studies.” 
The great challenge lies in the limited knowledge of the patophysiology and 
etiology of preterm birth. There are some propositions concerning the mechanisms 
involved in preterm birth. A hypothesis by Behrman et al [41], highlighted the role of 
uterine distension, decidual hemorrhage or thrombosis, inflammatory or infectious 
processes, activation of the hypothalamus-pituitary-adrenal axis and stress, which alone 
or in conjunction, may lead to pro-inflammatory activation of the decidua and 
membranes. Prostaglandins and metalloproteinases, in turn, along with other 
inflammatory agents, may promote cervical remodeling and/or uterine contractions 
leading ultimately to preterm labor and/or preterm premature rupture of membranes 
[41]. In contrast, Menon et al [42] categorized risk factors as static and dynamic, also 
proposing a complex and not fully clear interaction between diverse inflammatory, 
immunological, environmental, epigenetic mechanisms, among others, that culminate in 
senescence and “weakening” of amniotic membranes, decidual and myometrial 
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activation, cervical effacement and, finally, preterm birth. Multiple markers involved in 
these mechanisms are studied as potential predictors of preterm birth.  
Systematic reviews have identified diverse studies evaluating these different 
biological and biophysical markers, highlighting fetal fibronectin l (fFN) and insulin-like 
growth factor binding protein (phIGFBP-1), binding proteins present between the chorion 
of the amniotic membrane and the maternal decidua, and cervical length measurement 
in the second trimester of pregnancy by transvaginal ultrasound. Systematic reviews have 
concluded that those markers are not sufficiently accurate to be useful in clinical 
prediction of preterm birth, especially in asymptomatic women [33,43–45]. 
A Dutch prospective cohort study, including nearly 12 thousand women, assessed 
the performance of cervical length measurement in the prediction of preterm birth [46]. 
Measurement of the cervix was performed between 16 and 22 weeks of gestation. It was 
shown to be poor and did not vary significantly between nulliparous and multiparous 
women and among women considered to be at low or high risk. The area under the ROC 
curve ranged from 0.56 to 0.61 for the multiparous group and low-risk nulliparous group, 
respectively, i.e., the method fails to identify around 40 to 50% of women who will have 
preterm delivery. 
Fetal fibronectin in vaginal secretion does not show much superior results in 
asymptomatic women. A cohort study from the United Kingdom analyzed the 
performance of fFN collected from cervicovaginal secretion as a predictor of spontaneous 
preterm delivery at less than 34 weeks of gestation [47]. Almost 1,500 women were 
included and vaginal secretion was collected from 22 to 28 weeks. The study showed that 
levels above 50 ng/ml have a sensitivity of 46.5% and a specificity of 88.7%. The higher 
the cut-off point for fFN in vaginal secretion, the higher the negative predictive value 
(NPV) and specificity of fFN. When the cut-off point was 500 ng/ml, specificity and NPV 
were higher than 90%. However, its clinical application is still limited, since it is expected 
that a large part of the population does not have such high levels of fFN during this phase 
of gestation and the test has a very low sensitivity with this cut-off point, i.e., many 
women with preterm delivery do not achieve such high fFN levels in vaginal secretion 
during this period. 
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Other propositions have attempted to address the association between multiple 
factors involved in the development of preterm birth. A group of experts proposed a 
classification of women at risk for preterm delivery, according to phenotypes [5,48]. 
Empirically, those authors defined that the development of preterm birth is not exclusive 
to a single group of women who necessarily have similar characteristics and risk factors. 
On the contrary, probably different groups of women have conditions in common that are 
associated with preterm birth and their different subtypes. Conditions that potentially 
define phenotypes of preterm birth were divided into maternal, fetal and placental 
conditions. Conditions are not based on risk factors, but depend on conditions present in 
the index pregnancy that determine the occurrence of preterm birth. The application of 
this new classification could help understand the associations between determinants of 
preterm birth, measure the benefits of preventive measures and identify conditions that 
achieve the highest impact from these measures, and ultimately, understand the 
subgroups of women that are at higher risk for different subtypes of preterm birth. 
The authors applied this concept through a secondary analysis of an international 
multicenter cohort study named INTERGROWTH 21st [49]. Slightly more than 50 thousand 
women had estimates of gestational age calculated by obstetric ultrasound and 5,828 
women had preterm deliveries (10.5%). A cluster analysis of preterm births was 
conducted, grouped or not, according to one or more of 6 maternal conditions, 7 fetal 
conditions and 3 placental conditions. Finally, twelve clusters were identified, drawing 
attention to cluster 1 in which 1.747 women (30%) had none of the 16 predefined 
conditions. Over 80% of women from this cluster had preterm births either by preterm 
labor or P-PROM. On the other hand, the majority of women were divided into 11 clusters, 
charaterized by major conditions such as preeclampsia/eclampsia, chorioamnionitis, twin 
pregnancies or bleeding at the beginning of pregnancy, etc., showing that it is possible to 
identify determining factors in subgroups of women with preterm birth, helping to 
understand the etiology and identify women at higher risk. Nevertheless, this concept still 
requires reproducibility. Validation of cluster determination, along with their predefining 
conditions in other populations, is necessary.  
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Thus, we are faced with the need to better explore risk models for preterm birth, 
identify risk factors and their associations, helping to determine etiological theories and 
develop predictive models that are efficient at predicting spontaneous preterm birth. 
 
3. Prevention of preterm birth 
According to Geoffrey Rose [29], there are two prevention strategies: one based 
on individual preventive measures through the identification of individuals at higher risk 
of developing the condition; and the other based on measures of the general population, 
irrespective of the existence of risk factors. Available access to prenatal care, qualified 
childbirth and postpartum care, incentive programs for healthy lifestyle habits and 
protection of a woman’s right to health care are important strategies that may have an 
impact on maternal and perinatal health indicators, including preterm birth [50]. A good 
example of exposure that has preventive measures based on both strategies is smoking. 
Around 50% of American pregnant women stop smoking in the first trimester of 
pregnancy [51]. Individual policies such as counseling, stimulation of pharmacologic 
replacement of nicotine, psychological support and even financial incentives have an 
impact on the prevention of adverse perinatal outcomes. Population policies such as 
dissociating the image of the cigarette as a healthy and socially desirable habit through 
campaigns in the media, increase in taxes for the tobacco industry and laws that restrict 
areas where smoking is allowed also demonstrated a beneficial effect [51]. A systematic 
review including clinical trials testing different strategies for cessation of smoking showed 
that interventions reduced preterm births by approximately 15% [51]. Although 
continuous effort and specific public policies are necessary, this is a good example of how 
identifying the risk associated with prevention strategies may result in more cost-effective 
and better maternal and perinatal outcomes [51–53]. 
The identification of factors associated with a higher risk of developing 
spontaneous preterm birth may be useful both for understanding its pathophysiology and 
identifying women at higher risk who might benefit from prevention strategies. In the 
latter case, it may also possible to distinguish between screening for risk and prediction 
of preterm birth. Although both methods use risk factors as a basis for their models or 
algorithms, the method employed and its practical application may be quite distinct.  
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For example, women with transvaginal ultrasound assessment of cervical length 
between 20 and 25mm, measured in the second trimester by standardized technique [54] 
had an incidence of preterm birth ranging from 22% to 32% [55]. This incidence may reach 
56% in cervical length lower than 5mm [55]. The increased incidence in women with a 
cervix lower than 25mm, in comparison to the general population, confers a 4-fold to 5-
fold higher risk for preterm birth. Observational studies in different populations confirm 
this inverse association between uterine cervix measurement in the second trimester and 
prevalence of spontaneous preterm birth [46,55,56]. Therefore, a value lower than 25 mm 
was considered a “short” uterine cervix and a value higher than 25mm was considered a 
“normal” uterine cervix [46,55]. Based on uterine cervix measurement to stratify women 
at higher risk, several clinical trials have tested preventive interventions for spontaneous 
preterm birth and its associated to adverse perinatal events, initially comparing natural 
micronized progesterone (vaginal tablet) or hydroxyprogesterone caproate 
(intramuscular injection) with placebo. Systematic reviews with meta-analysis showed 
that the use of vaginal progesterone seems to be beneficial for the reduction in preterm 
birth at less than 37, 34 and 28 weeks and neonatal morbid conditions [57,58]. However, 
differences in reduction rates of different morbid conditions or even preterm birth may 
be attributed to different selection criteria for women included in clinical trials. 
The OPPTIMUM study, for example, a British multicenter study including 65 
centers in the United Kingdom and one in Sweden, published in 2016 (after the systematic 
review), aimed to evaluate not only the benefit of progesterone in reducing prematurity 
and neonatal morbidity, but also its long-term effect on the child [59]. The study selected 
women with singleton pregnancies at high risk for preterm birth based on: history of 
previous preterm birth, gestational loss in the second trimester or preterm premature 
rupture of membranes or cervical procedure and positive vaginal fetal fibronectin. A year 
after the beginning of the clinical trial, researchers decided to include women at “mid-
high” risk, defined by these women as having negative fetal fibronectin, but with a history 
of spontaneous preterm birth at less than 34 weeks or uterine cervix measuring less than 
25mm in the second trimester. This double-blind controlled study randomized more than 
600 women in each group (vaginal progesterone 200mg vs placebo) and demonstrated 
that progesterone was not beneficial for reducing preterm birth or the majority of 
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perinatal morbid conditions such as pulmonary bronchodysplasia, neonatal infection, 
necrotizing enterocolitis or neurological development and neurocognitive score at 2 years 
of age. However, it showed a reduction in neonatal death (non-adjusted Odds ratio of 
0.17 [0.06 – 0.49], p-value of 0.0009) and for cerebral alterations on ultrasound (non-
adjusted Odds ratio of 0.50 [0.31 – 0.84], p-value of 0.008). The authors of this study 
concluded that subgroups of women who might benefit from progesterone, are not easily 
identified by current screening strategies. This should encourage studies on new 
prevention strategies and also those aimed at identifying women that may be potentially 
eligible for receiving this treatment. 
Another technique studied for decades is cerclage which is primarily based on 
suture of the uterine cervix or isthmus-cervical region to prevent early 
effacement/dilatation of the cervix. Shirodkar technique [60], described in 1953, and a 
technique by McDonald [61] in 1957 are the basis for all the subsequently described 
variations. This technique was initially proposed for cases with a history of cervical 
insufficiency, a known cause of late abortion and extreme prematurity. A systematic 
review of Cochrane systematic review with 15 clinical trials showed advantages in 
prolonging pregnancy, decreasing neonatal morbidity and prematurity rate when 
indicated in women with a history of cervical insufficiency [62]. The advent of cervical 
measurement in the second trimester, associated with a history of preterm birth, seems 
to have improved the identification of women benefiting from cerclage to prevent 
preterm births, particularly in cases in which there is still no history of recurrent pregnancy 
loss [63]. This shows that the search for an association of risk factors in the prevention of 
preterm birth may still be very useful, even in situations where a good solution was 
apparently found, as for cervical incompetence and cerclage. 
It is also worth mentioning that another intervention was studied for preterm birth 
prevention in high-risk women. A pessary, a device made of firm silicone in the shape of 
a convex ring is inserted into the posterior vaginal fornix, fastened to the cervix. The 
theoretical mechanism for the prevention of preterm birth is based on: 1) a change in the 
axis of forces resulting from the uterine body and isthmus that act on the cervix, and 2) a 
potential closure of the cervix with consequent strengthening of the cervical canal and 
immunologic barrier of the cervix, preserving the amniotic membranes from contact with 
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the vaginal environment [64]. Although the subject has been studied since the middle of 
the twentieth century, the identification of women who actually benefit from this 
intervention remains a challenge. The PECEP (Pesario Cervical para Evitar Prematuridad) 
study published in 2012 was the first randomized study using the pessary (versus 
expectant management) to prevent preterm birth. Selecting pregnant women at high risk 
based on cervical length measurement in the second trimester, with slightly more than 
190 women per group, the study showed that the incidence of preterm births below 34 
weeks decreased by 80%. Subsequent studies demonstrated conflicting results and did 
not confirm such a reduction in the incidence of preterm births observed by Goya et al 
[64]. However, the selection of eligible women and the association with other 
interventions, such as progesterone, is heterogeneous among studies [65–68]. 
Despite the advances/benefits resulting from a combination of screening for risk 
and interventions, e.g. progesterone, pessary and cerclage in women selected on the basis 
of risk factors, there still seems to exist limitations and heterogeneity in screening. Better 
results from the use of these measures may be potentially hindered. Which women might 
actually benefit from the use of progesterone during prenatal care? Or, which women 
might not benefit from any preventive intervention? Furthermore, there is no consensus 
over which level of risk estimate a woman would be really considered at high risk. 
Improved identification of women at high (or low) risk for preterm birth with the 
development of prediction models that have good discriminatory performance may be 
quite relevant to advance the investigation of the benefits of using (or not) progesterone, 
pessary or any other form of preterm birth prevention. 
 
4. Risk assessment and prediction of preterm birth 
 The description of these prevention studies along with their interpretations are 
important to highlight the fundamental role of adequate screening of women who may 
benefit from prevention strategies. Distinctions must be made regarding the risk 
assessment model and a predictor model for an outcome. This distinction may actually 
help understand the clinical application of a screening strategy for women at high risk for 
preterm delivery.  
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As an example of marker of risk, the cervix is known to be independently 
associated with a higher risk for preterm birth [55,56]. Although this may be useful for 
implementation of differentiated care, suggesting screening and interventions for the 
subgroup of women with a short cervix, this practice is fragile in terms of the population 
and has a low impact on prevention [69]. The reason for this is because despite a higher 
risk for preterm birth, a woman with a short cervix has the highest odds of having a term 
birth. Furthermore, the shortening process of the cervix may not occur early in the 
recommended screening phase (second trimester, between 18 and 24 weeks). In 
summary, the cervix is a marker of low sensitivity (a considerable proportion of women 
with a short cervix are likely to deliver at term). At the same time, the marker has a low 
rate in general population, since a cervix of 25mm corresponds to a 5th and 3rd percentile 
in the population curve of cervical measurement [55]. A cohort with almost 3 thousand 
pregnant women evaluating the performance of 28 markers in the second trimester of 
pregnancy shows that a short cervix has a sensitivity of 36.8% for preterm birth at less 
than 35 weeks. This means that almost two-thirds of women with preterm birth below 
this gestational age would not be screened by this criterion, resulting in elevated false-
negative rates of the method. Therefore, despite the positive association with preterm 
birth, a short cervix seems to be an inappropriate marker to compose predictive models, 
resulting in low efficacy when employed in clinical practice [46,55,56]. Even serial 
measurements of the cervix, based on the theory that shortening of the cervix over the 
weeks could be a better predictor of preterm birth, showed a worse predicitive 
performance than a single measurement [70]. 
A prospective observational study included more than 9 thousand nulliparous 
pregnant women from 8 North-American centers evaluating the performance of fetal 
fibronectin and transvaginal measurement of the uterine cervix in predicting spontaneous 
preterm birth [71]. The area under the ROC curve was 0.59 for fetal fibronectin equal to 
or higher than 50 ng/dL and 0.67 for a cervix lower than 25mm. The model containing 
both variables had an area under the ROC curve of 0.67. The authors concluded that the 
performance was poor and of low clinical utility. 
In summary, systematic reviews have concluded that there are no markers in the 
literature that can be applied in clinical practice to predict spontaneous preterm birth with 
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a good performance [72] and that enable new preventive approaches and studies in this 
area.  
 
5. Metabolomics and Preterm Birth 
The term “omics sciences” is applied to the field of knowledge that focuses on 
genomic studies, gene identification, DNA sequence polymorphisms, genes and the 
genoma; transcriptomic, focused on the study of gene expression - RNAs; proteomic, 
when proteins/enzymes are identified and quantified; or metabolomics, when 
metabolites, a product of this chain interaction [73–76]. The application of each technique 
to investigate markers or pathophysiology of diseases, primarily those involving complex 
mechanisms that are still not fully elucidated, is basically dependent on the objectives and 
resources available. Actually, an integrated application of the various methods may be the 
option [75]. The main advantage of metabolomics is that is seems to be closer to disease 
phenotype, presenting the result of the final pathway of interactions between genes, 
RNAm and proteins. According to Dettmer, Aronov & Hammock [77]: 
“Genomi tells what can happen, transcriptomi what appears to be 
happening, proteomi what makes it happen, and metabolomi what has 
happened and what is happening”  
Metabolomics is the science that studies metabolites, small molecules present in 
different chains of the metabolism of an organism [78]. These small molecules may be 
substrates, products and cofactors of intracellular and extracellular chemical reactions 
such as aminoacids, biliary acids, carbohydrates, lipids, vitamins and others [79]. The 
group of metabolites in a certain sample or organism are termed metabolome. Diverse 
techniques are applied to identify and quantify metabolites such as mass spectrometry 
coupled to liquid or gas chromatography or magnetic resonance imaging. Furthermore, 
diverse configurations or variants may be used to obtain a better performance, depending 
on the metabolite of interest, its polarity, mass spectrum to be studied or other physical 
chemical characteristics of the metabolites and samples to be analyzed. Technological 
advances in instruments for data acquisition and bioinformatics have provided sufficient 
aid, so that metabolomics is able to identify and analyze hundreds or even millions of 
metabolites in a certain biological sample.  Studies on diverse applications in biological 
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samples demonstrate a high sensitivity in the detection and measurement of metabolites 
[78].  
By identifying and quantifying metabolites, this technique is capable of showing 
the fingerprint of metabolic interactions of the organism in a certain sample at a certain 
time. Metabolomics is a technique known as hypothesis-free, i.e., that does not require 
an initial hypothesis. Instead of testing a certain hypothesis, the technique may generate 
novel hypotheses through its results when elucidating markers and biological pathways 
involved in the process of disease development, which may not have been clarified 
[75,77,78].  It may be a relevant complementary tool for the construction of knowledge 
in diseases where pathophysiology has yet to be fully elucidated and possibly involves 
multiple complex genetic and environmental interactions, such as preterm delivery, 
preeclampsia and fetal growth restriction [78,79]. 
Metabolomics has been applied in biological samples for the investigation of 
processes ranging from embryogenesis to the emergence of complex diseases such as 
cancer, Parkinson’s disease, diabetes and depression [80]. In the area of maternal and 
perinatal health care, it has been mainly applied to identify biomarkers, which are 
clinically useful for the performance of diagnostic or prognostic prediction [75,79,81]. 
For example, serum samples collected at 15 weeks of gestation from a group of 
approximately 39 nulliparous pregnant women with a history of preeclampsia were 
analyzed and compared to 40 pregnant women without complications. An untargeted 
technique, which is not aimed at identifying a class or specific type of metabolite, was 
applied in a nested case-control study performed from a cohort study and 45 metabolites 
had significantly different levels in both groups in the identification phase, and were 
characterized as potential biomarkers. For validation, 14 metabolites were selected to 
compose the final model, resulting in an area under the ROC curve of 0.92 and an odds 
ratio of 23 (95%CI; 7-73) [82]. Another study using samples of a similar number of women 
who progressed to preeclampsia and samples collected a short time earlier (between 11 
and 14 weeks) showed more modest results, albeit still promising. The model containing 
4 metabolites has a detection rate of only 50%, assuming a false-positive rate of 10%, with 
an area under the ROC curve of 0.81 for cases of preeclampsia [83]. Few studies on the 
identification of biomarkers to compose prediction models for preterm birth have been 
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published until now and some narrative reviews of the subject have described a great 
heterogeneity in the methodology employed [75,79,81]. To date, there are no systematic 
reviews that analyze the performance of metabolomics in predicting spontaneous 
preterm delivery. 
Diverse reflections on the most effective method for investigating preterm birth 
using metabolomic markers should be made. First, there is the type of sample used (urine, 
blood, amniotic fluid, hair, vaginal secretion). Then, there is the time for sample collection 
(during clinical presentation of preterm birth or in the early phase of pregnancy when 
there is no symptom). Furthermore, metabolomics demands a high methodological rigor 
in the collection and storage of biosamples, since this is a highly sensitive method for 
identifying small low-weight molecules; various types of “noise,” or interference in data 
acquisition, may hinder the identification of these molecules. Heterogeneity in sample 
collection and storage may be the cause. In addition, a well-delineated study design, with 
well-defined outcomes, following clear classifications, associated with sequential 
validations of findings are crucial for reliability and reproducibility of this technique. 
Finally, still in the phase of data analysis, caution to some important considerations is 
emphasized. For example, usually hundreds or even thousands of metabolites are 
analyzed at the same time in a sample. Since the number of variables (metabolites) is 
much higher than the number of samples (individuals), analysis is very susceptible to 
significantly false results. To correct this effect, Bonferroni correction may be used, 
attenuating the significance of p-value according to the number of variables (metabolites) 
analyzed. The FDR (False Discovery Rate) concept may also be applied to control the 
number of false-positive conclusions, and only the “most promising” variables receive 
significance [84]. This technique was proposed by Benjamini & Hochberg [84] in the 1990s 
and is based on the proportion between the true null hypothesis (H0) and the rejected 
null hypothesis, decreasing the possibility of markers considered to be statistically 
discriminatory. Actually, these markers are not discriminatory. These are only two 
examples of methodological care required in the phase of data analysis. 
Many questions need to be answered concerning the mechanisms involved in the 
development of preterm birth: Why do some women have early cervical remodeling (with 
evident short cervix at transvaginal ultrasound in the second trimester) and others do not? 
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Which and how are the interactions between different risk factors including infection, 
vaginal bleeding and body mass index and how can they determine preterm birth? In 
theory, metabolomics depicts the final pathway resulting from these interactions and 
seems to be a useful approach not only to predict spontaneous preterm birth, but also to 
elucidate the diverse mechanisms involved. 
 
6. Conclusion 
To adequately address the investigation of preterm birth, its associated factors and 
perinatal outcomes, a robust methodological approach is required, using judicious and 
standardized definitions of exposures and outcomes. Based on this premise, a 
multifaceted comprehensive approach, albeit integrated, was proposed for data 
exploration on factors associated with preterm birth, its prediction and perinatal 
outcomes, capable of generating new knowledge of the theme.  
It is expected that the results of this approach may contribute to the prediction of 
the most effective performance and better understanding of the factors associated with 
spontaneous preterm birth and consequent adverse perinatal results, collaborating with 
the development and application of public policies to prevent preterm birth and its 
perinatal consequences. 
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2. OBJETIVOS 
2.1. Objetivo Geral 
Desenvolver uma abrangente abordagem aos fatores clínicos e 
epidemiológicos associados ao parto prematuro, seus preditores metabolômicos 
e respectivos desfechos perinatais. 
2.2. Objetivos Específicos 
2.2.1. Avaliar a associação do índice de massa corpórea e ganho de peso 
gestacional com os diferentes subtipos de parto prematuro e com 
desfechos perinatais. 
2.2.2. Identificar fenótipos maternos relacionados ao parto prematuro e 
suas respectivas condições associadas, características maternas e 
desfechos maternos e perinatais. 
2.2.3. Avaliar a aplicação da ciência ômica nos estudos em saúde materna 
e perinatal, com enfoque na metabolômica e na predição das principais 
complicações na gestação. 
2.2.4. Desenvolver um método padronizado para revisar sistematicamente 
os estudos em predição de prematuridade espontânea através de 
marcadores metabolômicos. 
2.2.5. Desenvolver o método e procedimentos utilizados em um estudo 
multicêntrico para investigar a predição de parto prematuro e outras 
complicações maternas e perinatais. 
2.2.6. Implementar e desenvolver um estudo para predição de parto 
prematuro e outras complicações maternas e perinatais, fornecendo 
subsídios metodológicos e descrevendo detalhes sobre os aspectos 
práticos dessa implementação e estratégias para a solução de dificuldades 
encontradas. 
2.2.7. Identificar um conjunto de marcadores metabolômicos, clínicos e/ou 
sociodemográficos preditivos de parto prematuro.  
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2.2.8. Avaliar a incidência e potenciais fatores de risco associados à 
ocorrência de parto prematuro espontâneo. 
2.2.9. Avaliar a ocorrência de desfechos perinatais adversos associados  
à prematuridade. 
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3. MÉTODO 
Para abordar mais alargada e profundamente os fatores associados ao 
parto prematuro e seus possíveis preditores, principalmente os potenciais e 
inovadores marcadores metabolômicos, foram utilizados e desenvolvidos mais de 
um projeto de pesquisa, gerando maior complexidade na elaboração de uma linha 
única de descrição de método. Fundamentalmente, houve no decorrer dessa tese 
o desenvolvimento completo de um modelo metodológico para identificação e 
validação de marcadores clínicos e metabolômicos, incluindo desde a concepção 
do desenho de um estudo em duas fases (fase de identificação e de validação de 
marcadores) até a implementação de um grande estudo de coorte multicêntrico 
no Brasil para estudar complicações maternas e perinatais. Outras análises e 
artigos, embora secundários, foram elaborados ou estão planejados para 
complementar a abordagem analítica sobre os fatores associados à 
prematuridade, assim como para registrar e tornar público o método e expertise 
desenvolvidos no decorrer desse caminho. Para a revisão sistemática, um artigo 
próprio para seu método é apresentando também como produto da tese, 
descrevendo pormenorizadamente os procedimentos empregados. O protocolo de 
revisão sistemática foi registrado na plataforma PROSPERO (PROSPERO 2018 
CRD42018100172) (1). 
Com isso, diferentes métodos e projetos de pesquisa foram utilizados para 
compor essa tese, que inclui artigos de descrição de protocolo, revisão narrativa, 
revisão sistemática, de análise secundária e de análise primária com dados 
originais. Para as análises primárias e secundárias com dados originais, foram 
utilizados dados dos seguintes estudos observacionais: do Estudo Multicêntrico 
de Investigação em Prematuridade no Brasil – EMIP, do Preterm Screening and 
Metabolomics in Brazil and Auckland – Preterm SAMBA e do Screening of 
Pregnancy Endpoints – SCOPE. Apesar do método de cada análise ser 
detalhadamente descrito nos respectivos artigos, serão descritos nessa sessão 
alguns aspectos relevantes dos métodos adotados de acordo com a fonte dos 
dados (Estudos EMIP, Preterm SAMBA ou SCOPE) e com o tipo de artigo (revisão 
sistemática, narrativa ou de protocolo). Os estudos EMIP e Preterm SAMBA foram 
desenvolvidos dentro da Rede Brasileira de Estudos em Saúde Reprodutiva e 
Perinatal, criada e coordenada por investigadores do Departamento de 
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Tocoginecologia da Faculdade de Ciências Médicas da Unicamp. Essa Rede foi 
criada em meados de 2008 com o objetivo de fomentar e organizar 
profissionalmente os estudos em saúde materna e perinatal nos serviços 
acadêmicos universitários do Brasil (2). Já tendo feito pouco mais de 10 anos 
desde sua criação, a Rede organizou e implementou vários estudos multicêntricos, 
observacionais e ensaios clínicos, em tópicos relevantes da área. Além disso, tem 
proporcionado a capacitação de muitos docentes e jovens pesquisadores em 
diversas regiões do país, contribuindo ainda mais com o avanço científico e 
tecnológico em nossa área e para a implementação de novos estudos 
multicêntricos contando a participação de pessoal qualificado (2). O financiamento 
de estudos da Rede soma atualmente pouco mais de 4 milhões de reais que 
ajudaram não só no desenvolvimento dos projetos de pesquisa, mas também a 
estruturar os centros participantes e a aumentar a interação com outros parceiros 
internacionais, que tem sido fundamental para a manutenção de suas atividades 
e de novas colaborações em estudos internacionais. Os estudos em que essa tese 
se baseia são todos provenientes diretamente das atividades da Rede e são, sem 
dúvida, um trabalho conjunto de equipe(s). 
 
Estudo Multicêntrico de Investigação em Prematuridade no Brasil - EMIP 
O estudo EMIP teve o objetivo de avaliar de forma abrangente a prevalência 
de partos prematuros e seus fatores associados no Brasil. Foi um estudo 
multicêntrico de corte transversal com componente caso-controle aninhado que foi 
desenvolvido em 20 maternidades do Sudeste, Sul e Nordeste do país, 
consideradas “de referência” em suas sub-regiões. O método do estudo já foi 
publicado anteriormente (3,4). Resumidamente, o EMIP explorou a ocorrência de 
prematuridade de acordo com os seus três subtipos: espontânea, (devida ao 
trabalho de parto espontâneo), ruptura prematura pré-termo de membranas e 
terapêutica (quando houve uma condição materna ou fetal que na avaliação do 
prestador de cuidado à saúde, colocava em risco a continuidade da gestação e 
que, por isso, motivou a resolução da gestação em idade gestacional pré-termo). 
Parto prematuro foi definido como aquele que ocorreu antes de 37 semanas de 
gestação, estimada ou pela data da última menstruação, pelo ultrassom, por 
ambos ou, enfim, pelo método de escore de New Ballard (5). 
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A equipe de assistentes de pesquisa realizou uma vigilância de todos os 
partos prematuros ocorridos de abril de 2011 a julho 2012, incluindo mulheres com 
gestações de feto único e gestações múltiplas. Mulheres que tiveram parto a termo 
logo após os casos de parto prematuro foram convidadas a participar para compor 
o grupo controle, até que o tamanho amostral para o grupo controle fosse atingido. 
O cálculo amostral resultou na necessidade de haver ao menos 1.054 sujeitos em 
cada um dos quatro subgrupos (3 de casos e 1 de controle), ao considerar uma 
prevalência de prematuridade de 6,5% em 2006. Os dados foram obtidos através 
de entrevista com a mulher ainda na internação pós-parto e de revisão de dados 
do prontuário dela e do recém-nascido e do cartão de pré-natal. Os dados do 
recém-nascido foram registrados até 56 dias após o parto ou até a alta, o que 
ocorresse primeiro. Foi utilizada uma ficha de coleta de dados contendo mais de 
300 variáveis abrangendo dados clínicos, sociodemográficos, sobre as 
características de assistência ao pré-natal e ao parto prestadas, sobre a 
ocorrência de complicações ou morbidade durante a gestação ou puerpério e de 
desfechos maternos e perinatais (Anexo 1). Essas informações, então, foram 
repassadas a um sistema online OpenClínica® de banco de dados. 
Diversos procedimentos como checagem manual dos dados, visitas de 
monitoramento in loco e análise de consistência interna dos dados (conferência 
das frequências e do cruzamento de variáveis, etc.) foram realizados para 
assegurar confiabilidade aos dados. O acesso ao banco de dados era restrito e 
hierárquico, conforme o papel desenvolvido pelos diferentes pesquisadores. 
Todas participantes assinaram termo de consentimento livre e esclarecido e 
tiveram participação voluntária. O estudo teve aprovação ética dos respectivos 
Comitês de Ética em Pesquisa (CEP) locais e foi referendado pelo Comitê 
Nacional de Ética em Pesquisa – CONEP (Anexo 2), seguindo os preceitos éticos 
das normas regulamentadoras de pesquisas envolvendo seres humanos previstos 
da Resolução 196/96 do Conselho Nacional de Saúde e na Declaração de 
Helsinki. A identidade das participantes foi e é mantida confidencial. Esse projeto 
foi contemplado com auxílio à pesquisa no contexto do programa PPSUS 
financiado conjuntamente pelo CNPq e Fapesp. 
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Preterm Screening and Metabolomics in Brazil and Auckland – Preterm 
SAMBA 
O projeto de pesquisa Preterm SAMBA é uma iniciativa com colaboração 
internacional entre pesquisadores do Departamento de Tocoginecologia da 
FCM/Unicamp e pesquisadores da Universidade de Auckland, Auckland, Nova 
Zelândia, e University College Cork, em Cork, Irlanda. O estudo tem como objetivo 
principal desenvolver um teste preditivo para parto prematuro espontâneo. Para 
isso, o projeto contou com dois desenhos de estudo: um componente caso-
controle desenhado para desenvolver um modelo preditor de parto prematuro 
espontâneo e um componente de coorte prospectivo para validação do modelo 
preditor. A fase de desenvolvimento foi realizada utilizando-se dos dados e 
amostras do Estudo SCOPE, enquanto para a fase de validação, foi planejado, 
implementado e desenvolvido um estudo de coorte com gestantes nulíparas de 
baixo risco de 5 maternidades brasileiras. Os detalhes metodológicos, técnicos, 
operacionais e sobre o desenvolvimento desse estudo de coorte são apresentados 
em dois artigos como produtos dessa tese. Em suma, gestantes elegíveis foram 
incluídas antes de 21 semanas de gestação e realizaram até três visitas do estudo: 
obrigatória entre 19 e 21 semanas e opcional entre 27 e 29 semanas e entre 37 e 
39 semanas. Dados clínicos, sociodemográficos, epidemiológicos, 
antropométricos, nutricionais, sobre hábitos de vida e amostras biológicas (sangue 
e cabelo) foram coletados na primeira visita. Na segunda e terceira visitas, apenas 
dados clínicos e antropométricos. Após o parto, desfechos primários (ocorrência 
de parto prematuro), e secundários (pré-eclâmpsia, restrição do crescimento fetal 
e diabetes mellitus gestacional) foram sistematicamente coletados. 
Para identificar os fatores de risco clínicos para a ocorrência de parto 
prematuro espontâneo e avaliar a ocorrência de desfechos perinatais adversos 
associado à prematuridade, utilizamos os dados desta coorte brasileira do 
componente de validação do estudo Preterm SAMBA. O estudo foi aprovado no 
CEP do centro coordenador (Anexo 3) e em todos os centros participantes. 
Screening of Pregnancy Endpoints - SCOPE 
O primeiro componente do projeto, desenvolvimento do modelo preditor, ou 
de descobrimento,  consiste em um estudo caso-controle com mulheres que 
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participaram do estudo SCOPE (6,7), um estudo de coorte prospectivo 
multicêntrico que recrutou 5.690 mulheres nulíparas de baixo risco entre novembro 
de 2004 e agosto de 2008 de diferentes regiões - Nova Zelândia, Austrália, Irlanda 
e Reino Unido, criando um banco de dados e de material biológico dessas 
mulheres e recém-nascidos (sangue, cabelo, urina, sangue de cordão umbilical, 
etc.). Onze instituições financiaram essa coorte internacional que teve aprovação 
ética em todos os respectivos centros participantes (6). Para essa análise, 
estabelecemos um estudo caso-controle composto por mulheres de Cork, Irlanda, 
e Auckland, Nova Zelândia, que tiveram partos prematuros espontâneos antes de 
37 semanas. Amostras de soro colhidas às 15 e 20 semanas de gestação e 
armazenadas em freezer a -80°C foram utilizadas para análise em espectrometria 
de massa acoplada a cromatografia gasosa. 
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4. RESULTADOS 
4.1. Artigo Role of Body Mass Index and gestational weight gain on preterm 
birth and adverse perinatal outcomes 
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Abstract 
The relationship of body mass index (BMI) and weight gain (WG) with the occurrence of 
preterm birth (PTB) remains controversial in the literature. To evaluate the association 
between the different categories for maternal BMI and WG per initial BMI with the 
different PTB subtypes and perinatal outcomes, we conducted a secondary analysis of a 
multicentre cross-sectional plus a nested case-control study including PTB from 20 centers 
in Brazil. Pre-pregnancy underweight was associated with lower risk of provider-initiated 
PTB, while overweight and obesity were associated with higher risk of provider-initiated 
PTB and lower risk of spontaneous preterm birth. An insufficient gestational weight gain 
was associated with a higher prevalence of spontaneous PTB and preterm premature 
rupture of membranes, and an excessive rate with a higher prevalence of provider-
initiated PTB or preterm premature rupture of membranes. Regardless initial BMI, the 
greater the rate of WG, the higher the predicted probability for all PTB subtypes, except 
for spontaneous PTB in underweight and normal BMI women. Briefly, further studies 
evaluating the risk for PTB should consider that the role of WG might be different 
according to initial BMI and PTB subtype.  
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INTRODUCTION 
Preterm birth (PTB) is an increasing health concern and a major cause of neonatal mortality 
and long-term morbidity worldwide1. To develop effective strategies to reduce preterm 
birth, it is important to assess the causes and risk factors involved in its etiology. Body 
mass index (BMI) in pre- and early pregnancy and weight gain during pregnancy were 
already associated with preterm birth, however the exact role they play in determining 
preterm birth is still to be determined2. 
Obesity and overweight are also recognized as a growing global health problem3. The 
prevalence of overweight among adult women globally increased from 29.8% in 1980 to 
38% in 2013, especially in middle-income countries4. For mothers, major adverse health 
outcomes are related with obesity as gestational diabetes, pregnancy-induced hypertension, 
preeclampsia, postpartum hemorrhage, and caesarean delivery5. These complications of 
pregnancy are known to contribute to medically indicated PTB and are more common in 
overweight and obese women2,6. On the other hand, low early pregnancy BMI has been 
consistently reported as a risk factor for preterm birth, especially for spontaneous preterm 
birth (sPTB), in comparison with women of any other weight status7–9. 
Considerably fewer studies have evaluated the association between gestational 
weight gain and preterm birth; in many cases with contradictory results, as well as the 
majority of them has been conducted in high-income countries that have different contexts, 
such as racial, cultural, and socioeconomic factors, compared to low and middle-income 
countries. In addition, these studies have generally failed to distinguish between the 
different preterm births subtypes (sPTB, PROM-PTB and pi-PTB) and the rate of 
gestational weight gain, limiting their ability to delineate the dose-response relationship 
between gestational weight gain and preterm birth subtypes10–12. Therefore, it is still 
necessary to evaluate the association between the early pregnancy´ BMI and gestational 
weight gain with the occurrence of preterm birth and perinatal outcomes, considering the 
rate of gestational weight gain as a modifier factor for adverse maternal and perinatal 
outcomes in developing world13.  
A retrospective cohort study with almost 9 thousand women delivering singleton 
babies between 2006 and 2009 in Lima, Peru, showed an independent association between 
the rate of gestational weight gain and preterm birth (especially sPTB), which varies 
depending on the pre-pregnancy BMI. This association was protective in underweight 
women, however in overweight and normal BMI women both very low rates and very high 
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rates of gestational weight gain were associated with an increased preterm birth rate. These 
results are important for public health and highlight the need for further studies to expand 
our knowledge on the determinants of preterm birth10.  
 This study is part of the Brazilian Multicenter Study on Preterm Birth (EMIP), one 
of the most comprehensive epidemiological study on preterm birth in Brazil, conducted in 
20 referral obstetrical facilities in different geographical regions of the country. The 
purpose of this analysis is to evaluate the association between pre-pregnancy or early 
pregnancy BMI and the gestational weight gain with the risk of preterm births and their 
subtypes. Secondly, we aim to assess the impact of the gestational weight gain and early 
pregnancy BMI on the severity of adverse perinatal outcomes among preterm births. 
RESULTS 
From all the 33,740 births surveyed by EMIP study, 4,150 were preterm births while 1,146 
were selected to build the control group of term births (Figure 1). After excluding outliers’ 
data and considering all preterm and term births, 4,506 (85%) had information about 
early/pre-pregnancy BMI and 4,193 (79.2%) had complete information to calculate the 
gestational weight gain (Figure 1). Although the majority of women had normal pre-
pregnancy BMI (56.1%), approximately 85% were considered as having inadequacy of 
gestational weight gain, insufficient or excessive (data not shown). Additionally, more than 
one third of women were overweight or obese at the beginning of pregnancy (35.4%). 
Table 1 shows the risk estimates for preterm birth according to maternal early/pre-
pregnancy BMI and adequacy of weight gain during pregnancy. Overweight and obesity 
were associated with higher risk for pi-PTB, however with lower risk for sPTB. 
Underweight was associated with a 40% lower risk for pi-PTB. An insufficient RWG 
during pregnancy, regardless the initial BMI, was associated with increased risk for sPTB 
(1.7 fold) and PROM-PTB (1.5 fold). Women with excessive RWG were more likely to 
have PROM-PTB (1.4 fold) and pi-PTB (2 fold).  
Figures 2, 3, 4 and 5 show predicted probabilities for preterm birth subtypes for 
women respectively with underweight, normal BMI, overweight and obesity according to 
the RWG (per week). The greater the RWG of overweight and obese women, the higher 
the predicted probability for all subtypes of preterm birth. In women with underweight or 
normal BMI, the trend of increased probability according to higher RWG only remains for 
PROM-PTB and pi-PTB. The probability for spontaneous preterm birth in women with 
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underweight, however, remains bordering on stable regardless the RWG, while it decreases 
the greater the RWG in women with normal BMI. 
Women with insufficient RWG had a proportionally higher prevalence of preterm 
below 28 weeks and between 28 and 33 weeks of gestation (Table 2). Newborns of women 
with insufficient RWG had higher proportion of NICU admission. 
The multivariate analyses showed that fetal malformation, history of vaginal bleeding 
during pregnancy, maternal morbidity and multiple pregnancy were independently 
associated with any adverse perinatal outcome in women with preterm birth (Table 3). 
Adequacy of weight gain has not shown to be independently associated with APO, while 
initial BMI were poorly associated with pi-PTB. 
DISCUSSION 
EMIP study was a comprehensive survey on preterm birth in Brazil and, during the study 
progress, the prevalence of 6.5% was confirmed to be underestimated according to updated 
official data of the Brazilian Government (around 10% in 2011)14. Therefore, the 
surveillance of less than 37,000 deliveries was sufficient to achieve the number of 
participants in each group. The maternal characteristics of EMIP study has been already 
published elsewhere15,16, but we highlight that more than one third of participant women 
were overweight or obese at the beginning of pregnancy. The high estimated rates of 
Brazilian women aged between 25-34 years that are overweight obese justify the concern 
with endemic obesity and overweight especially in middle and high-income countries. 
Traditionally, early BMI has been used as a proxy of nutritional status at the beginning of 
pregnancy17, and has been largely studied as a risk factor for preterm birth 2,18,19. Although 
conventional, early BMI is an unmodifiable marker for the index pregnancy. Therefore, the 
current analyses included the evaluation of the weight gain during pregnancy as it could 
possibly represent a more dynamic and modifiable nutritional status during pregnancy. 
There are conflicting results in the literature regarding the risk of preterm birth and 
maternal early BMI2,18,19. In general, underweight are related with higher risk for sPTB and 
obesity with PROM and pi-PTB. However, many studies do not consider the preterm 
subtypes separately in the analyses, which is the main limitation for systematic reviews, as 
well as uniform categorization of BMI. According to a systematic review of maternal BMI 
and risk for PTB, although 39 studies published in 40 years on this topic, the lack of 
standardization of BMI limits the analyses and weakens the results and evidence2. The 
calculation of gestational weight gain is also another potential limitation on observational 
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studies, mainly in retrospective cohorts. Many studies calculate the total gestational weight 
gain, which complicates the comparison between a preterm and term delivery, not 
accounting for the expected lower weight gain in shorter gestational length. Two recent 
systematics reviews addressed the risks for adverse neonatal outcomes according to IOM 
gestational weight gain categories. Goldstein et al20 and Kominiarek et al21 showed that 
total weight gain below the recommendations were associated with higher risk for preterm 
birth OR 1.70 (CI 95% [1.32-2.20]) and OR 1.47 (CI 95% [1.31-1.64]), respectively.  
Differently to what was previously described by IOM Guidelines22, EMIP study 
results suggest that abnormal BMI and inadequacy of weight gain might have different 
effects on the risk for preterm birth subtypes.  In our study, women with overweight and 
especially obesity were associated with higher risk for pi-PTB, however with lower risk for 
sPTB. Obesity and overweight are established risk factors for metabolic disorders such as 
gestational diabetes, hypertension, preeclampsia, polyhydramnios and others, which are 
associated with maternal complications and consequently with higher risk for pi-PTB2,16,23. 
Observational studies suggest that the myometrial function of obese women is affected due 
to an abnormal response of oxytocin, whose receptors are decreased in myometrial biopsies 
in obese women at term24–27. This alteration is associated with higher rates of postdates 
pregnancies and slower labour progression in obese women compared to non-obese. 
Additionally, there is a low-evidenced hypothesis regarding the effects of endogenous 
oxytocin in food intake and body weight. Higher levels of endogenous oxytocin and/or 
overexpression of oxytocin receptors might reduce food intake and increase energy 
expenditure, reducing body weight28. Considering that, these women would have higher 
risk for prematurity, but a protective mechanism for obesity.  
On the other hand, a population-based cohort study of almost 1.6 million singleton 
deliveries in Sweden from 1992 through 2010 showed an increase risk for sPTB, especially 
extremely preterm, in overweight and obese pregnant women29. Obesity is characterized 
by inflammatory up-regulation, being associated with proinflammatories cytokines and 
adipokines and with alterations of hypothalamic-pituitary-adrenal axis, which is 
responsible for releasing corticotrophin-releasing hormone. In high values, it is known as 
a risk factor for premature rupture of membranes, preterm labour, eclampsia and 
pregnancy-induced hypertension29–31. Those conflicting evidences indicates that multiple 
underlying mechanisms might play a role at the risk for PTB in women with different BMI. 
According to our analyses, the effects of gestational weight gain in the risk for PTB 
depended on the initial BMI and on the preterm subtype. In general, excessive RWG was 
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associated with a higher probability for preterm birth, especially for pi-PTB in overweight 
and obese women. Carnero and colleagues conducted a retrospective cohort study in Peru 
and found that women with overweight and normal BMI have a “U-shaped” curve of 
association in which both low and high RWG were associated with an increased risk for 
preterm birth, especially pi-PTB10. The U-shaped form of association is in agreement with 
the literature, which shows that extremes of RWG are important risk factors for PTB22,32–
34. Therefore, pregnant women should be in the middle of this curve to minimize the risk.  
Although we did not observe such association in our study, our findings demonstrate that 
RWG might determine different effects on the risk for PTB depending on the initial BMI. 
Insufficient weight gain during pregnancy was related to more severe prematurity 
and higher admission to NICU in our analyses. Insufficient weight gain is associated with 
adverse perinatal outcomes as small for gestational age and spontaneous preterm birth, but 
it seems to depend on the initial BMI category35. Spontaneous preterm birth was associated 
with insufficient weight gain, but it is usually related with lower prevalence of very and 
extreme premature than pi-PTB36. Therefore, the higher prevalence of sPTB in women with 
insufficient RWG do not explain higher proportion of very and extreme prematurity. A 
separate analysis of insufficient weight gain considering the different initial BMI could be 
useful to determine underlying motivations for this association. 
Although our analyses were performed according to international recommendations 
for RWG, for BMI categories and for preterm subtypes, we identified some potential 
limitations In order to concretize this analysis, the formula of RWG we used assumes the 
same weight gain in the first trimester for all women. Although the weight gain 
recommended by the IOM in the first trimester is the same for all women regardless the 
initial BMI, having 0.5kg or 2kg of weight gain do could represent substantial difference 
on the RWG mainly for underweight women. Additionally, we were not able to address 
another important information as weight loss in the beginning of pregnancy, that happens 
with a portion of women and affect the first trimester and total weight gain. Another critical 
point was the fact that only 8.5% of participating women in our study were underweight. 
The small number of underweight women weakens the analyses, especially when divided 
in subgroups of PTB or RWG categories. Additionally, the likelihood of underweight 
women to have excessive weight gain seems to depend on the ethnicity and environmental 
aspects10,35,37. In Brazil, underweight women are more likely to have insufficient weight 
gain and unlikely to have excessive gain38. An excessive weight gain for underweight and 
obese women might result in different effects38. A recent systematic review and meta-
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analysis gathering information of women from USA, Europe and Asia showed that 
ethnicity might play a major role on the association of maternal BMI and gestational weight 
gain with the risk for preterm birth 39. Gestational weight gain below IOM recommendation 
was associated with higher risk for preterm birth in North American and European (OR 
1.35 [CI 95% 1.17 - 1.56]), but not in Asian pregnant women (OR 1.06 [CI 95% 0.78 – 
1.44]). Authors acknowledge the fact that IOM guidelines may not apply for all 
populations, as for Asian pregnant women. Specific BMI and weight gain normality and 
recommended parameters should be established for each population. 
Although we have used standard clinical proxies for nutritional status in pregnancy, 
maternal BMI and weight gain during pregnancy are related to other several aspects of 
biological, food intake and lifestyle conditions that were not assessed at all. The earliest 
idea that underweight would be exclusively related with undernutrition and obesity with 
overconsumption, lately high calories but poor-nutrient food are linked with obesity and 
low socio-economic status40.  
Initial BMI and weight gain during pregnancy have already been reported as risk factors 
for neonatal adverse outcomes41. We performed a logistic regression analyses to identify 
whether initial BMI or weight gain during pregnancy have association with any adverse 
perinatal outcome (APO) in preterm newborns. Nevertheless, no consistent association was 
observed except know risk factors as multiple pregnancy, fetal anomaly, maternal 
morbidity and vaginal bleeding.  
Despite the limitations of our study, there are great lessons that might be considered 
in future studies evaluating the burden of initial BMI and weight gain on the risk for PTB: 
1) To use the rate of weight gain during pregnancy (per week) and not total weight gain, 
which does not account for the length of pregnancy; 2) To consider the preterm birth 
subtypes in separate instead preterm birth as a unique syndrome, as the underlying 
conditions, motivators and outcomes are not the same; and 3) To use the adequacy of 
weight gain during pregnancy per initial BMI, once the weight gain might play different 
effects depending on the initial BMI category. The EMIP study findings highlight the need 
for further studies and for standardizations on preterm birth assessment of risk considering 
nutritional status.  
MATERIAL AND METHODS 
Study design. This is a secondary analysis of data from a multicenter cross-sectional study 
plus a nested case-control study called EMIP that involved 20 low and high-risk healthcare 
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facilities in three different geographical regions of Brazil, the Northeast, Southeast and 
South. The methodological details of EMIP study were already published elsewhere15,42. In 
brief, the data was collected from April 2011 to March 2012, using a form with 306 
variables especially developed for this study. All women with preterm birth were identified 
and invited to participate, including those with multiple pregnancies and stillbirths. The 
very next woman with term birth after the preterm delivery was invited to participate in the 
control group, until reaching estimated sample size. In case of non-acceptance, the next 
was invited. The data collection procedure included an interview with participants until 
discharge, and a review of the maternal and newborn medical records and prenatal chart. 
After data was collected for each individual case and the form was completed and checked, 
information was included in the online database system that used a special platform for 
clinical studies, the OpenClinica®. 
The sample size was calculated using the official prevalence of preterm births in 
Brazil in 2009 of around 6.5% at the time of the research proposal. Considering an 
acceptable absolute difference of about 0.25% between the sample and the population 
prevalence, as well as a type I error of 5%, 37,000 deliveries were necessary to cover for 
obtaining the sample size. For the case-control component, each group (preterm subtypes 
and controls) had an estimated sample size of 1,054 women. The samples size was 
calculated based on the primary objectives of EMIP study as previously published, the 
current analyses is performed in function of the data collected. 
Full ethical approval has been obtained by the National Council for Ethics in 
Research (CONEP) and by the Institutional Review Board of each participating center. 
Before enrolment, all individual signed an Informed Consent Form. Several procedures 
were adopted to ensure high quality of data including preparatory meetings for training 
assistants and collaborators, development of detailed standard operating procedures 
manuals (SOP’s) explaining how to manage the questionnaire and the database, monitoring 
site visits, sustained monitoring of data entry by the coordinating center and fast 
identification and correction of errors. All methods were performed in accordance with the 
principles stated in the Brazilian National Heath Council (Resolution CNS 196/96) and 
with local/institutional guidelines and regulations in every stage of this study.  
Outcomes and variables. The main outcomes for this analysis are the occurrence of 
preterm birth, defined as delivery below 37 weeks, due to spontaneous onset of labour 
(sPTB), pre-labour rupture of membranes (PROM-PTB) or medically indicated because of 
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maternal or fetal compromise or both (pi-PTB); and term birth, defined as childbirth at or 
after 37 weeks. The secondary outcomes were the categories of gestational age (<28 weeks, 
28-33 weeks and 34-36 weeks of pregnancy)1, fetal death, and the neonatal outcomes Apgar 
score <7 at five minutes, admission to neonatal intensive care unit (NICU), neonatal death 
before discharge and any adverse perinatal outcome (APO: a composite variable defined 
as the occurrence of any previous neonatal adverse outcomes).  
The maternal independent variables were: pre- or early pregnancy BMI, categorized 
as underweight (<18.5 kg/m2), normal (18.5-24.99 kg/m2), overweight (25-29.99 kg/m2) 
and obese (≥30 kg/m2)22. The early pregnancy BMI was calculated using the first weight 
recorded at prenatal chart, since up to 20 weeks of gestation, and measured height. 
Adequacy of weight gain during pregnancy was based on the rate of weight gain (RWG), 
calculated using the following formula: RWG= (first maternal weight in pregnancy - last 
maternal weight)/(gestational age at delivery - 12). The adequacy of weight gain was then 
categorized as insufficient when RWG <0.44 kg/w for underweight, <0.35 kg/w for normal, 
<0.23 kg/w for overweight or <0.17 kg/w for obese; adequate when RWG 0.44-0.58 kg/w 
for underweight, 0.35-0.50 kg/w for normal, 0.23-0.33 kg/w for overweight or 0.17-0.27 
kg/w for obese; and excessive when RWG ≥0.58 kg/w for underweight, ≥0.50 kg/w for 
normal, ≥0.33 kg/w for overweight or ≥0.27 kg/w for obese, according to the pre- or early 
pregnancy BMI as recommended by the Institute of Medicine (IOM)22. The current IOM 
guidelines recommend the same weight gain during the first trimester despites the 
categories of BMI. The lower and upper limits to categorize the adequacy of estimated 
weight gain are narrower as compared to other trimesters. Considering these, we subtracted 
12 weeks from the gestational age, considering that there is almost no difference on weight 
gain through women of different BMI in this period. Moreover, great part of Brazilian 
women initiates prenatal care after the first trimester.  
Statistical analyses. Statistical analyses were conducted to estimate risk for all PTB 
subtypes, using Odds Ratio (OR) with 95% confidence intervals (CI) for BMI and adequacy 
of weight gain categories, adjusting for cluster effect design. We estimated the probability 
for each preterm birth subtype according to initial BMI category and RWG during 
pregnancy using binary logit analyses optimized by Fisher´s scoring. The dotted lines in 
each figure of predicted probability delimit the lower and upper limits of recommended 
weekly RWG according to IOM. The area in orange between the lines, then, shows the 
recommended RWG for each initial BMI and the upper and lower values are, respectively, 
considered excessive and insufficient RWG. The occurrence of adverse perinatal outcomes 
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according to adequacy of weight gain during pregnancy, which is controlled by gestational 
age, was evaluated by χ2 tests. Statistical significance was considered when p-value <0.05. 
Stepwise multiple analysis by non-conditional logistic regression was run to identify 
factors independently associated with APO in women with preterm birth. To estimate the 
likelihood of each preterm birth subtype according to early BMI, we dismissed outliers of 
weight gain, ignoring data of women with weight gain above 99th percentile and below the 
percentile 1. Statistical analyses were performed using SAS System for Windows 
(Statistical Analysis System), version 9.4. SAS Institute Inc, 2002-2008, Cary, NC, USA. 
Institute Inc, 2002-2008, Cary, NC, USA. This manuscript follows STROBE statement43. 
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Figure 1.  Flow chart of participants in the study according to the adequacy of weight gain (WG) 
 
Figure 2. Probability of different types of preterm birth for underweighted women according to 
weight gain rate 
 
Figure 3. Probability of different types of preterm birth for women with normal weight according 
to weight gain rate 
 
Figure 4. Probability of different types of preterm birth for overweighed women according to 
weight gain rate 
 
Figure 5. Probability of different types of preterm birth for obese women according to weight gain 
rate 
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Figure 3. Probability of 
different types of preterm birth 
for women with normal weight 
according to weight gain rate 
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Figure 4. Probability of 
different types of preterm birth 
for overweighed women 
according to weight gain rate 
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Figure 5. Probability of different 
types of preterm birth for obese 
women according to weight gain 
rate 
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Table 1. Risk estimates of different subtypes of preterm birth according to maternal initial body mass index (BMI) and adequacy of weight 
gain 
 sPTB OR* (95% CI) PROM-PTB OR* (95% CI) pi-PTB OR* (95% CI) Term birth 
Initial Body Mass Index a        
Underweight 144 (11.5) 1.26 [0.93-1.70] 100 (9.8) 1.16 [0.84-1.60] 56 (4.5) 0.62 [0.43-0.89] 82 (8.3) 
Normal 782 (62.6) 1 577 (56.6) 1 604 (48.2) 1 565 (57.4) 
Overweight 226 (18.1) 0.74 [0.59-0.92] 210 (20.6) 0.92 [0.73-1.16] 338 (27.0) 1.43 [1.16-1.77] 209 (21.2) 
Obese 98 (7.8) 0.54 [0.40-0.72] 132 (12.9) 0.99 [0.75-1.31] 254 (20.3) 1.76 [1.37-2.26] 129 (13.1) 
        
Adequacy of Weight Gain b        
Insufficient 401(34.5) 1.76 [1.34-2.31] 271 (28.6) 1.54 [1.15-2.06] 230 (19.8) 1.28 [0.95-1.71] 241 (26.2) 
Adequate 172 (14.8) 1 133 (14.0) 1 136 (11.7) 1 177 (19.2) 
Excessive 590 (50.7) 1.19 [0.93-1.53] 543 (57.3) 1.45[1.11-1.88] 797 (68.5) 2.01 [1.56-2.59] 502 (54.6) 
        
Total 1,470  1,173  1,435  1,121 
OR*: Odds ratio adjusted for the cluster effect design in comparison with term birth group. CI: Confidence interval.  
sPTB: Spontaneous preterm birth. PROM-PTB: preterm premature rupture of membranes. pi-PTB: provider-initiated preterm birth. 
Missing information for: a) 693 b) 1006 cases. 
Values in bold mean they are statistically significant. 
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Table 2. Perinatal outcomes according to the adequacy of weight gain during pregnancy in 
preterm births 
Perinatal outcomes 
Adequacy of Weight Gain  
Insufficient Adequate Excessive p-value 
Gestational age [n=3273]    <.0001 
<28 weeks 65 (7.2) 23 (5.2) 134 (3.2)  
28-33 weeks 261 (28.9) 108 (24.5) 562 (23.9)  
34-36 weeks 576 (63.9) 310 (70.3) 1234 (72.9)  
Apgar score <7 at 5 minutes [n=3234] 96 (10.8 ) 30 (6.9) 179 (9.4) 0.0511 
NICU admission[n=3060] 653 (64.3) 602 (57.2) 598 (60.3) 0.0045 
Fetal death [n=3273] 41 (6.4) 11 (2.9) 71 (2.1) 0.1714 
Neonatal death before discharge [n=3127] 71 (8.3) 25 (5.9) 139 (7.5) 0.2996 
Any adverse perinatal outcome (APO)* [n=3273] 522 (57.9) 233 (52.9) 1133 (58.7) 0.0786 
     
*Any adverse perinatal outcome (APO): Apgar score <7 at 5 minutes or NICU admission or neonatal death before 
discharge. 
P-values in bold mean they are statistically significant. 
 
 
73 
 
 
 
Table 3. Variables independently associated with any adverse perinatal outcome (APO) in 
women with all types of preterm births: stepwise multiple analyses by non-conditional logistic 
regression  
Any preterm birth [n=3040] ORadj 95% CI p-value 
Fetal malformation 6.73 4.85 - 9.34 <.0001 
Vaginal bleeding 1.42 1.19 – 1.71 0.0001 
Maternal morbidity 1.31 1.12 – 1.55 0.0010 
Multiple pregnancy 1.42 1.09 – 1.84 0.0079 
Spontaneous preterm birth [n=1093]    
Fetal malformation 8.35 4.75 – 14.67 <.0001 
Multiple pregnancy 1.88 1.28 – 2.77 0.0013 
Vaginal bleeding 1.61 1.20 – 2.17 0.0016 
Number of C-section 0.77 0.61 – 0.97 0.0281 
Preterm birth due to PROM [n=898]    
Fetal malformation 7.72 4.13 – 14.46 <.0001 
Vaginal bleeding 1.65 1.16 – 2.28 0.0047 
Number of C-section 1.47 1.11 – 1.95 0.0068 
Provider-initiated preterm birth [n=1049]    
Fetal malformation 5.01 2.87 – 8.74 <.0001 
Initial BMI 0.97 0.95 – 0.99 0.0178 
ORadj: Odds ratio adjusted the cluster effect design and for all predictors in this final model; CI: confidence interval of OR; 
p: p-value. Predictors entering the model: maternal age, parity, number of previous vaginal birth, number of previous 
cesarean sections, number of abortion (nulliparous: 0/ ≥1: 1); schooling (≥12:0, <12:1), adequacy of weight gain during 
pregnancy (Adequate:0/Insufficient or Excessive:1); initial BMI (kg/m2); maternal morbidity* (no: 0/ yes: 1); vaginal 
bleeding (yes: 1/ no: 0) multiple pregnancy (yes: 1/ no: 0); fetal malformation (yes: 1/no: 0). 
*Defined as having any of the following: anemia, chronic hypertension, pre-pregnancy diabetes, gestational diabetes, 
gestational hypertension, preeclampsia/eclampsia/HELLP, hypo/hyperthyroidism, HIV, cardiac disease, renal disease, lung 
diseases, epilepsy, systemic lupus erythematosus or thrombophilia/thrombosis. 
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Abstract 
Objective: Exploring a conceptual framework of clinical conditions associated with 
preterm birth by cluster analysis, assessing determinants for different subtypes of preterm 
birth and related maternal and neonatal outcomes.  
Methods: Secondary analyses of the Brazilian Multicentre Study on Preterm Birth study. 
A surveillance of 33,740 births was held from April 2011 to July 2012 in 20 maternities, 
identifying 4,150 preterm deliveries. An adapted k-means model and Fuzzy algorithm was 
used to identify the clusters, using predefined conditions. The mains outcomes were 
clusters and maternal and neonatal outcomes. 
Results: Three clusters of preterm birth phenotypes were identified: Cluster 1 with women 
who had preterm delivery but had not had any of the predefined conditions, Cluster 2 
characterized by mixed conditions, and Cluster 3 that is mostly comprised of women who 
had preeclampsia/eclampsia/HELLP syndrome and fetal growth restriction. The prevalence 
of the different preterm subtypes was statistically different through the 3 clusters, 80% of 
provider-initiated preterm birth in Cluster 3 to 6.62% in Cluster 1. Although some maternal 
characteristics were different between clusters, maternal and neonatal outcomes did not 
differ. 
Conclusions: The analysis showed three clusters with distinct phenotypes. Women from 
the different clusters had different subtypes of preterm delivery and maternal and 
pregnancy characteristics. 
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Introduction 
The limitations of current predictive algorithms reflect the multifactorial 
nature of spontaneous preterm birth (sPTB), and the need to apply new strategies 
that can identify specific groups at risk. Known risk factors can play different role 
in distinct subgroups of women [1]. There might have different pathways and 
complex interactions of conditions related with sPTB occurrence. A group of 
specialists proposed a new conceptual framework for preterm birth, selecting 
conditions presented in the index pregnancy based on maternal, fetal and placental 
conditions that are not necessarily risk factors for preterm birth, but that are 
reasonably part of its pathways [2, 3]. Possibly, there is not only one clinical 
phenotype related to preterm birth and the identification of those phenotypes might 
contribute to bring to light the complex interactions of underlying conditions related 
its occurrence. 
A recent clustered designed analysis using an multi-ethnic international 
multicentre study showed that 30% of all spontaneous preterm births do not have 
any maternal, fetal or placental conditions identified that could be related to the 
occurrence [4]. On the other hand, there were clusters such as pre-eclampsia and 
preterm antepartum stillbirth that showed high correlation with women who had 
pre-eclampsia and severe maternal conditions, respectively. Also, it was possible 
to specify the most frequent clinical conditions related to its occurrence. 
Furthermore, not only the predisposing causes were shown to be different in the 
different clusters, but the maternal and neonatal outcomes were also distinct [4]. A 
secondary analysis using a database of spontaneous preterm birth cases 
performed a different clustering approach, establishing 9 clinical phenotypes 
divided in 3 levels of evidence for each [5]. After a hierarchical cluster analyses, 
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preterm birth cases were grouped into 5 clusters characterized by different 
conditions as maternal stress, premature rupture of membranes, familial factors, 
maternal morbidities and multifactorial. According to the authors, women from the 
same cluster are more likely to share common causes and common genetic 
predispositions [5]. 
In the current analyses, we aim to perform a secondary analysis of The 
Brazilian Multicenter Study on Preterm Birth (EMIP) to identify if there is a 
clustering correlation of clinical, maternal and fetal conditions with preterm birth 
subtypes and demonstrate maternal and neonatal outcomes related to the final 
clusters. Clustering analysis applied to preterm birth determinants is an innovative 
approach to identify groups of women that would require special attention, 
interventions and surveillance depending on the conditions associated with the 
different subtypes of preterm birth and also the maternal and perinatal outcomes. 
This is expected to be helpful for the identification of clinical phenotypes related to 
specific subtypes of preterm birth and, therefore, better study its determinants and 
associated outcomes as those maternal clinical conditions can be identified by 
clinicians and health care providers during antenatal care. 
Methods 
We performed a secondary cluster analysis using data of EMIP study, a 
multicentre cross-sectional study with a nested case-control component of preterm 
birth conducted between April 2011 and September 2012 that collected 
comprehensive data related to the 3 subtypes of preterm births in 20 referral 
maternities in 3 regions of Brazil [6–8]. Briefly, EMIP study was a comprehensive 
observational study that identified all preterm births that occurred in the referral 
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facilities among more than 33 thousand births, as showed in Figure 1, collecting 
more than 300 variables related to potential associated factors and maternal and 
neonatal outcomes. Information about medical history, sociodemographic status 
and pregnancy, delivery and postpartum details were retrospectively collected after 
childbirth through an interview with the participating women and review of the 
medical record that included prenatal chart and hospital medical record. Maternal 
and neonatal data were collected until discharge or 40 days after birth.  
All participating women signed an informed consent form. The ethical 
principles stated in the Brazilian National Heath Council (Resolution CNS 196/96) 
were respected. The study also complies with the Declaration of Helsinki amended 
in Hong Kong in 1989. The study was previously approved by the local IRB of the 
coordinating centre, by each local IRB of all participating centres and by the 
National Ethics Committee for Research (CONEP). 
We adapted the concept framework and maternal, fetal and placental conditions 
used by Barros et al, defining them as potential conditions direct or indirectly 
related with the occurrence of preterm birth (Table 1) [3, 4]. Those conditions were 
used to establish different preterm phenotypes.  
Preterm birth was classified as spontaneous preterm birth (sPTB), due to 
spontaneous onset of labour, premature rupture of membranes preterm birth 
(PROM-PTB) or provider-initiated preterm birth (pi-PTB), due to maternal and/or 
fetal conditions motivating preterm delivery.  
Maternal and neonatal outcomes as mode of delivery, gestational age 
category (extreme preterm, moderate preterm and late preterm), Apgar score <7 
at 5 minutes, admission to neonatal intensive care unit (NICU), neonatal near miss 
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(using the pragmatic criteria defined as having birth weight below 1700 g or Apgar 
score below 7 at 5 minutes of life or gestational age below 33 weeks) and neonatal 
death before discharge were distributed according to the clusters. Some maternal 
and pregnancy characteristics were also addressed according to preterm birth 
clusters. Adequacy of weight gain was categorized as insufficient, adequate and 
excessive according to Institute of Medicine definition for weekly rate of weight gain 
[9]. 
Statistical Analysis 
A cluster analysis was conducted to identify the clusters, according to the 
predefined maternal, fetal and placental conditions showed on Table 1. A k-modes 
model, variation of k-means model for categorical variables, was applied to identify 
the clusters from the predefined conditions using a Fuzzy algorithm. The number 
of final clusters was determined by automatized methods (no predefined number 
of clusters was set). χ2 tests were used to evaluate significant difference of 
maternal and neonatal outcomes between clusters. All analysis were conducted 
using SAS software, version 9.4. 
Results 
Preterm birth cases were clustered into 3 clusters according to the 12 
maternal, fetal and placental predefined conditions (Table 1). The prevalence of 
the main condition and the subsequent other most frequent conditions in the 3 
clusters are presented in Table 2. Cluster 1 represents 15.7% of all women who 
had preterm birth in EMIP study and is characterized by women who did not had 
any maternal, fetal and/or placental defined conditions. Cluster 2 comprises 55.9% 
of all preterm births, being characterized by a set of conditions: 42.5% of women 
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of this cluster had extra uterine infection, 34.9% had maternal chronic disease and 
approximately 20% had mid-late pregnancy bleeding. All women who had clinical 
chorioamnionitis, almost 90% who had antepartum stillbirth and more than 80% 
who had multiple pregnancy were in the cluster 2 (Table 2 and Table 3). Cluster 3 
comprises 28.4% of preterm cases of which 85% had 
preeclampsia/eclampsia/HELLP syndrome and 32% had fetal growth restriction. 
Table 3 shows the distribution of the 11 predefined conditions in the 3 
clusters, detailing the prevalence and concentration of a given condition in the 
clusters. Although only 7.46% of women in cluster 2 had clinical chorioamnionitis, 
all women with clinical chorioamnionitis were clustered in cluster 2.  
The preterm birth subtype was statistically different according to the cluster 
as demonstrated in Table 4. More than 90% of women of Cluster 1 had sPTB or 
pPROM-PTB. The proportion of women with pi-PTB was slightly higher in women 
of cluster 2 (20%) and much higher in cluster 3 (80.9%).  
The maternal and neonatal outcomes did not differ between clusters as shown in 
Table 5. Caesarean section was the most prevalent mode of delivery, ranging from 
52.7% to 55% of preterm births. 
Table 6 shows maternal and pregnancy characteristics according to the 
different clusters. White women, obesity (BMI >25), excessive weight gain during 
pregnancy and previous C-section were more prevalent in Cluster 3 than in 2, and 
more prevalent in Cluster 2 than in 1. All the other characteristics were not 
statistically different between clusters. 
Discussion 
Main findings 
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The 4,150 preterm births of EMIP study were clustered into only 3 clusters, 
which are presented with very different clinical conditions (phenotypes): the first 
one with no conditions associated, the second with mixed conditions and the third 
related with preeclampsia and fetal growth restriction. No differences in maternal 
and perinatal outcomes were observed between clusters, except for subtype of 
preterm birth showing a prevalence of pi-PTB significantly higher in cluster 3.  
Strengths and Limitations 
We performed an unsupervised data-driven cluster analysis, which means 
that we neither predefined pre-clusters nor established the initial number of 
clusters. This methodological approach enables a more genuine clustering of the 
cases according to the predefined clinical conditions. The reproducibility of cluster 
analysis might depend on the dataset, and also on the availability definition of 
clinical conditions. Nevertheless, we consider that the selected clinical conditions 
are reproducible and common conditions addressed in preterm birth studies, 
potentially available regardless the setting or population. The EMIP study followed 
standardized data collection protocols and several procedures to assure data 
quality [10]. Nevertheless, the study presents some limitations: 1) the absence of 
data regarding cervical length, a maternal condition highly associated with the 
occurrence of spontaneous preterm birth [11]; 2) it was an observational study with 
retrospective data collection after childbirth for variables related with pregnancy. 
Therefore, definition for some conditions was based only on the report of 
participating women or on medical record/prenatal chart, limiting the 
standardization and audit. 3) the definition of maternal chronic disease was based 
on different diseases with potentially distinct effects for maternal and fetal health 
during pregnancy. 
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Interpretation 
We have adapted the conceptual framework used by Barros et al. to 
determine the predefined conditions potentially associated with PTB [4]. We have 
identified a much smaller number of clusters, indicating that the final number of 
clusters might depend on the criteria for predefined conditions and on the clustering 
method. In our analyses, the number of clusters was set by the model, avoiding 
external adjustments, while Barros et al. preferred to use a 2-step cluster analysis, 
which enabled the development of preclusters and the adjustment of the final 
clusters. We consider that the different methodological approaches might play a 
significant role on the different findings.  
The new conceptual framework still requires validation and possibly new 
conditions need to be added in the model. For instance, information on cervical 
length was unavailable for Barros et al. analysis, and less than 5% of women in 
our study had cervical length at 20-24w recorded (data not shown). We consider 
this is an important condition to be addressed, as also maternal anthropometric 
status at the beginning of pregnancy. 
The proportion of women in Cluster 1 (without any predefined condition) is 
meaningful. Exactly 15% of all women with preterm birth did not have any of the 
twelve conditions potentially associated with PTB. The prevalence of women 
without any conditions was even higher (30%) in the multicountry population-based 
study of Barros et al [4]. Clinical and epidemiological data seems to have limited 
performance in recognizing conditions related to the occurrence of preterm birth 
[12, 13].  
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The mechanisms of preterm and term labour are not completely understood. 
The proportion of women that had pi-PTB or sPTB/pPROM-PTB in the different 
clusters was statistically different. The analysis of clinical characteristics of women 
from different clusters was an effort to explain why. Women in cluster 1 had low 
rate of pi-PTB. The absence of maternal morbidity or any other related conditions 
in this cluster could indicate that spontaneous preterm birth due to spontaneous 
onset of labour or pPROM often are presented without any maternal obstetric 
condition as a background, confirming the great challenge of recognizing the 
mechanisms of the determinism of preterm labour or pPROM. Esplin et al. 
performed a cluster analysis of 1,028 women with preterm birth, and showed one 
cluster with strong familial history of PTB that might have genetic contribution 
based on insulin gene analysis [5]. The identification of specific groups of women 
sharing common genetic and clinical conditions might provide better understanding 
of complex interaction of different biological systems related with preterm birth 
(maternal, fetal and placental) [2, 3, 14]. 
Cluster 2 is characterized by women with mixed conditions (extrauterine 
infection, maternal morbidity, clinical chorioamnionitis, vaginal bleeding during 
pregnancy and multiple pregnancy). Although all the conditions are known risk 
factors for preterm birth, it is difficult to determine the role of each condition in the 
occurrence of preterm birth in this cluster. Almost 80% of women in the mixed 
conditions cluster (cluster 2) had sPTB or pPROM-PTB, confirming that women 
with this subtype of preterm birth may have a multiplicity of conditions which cluster 
analysis resulted into inseparable group – in contrast with Barros et al findings.  
Not surprisingly women clustered with preeclampsia/eclampsia/HELLP 
syndrome also presented fetal growth restriction as a secondary most frequent 
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condition (Cluster 3). Both conditions are “Great Obstetrical Syndromes” that are 
directly linked with ischemic placental disease, sharing common altered 
placentation mechanisms [15, 16]. Hypertensive disorders and fetal growth 
restriction are the most important causes motivating pi-PTB due to maternal or fetal 
conditions [8, 17], what explains the high rates of pi-PTB in cluster 3. The 
prevalence of obesity and excessive weigh gain during pregnancy were higher in 
cluster 3 than in the other clusters. Both conditions are considered risk factors for 
hypertensive disorders, but not for fetal growth restriction [18]. It is estimated that 
only around 12% of ischemic placental disease in preterm births are presented with 
PE and fetal growth restriction [19]. Although there is a concurrence of PE and fetal 
growth restriction, which is followed by poorer outcomes, the risk factors and 
conditions associated with each condition are not invariably overlapped [19, 20]. 
Although we have identified 3 different clusters with very distinct clinical 
phenotypes, we consider that a better definition of predefined conditions can 
provide better description of the clusters, as we had only three clusters and one of 
them was presented with multiple mixed conditions. Esplin et al. proposed a score 
discriminating clinical conditions according the different level of evidence of the 
association with preterm birth (possible, moderate and strong) [5]. The idea seems 
to be to refine the presentation of the clinical phenotype of each cluster. Data 
mining could be another helpful clustering technique to determine clinical 
conditions and the correspondent clusters. This approach is used to interpret big 
data in complex syndromes with multiple interaction systems as genome data [21–
24]. The combination of phenotype clusters with biological markers could be an 
innovative initiative to study and predict preterm birth.  
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In conclusion, the three clusters showed different phenotypes of women: 
women without any predefined conditions, women with mixed conditions and 
women with hypertensive disorders in pregnancy and fetal growth restriction. 
Although the maternal and neonatal outcomes were not different, women of 
different clusters had different subtypes of preterm delivery. Standardized methods 
and larger datasets might provide more reliable and helpful findings that could 
contribute with the study of preterm birth phenotypes. 
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Figure Legend 
 
 
Figure 1. Flowchart of EMIP study – Preterm Birth component (sPTB: spontaneous preterm birth; pPROM-
PTB: preterm birth due to preterm premature rupture of membranes; pi-PTB: provider initiated preterm birth). 
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Table 1. Definition of maternal, fetal and placental conditions possibly associated with preterm birth 
Condition Definition 
Maternal  
Extrauterine infection during pregnancy 
Prenatal care chart or medical record detailing occurrence 
during pregnancy of syphilis, tuberculosis, HIV, HPV, hepatitis, 
febrile diarrhoea, pneumonia, sinusitis, toxoplasmosis, genital 
herpes, asymptomatic bacteriuria, cystitis, pyelonephritis or 
sepsis. 
Clinical chorioamnionitis 
Medical record showing the occurrence of clinical 
chorioamnionitis. 
Maternal chronic disease 
Medical record showing history of diabetes, HIV, chronic 
hypertension, hypo/hyperthyroidism, nephropathy, sickle cell 
disease or other chronic anaemia, cardiopathy, pneumopathy, 
epilepsy, lupus, other collagenosis, chronic gastrointestinal, 
psychiatric, neurologic or orthopaedic diseases, neoplasms, 
thrombosis, thrombophilia or bariatric surgery. 
Preeclampsia/Eclampsia/HELLP syndrome 
Medical record of having preeclampsia, eclampsia and/or HELLP 
syndrome. 
Fetal  
Antepartum Stillbirth 
Antepartum stillbirth (after 22weeks of gestation) before or 
after hospital admission. 
Fetal Growth Restriction (suspicious or 
confirmed) 
Cases suspicious or confirmed of fetal growth restriction 
including cases whose ultrasound scan showed fetal estimated 
weight under the 10th percentile during prenatal care or 
birthweight was considered small for gestational age. 
Perinatal sepsis 
Medical record describing clinical or laboratory diagnosis of 
neonatal sepsis. 
Multiple pregnancy 
Pregnancy with more than one live fetus after 12 weeks of 
gestation. 
Fetal anomaly 
Suspicious (ultrasound findings of fetal anomaly) or confirmed 
minor or major fetal anomaly (after childbirth). 
Placental  
Early bleeding Women who reported bleeding before 13 weeks of gestation. 
Mid-/late-pregnancy bleeding 
Women who reported vaginal bleeding after 14 weeks of 
gestation. 
None Cases in which none of the previous conditions are present. 
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Table 2. Distribution of clusters of phenotypes of preterm birth according to maternal, fetal and 
neonatal conditions 
Cluster No (%) Main Condition (%) Other most frequent Conditions (%)a 
Cluster 1 650 (15.7) None  
Cluster 2 2,319 (55.9) 
Extrauterine infection 
(42.5) 
Maternal chronic disease (34.9)  
Mid—late pregnancy bleeding (20.2) 
Multiple pregnancy (15.6) 
Clinical chorioamnionitis (7.5)  
and Antepartum stillbirth (6.3)  
Cluster 3 1,181 (28.4) 
Preeclampsia/Eclamp
sia/HELLP syndrome 
(85.8) 
Fetal growth restriction (32.2in) 
All 4,150 (100)   
aOnly conditions with prevalence above 30% or almost exclusively of the cluster (80%) 
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Table 3. Distribution of maternal, fetal and placental conditions according to clusters of preterm birth phenotype  
Condition Cluster 1 Cluster 2 Cluster 3 
Extrauterine infection n 0 986 343 
Row % 0 74.19 25.81 
Column % 0 42.52 29.04 
Clinical Chorioamnionitis n 0 173 0 
Row % 0 100.0 0 
Column % 0 7.46 0 
Maternal chronic disease n 0 809 222 
Row % 0 78.47 21.53 
Column % 0 34.89 18.80 
Preeclampsia/Eclampsia/HELLP 
syndrome n 
0 51 1,013 
Row % 0 4.79 95.21 
Column % 0 2.20 85.77 
Antepartum Stillbirth n 0 147 17 
Row % 0 89.63 10.37 
Column % 0 6.34 1.44 
Fetal Growth Restriction n 0 49 380 
Row % 0 11.42 88.58 
Column % 0 2.11 32.18 
Perinatal sepsis n 0 564 212 
Row % 0 72.68 27.32 
Column % 0 24.32 17.95 
Multiple pregnancy n 0 362 75 
Row % 0 82.84 17.16 
Column % 0 15.61 6.35 
Fetal anomaly n 0 383 112 
Row % 0 77.37 22.63 
Column % 0 16.52 9.48 
Early bleeding n 0 431 134 
Row % 0 76.28 23.72 
Column % 0 18.59 11.35 
Mid-/late- pregnancy bleeding n 0 468 86 
Row % 0 84.48 15.52 
Column % 0 20.18 7.28 
None n 650 0 0 
Row % 100.00 0 0 
Column % 100.00 0 0 
Total n 650 2,319 1,181 
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Table 4. Preterm birth subtypes according to preterm birth phenotype clusters 
Cluster 
Cluster 1 
(%) 
Cluster 2 
(%) 
Cluster 3 
(%) 
p-value 
sPTB 52.77 43.90 11.01 <0.0001 
pPROM-PTB 40.62 35.88 8.04  
pi-PTB 6.62 20.22 80.95  
All cases 100 100 100  
P-values in bold mean they are statistically significant. sPTB: Spontaneous preterm birth, pPROM-PTB: preterm birth due to preterm premature rupture of membranes, pi-PTB: provider-
initiated preterm birth. 
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NICU: neonatal intensive care unit. Missing information for: a (69), b (597), c (13), d (198) cases. 
 
 
Table 5. Maternal and neonatal outcomes according to preterm birth phenotype clusters 
Maternal and neonatal outcomes 
Cluster 1  
N (%) 
Cluster 2 
N (%) 
Cluster 3 
N (%) 
p-value 
Caesarean section 55.0 52.7 53.9 0.528 
Preterm birth <28wks 7.6 7.3 7.3 0.959 
Preterm birth <32wks 20.3 21.3 21.5 0.822 
Preterm birth 34-36wks 62.4 62.6 62.9 0.977 
Apgar score <7 at 5 minutes a 10.0 10.0 11.8 0.227 
NICU >7 days b 34.1 34.2 32.0 0.492 
Neonatal near miss c 35.5 33.3 33.0 0.510 
Neonatal death before discharge d 9.5 8.5 7.3 0.257 
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Table 6. Maternal and pregnancy characteristics according to preterm birth phenotype clusters 
Characteristics 
Cluster 1  
N (%) 
Cluster 2 
N (%) 
Cluster 3 
N (%) 
p-value 
Age a    0.8503 
<19y 126 (19.41) 496 (21.39) 242 (20.49)  
19-35y 428 (65.95) 1,488 (64.17) 764 (64.69)  
>35y 95 (14.64) 335 (14.45) 175 (14.82)  
Ethnicity     0.0424 
White 262 (40.31) 1,023 (44.11) 548 (46.40)  
Non-white 388 (59.69) 1296 (55.89) 633 (53.60)  
Schooling b     0.1261 
<12y 125 (80.53) 1,792 (78.67) 948 (81.51)  
≥12y 125 (19.47) 486 (21.33) 215 (18.49)  
Family Income c    0.1829 
<400 USD 354 (60.62) 1,307 (61.65) 636 (58.30)  
≥400 USD 230 (39.38) 813 (38.35) 455 (41.70)  
Initial BMI d     <0.0001 
<18,5 58 (10.74) 193 (9.53) 51 (4.99)  
18,5-25 343 (63.52) 1161 (57.31) 486 (47.51)  
>25 139 (25.74) 672 (33.17) 486 (47.51)  
Adequacy of weight gain e    <0.0001 
Insufficient 191 (38.20) 575 (30.49) 172 (18.01)  
Adequate 83 (16.60) 246 (13.04) 112 (11.73)  
Excessive 226 (45.20) 1065 (56.47) 671 (70.26)  
Nulliparity 306 (47.08) 1130 (48.73) 539 (45.64) 0.2150 
Parity>2 66 (10.15) 253 (10.91) 147 (12.45) 0.2530 
Previous PTB f 124 (19.14) 433 (18.72) 255 (21.67) 0.1105 
Previous SGA g 107 (16.72) 365 (15.90) 220 (18.66) 0.1191 
Previous C-section h 131 (20.15) 475 (20.49) 296 (25.06) 0.0046 
Smoking, alcohol or other 
drugs i 
97 (14.99) 386 (16.79) 185 (15.74) 0.4812 
Stress j 276 (42.86) 937 (40.85) 507 (43.19) 0.3536 
P-values in bold mean they are statistically significant. Missing information for: a) 1, b) 67, c) 355, d) 561, e) 809, f) 12, g) 35, h) 
1, i) 29, j) 38. 
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4.3. Artigo Metabolomics applied to maternal and perinatal health: a review of 
new frontiers with a translation potential 
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Abstract 
The prediction or early diagnosis of maternal complications is challenging mostly because 
the main conditions, such as preeclampsia, preterm birth, fetal growth restriction, and 
gestational diabetes mellitus, are complex syndromes with multiple underlying 
mechanisms related to their occurrence. Limited advances in maternal and perinatal 
health in recent decades with respect to preventing these disorders have led to new 
approaches, and “omics” sciences have emerged as a potential field to be explored. 
Metabolomics is the study of a set of metabolites in a given sample and can represent the 
metabolic functioning of a cell, tissue or organism. Metabolomics has some advantages 
over genomics, transcriptomics, and proteomics, as metabolites are the final result of the 
interactions of genes, RNAs and proteins. Considering the recent “boom” in metabolomic 
studies and their importance in the research agenda, we here review the topic, explaining 
the rationale and theory of the metabolomic approach in different areas of maternal and 
perinatal health research for clinical practitioners. We also demonstrate the main 
exploratory studies of these maternal complications, commenting on their promising 
findings. The potential translational application of metabolomic studies, especially for the 
identification of predictive biomarkers, is supported by the current findings, although they 
require external validation in larger datasets and with alternative methodologies. 
 
Keywords: Maternal health (MeSH), Metabolomics (MeSH), Translational Medical 
Research (MeSH), Prediction 
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Introduction 
In addition to the vast knowledge already available in physiology, pathology and 
therapeutics, there are still some key areas lacking the global and equally spread 
advantages of health sciences. One of these areas is undoubtedly maternal and perinatal 
health. Although a significant improvement has been achieved worldwide during the last 
two decades with the focus provided by the United Nations’ Millennium Development 
Goals (1) and currently by the Sustainable Development Goals (2), the capacity for 
predicting the most prevalent and hazardous conditions affecting pregnancies, mothers 
and babies is still very limited. Without prediction, there is no prevention, the pillar for 
providing good public health. Therefore, generally speaking, there are no available 
options other than trying to perform an early diagnosis of those potentially harmful 
conditions, including preterm birth (PTB), preeclampsia (PE), gestational diabetes mellitus 
(GDM), fetal growth restriction (FGR), maternal and fetal infections and other conditions 
possibly associated with severe maternal morbidities. However, early diagnosis is almost 
always more expensive and not truly available for a significant proportion of populations, 
especially those in low- and middle-income settings. 
Considering all these aspects, the purpose of the current review is to summarize the 
already existing knowledge on technologies that possibly represent new frontiers and 
future tools for predicting maternal and perinatal conditions responsible for a significant 
burden of disease in women and children in the world. Metabolomic biomarkers are one 
of these new promising tools and deserve special attention due to their potentially 
important role in the management approach for such conditions in the near future. 
Metabolomics as part of omics technologies 
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The study of the biological systems of an organism leads to the understanding of complex 
interactions between the genes, their products (RNAs, proteins, and metabolites) and 
many environmental factors that determine their functioning (3, 4). The recent 
development of what is called systems biology enables the recognition of these 
integrative pathways. The field of systems biology is related to the capacity to identify 
thousands of biological molecules and to establish their interactions using advances in 
bioinformatics, statistics, and high-throughput techniques of sample analysis. The “omics” 
sciences emerged from this concept of integrative analysis in the field of systems biology 
and includes genomics, for the study of a set of genes (genome); transcriptomics, for a set 
of RNAs (transcriptome); proteomics, for a set of proteins (proteome); and metabolomics, 
for a set of metabolites (metabolome), as shown in Figure 1. 
 Figure 1. Omics science components of biological systems 
The clinical importance of omics sciences arises from the innovative approach of the 
dynamic regulations of biological systems, which can be explored by both holistic and 
reductionist strategies (5). A reductionist strategy is the use of only one part of a complex 
system or only one hypothesis to build conclusions or to understand the determinants of 
the whole process. On the other hand, a holistic approach considers multiple interactions 
and complexities to elucidate the whole system. Prevalent maternal complications, such 
as PE, PTB, GDM or FGR, are commonly addressed using a reductionist approach. For 
instance, a woman with a short cervix is considered to have a higher risk for PTB, or a fetus 
with an estimated weight below the 10th percentile is considered growth restricted. The 
omics sciences enable discovery-driven studies with a holistic and hypothesis-free 
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approach and may provide the key step forward in addressing complex research problems 
in maternal and perinatal health, decreasing bias and confounders (3, 6-10). 
Genomics 
Genomics is the study of genes and their functions and demonstrates the gene 
codification for proteins that modulate biological systems. Therefore, genomics may be 
useful to determine the genetic predisposition for a particular disease, identifying the 
genes involved in its pathophysiology. Genomics studies are more commonly performed 
using the candidate gene approach, through which preselected genes are sequenced. The 
complex interactions of genes in the development of a pathologic phenotype and the 
presence of nongenetic factors limit the results of this approach. Regularly, there is not 
only one gene involved in the development of a disease but also groups of genes. 
Moreover, parts of a gene (locus) can be related to the development of the disease, while 
other parts might be related to its prevention, and the polymorphisms and mutations of 
genes can determine a wide variance in gene expression. The genome-wide sequencing 
techniques of the exome can demonstrate a more complete view of the genetic 
predisposition and establish individuals’ prognostics and treatment resistance (11, 12). 
The main potential limitations of genomics are high cost and uncertainty between gene 
codification and gene expression/phenotype. Only a small portion of the whole genome 
will be translated, and there are several mechanisms and processes that control the 
expression of genes (methylation, acetylation, epigenetic mechanisms, imprinting, etc.). 
Therefore, having the gene codification for a disease does not mean it will develop. 
Transcriptomics 
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The next step to understand the development of a disease would be the study of gene 
expression. Transcriptomics is a step-forward technique compared to genomics in terms 
of downscaling genetic predispositions. Transcriptomics determines mRNA expression 
using many techniques, such as microarray-based methods, which are used to measure 
mRNA transcript levels, and sequence-based methods, such as serial analysis of gene 
expression (SAGE), cap analysis of gene expression (CAGE), massively parallel signature 
sequencing (MPSS) and RNA-Seq technology (13). RNA-Seq appears to be the most 
advantageous transcriptomics approach since it requires a small amount of RNA and is a 
more precise, “clean” (less background signal) and much lower-cost method considering 
the high-throughput technology (13). The expression of mRNA in a particular tissue can 
differ according to the timeframe observed. For instance, the expression of 
proinflammatory proteins during labor is different from that during other pregnancy 
periods (4, 14). Therefore, it is possible to compare the expression of mRNA in a tissue 
using arrays with tens or hundreds of genes and determine down- or upregulation of the 
gene expression according to the level of mRNA (4). The overexpression of a gene at a 
given phase of the biological process related to the development of a particular pathologic 
condition can uncover key points of the physiopathology of the disease and potential 
targets for prevention and treatment. 
Despite these benefits, transcriptomics faces similar limitations to genomics. There is 
a recent conceptual discussion against the traditional idea that the final products of our 
genes are mostly proteins: gene (DNA) → mRNA → protein (15). The main genome-wide 
sequencing projects have targeted only long protein-coding mRNAs, given this classical 
interpretation. However, more recent studies have identified many other gene-encoded 
contributors as long noncoding RNAs that play different roles in biological systems and 
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metabolic pathways but do not encode proteins (16, 17). The various mechanisms that 
take part in the regulation of gene expression, such as chromatin remodeling, adenylation, 
elongation, splicing, editing, nuclear export, and degradation, may limit the unbiased 
recognition of all mechanisms between gene expression and the clinical phenotype (15). 
These mechanisms seem to be extremely complex, requiring more developed research 
techniques and new approaches for the study of biological systems (5, 18, 19). 
Proteomics 
Proteins are key instruments of biological systems, and their abnormalities can cause or 
be a consequence of organism dysfunctions. The study of the proteins contained in a 
sample is called proteomics, which basically includes identification and quantification (3). 
Proteomics is a promising approach that reflects genetic and environmental effects in the 
development of pathological conditions. According to an evolutionary hypothesis 
regarding protein function, there are some proteins involved in the various metabolic 
pathways of an organism and others related to gene regulation and expression, including 
intra- and extracellular signaling and the mechanisms of gene expression (20). The 
abundance of proteins required to perform such roles is different depending on the 
complexity of their functions. Contrary to what would be obvious, highly specialized 
biological processes do not require high protein availability. Moreover, protein activity 
can vary depending on many factors, such as the concentration of substrates and the 
presence of other coenzymes. Therefore, the abundance of proteins seems not to be a 
reliable parameter to address their function. In addition to proteomics limitations, 
isolating proteins from blood remains a difficult task, and there is no single reliable, 
accurate and reproducible method capable of obtaining all proteomes (20). 
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Metabolomics 
The metabolic pathway comprises different biochemical reactions occurring in the 
intracellular or extracellular compartment. Metabolites are the substrates and products 
of these metabolic reactions, which require enzymes (proteins), minerals, vitamins, and 
other cofactors. Metabolomics is the study of the set of metabolites of an organism, 
identifying and quantifying them with higher sensitivity and more reliable reproducibility 
(21). The set of these small low-weight molecules is called the metabolome, which is a 
fingerprint of the metabolism at a given time (3, 4, 7). Therefore, it is possible to 
understand the metabolism at that moment or, depending on the sample, to understand 
the metabolism of days to months ago. The hairs, for example, are stable, contain 
endogenous compounds, and reflect environmental exposure for many months prior (22). 
Human metabolomic research emerged from previous experience with plants, microbes, 
and other less complex mammals after years of bioinformatics/statistics advances to 
address massive output data (3, 4, 7). Metabolomics in maternal and perinatal health may 
enable the identification of biomarkers related to maternal and perinatal complications 
and the understanding of the physiopathology of the most complex and prevalent 
diseases, such as PE, PTB, GDM, FGR, maternal/fetal infections and other severe maternal 
morbidities (10, 23-25). 
Advantages of metabolomics include its hypothesis-free and unbiased approach and 
the downstream result of gene expression, being the closest to the phenotype of the 
omics sciences. Different technologies have to be employed to identify and quantify fatty 
acids, bile acids, ketone bodies, amino acids, peptides, carnitines, carbohydrates, 
vitamins, xenobiotics, steroids, etc. The modalities generally used are gas 
chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry 
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(LC-MS) and nuclear magnetic resonance (NMR) spectroscopy. GC-MS and LC-MS can 
identify and quantify tens of thousands of metabolites at one time, creating substantial 
output data in mass spectrum format, as shown in Figure 2. Mass spectrometry consists 
of the following components: 1) Sample inlet, a system that differs between GC-MS and 
LC-MS; 2) Ion source that ionizes molecules of the sample; 3) Analyzer that separates 
molecules through a long tube under vacuum according to their mass and charge (using 
the mass-to-charge ratio – m/z or the time-of-flight method to discriminate different 
metabolites); 4) Ion detector that detects different metabolites with a sensitivity capable 
of differing isomeric molecules and measuring the quantity of ions converted into 
electrical signals. The more molecules that are present, the greater is the electrical signal; 
and 5) Data analysis system matched to a computer that interprets the signal as a mass 
spectra data (3, 5, 9, 25). The next step is to identify metabolites using their m/z values 
and to compare them with their corresponding molecules in a previously known library, 
namely, the Human Metabolome Database - www.hmdb.ca (26). 
Figure 2. Mass spectrometry spectrum – scheme of metabolite output data 
There are many different customizations when using metabolomic analytical methods, 
allowing better identification of a specific range of mass of molecules or metabolites with 
different solubilities (5, 21). The advantages and disadvantages of each method should be 
considered according to the experimental objectives. NMR methods require minimal 
sample preparation, preserving the samples in their natural form and can identify 
metabolites in intact tissues (3-D tissues). However, NMR-based metabolomics has lower 
sensitivity and requires a greater sample volume. Mass spectrometry-based methods (GC 
or LC-MS) are usually used as complementary methods, depending on the molecular 
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polarity (polar or nonpolar), sample solubility, and choice for targeted or untargeted 
metabolomic analyses (3, 5, 27). The untargeted approach means the study of the whole 
set of metabolites in a given sample, while the targeted approach refers to the 
identification of a specific group. The untargeted approach is normally employed to 
identify new potential predictor biomarkers, and a targeted approach is commonly used 
for validation analysis to measure previously known metabolites in a given sample (3, 9). 
Especially in untargeted studies, there is a high possibility of returning to the biochemical 
reactions and to the metabolic pathways with which the identified metabolites are 
involved. This approach would present an opportunity to address complex diseases that 
are related to different biological systems (inflammatory, metabolic, energetic, 
immunologic, etc.). 
Tissues and samples for exploring metabolomics 
The use of appropriate biological samples is a key issue in defining the experimental 
design for metabolomic experiments. Considering pregnancy and childbirth, the available 
biological tissues can come from the mother (plasma, urine, vaginal fluids, milk, and hair), 
the fetus/newborn (amniotic fluid, umbilical cord blood, plasma, urine, meconium, saliva 
and other fluids from the infant), or the placenta. The choice will depend upon each study 
and the investigating aim defined (3, 10). 
The most commonly used biological sample is plasma, which is easy to obtain and rich 
in proteins and metabolites. In biomarker discovery, the final goal is to characterize 
markers that could enable the early identification of high-risk conditions, and the obvious 
and most simple screening test would be a blood sample (3, 10, 23). However, many 
biomarkers are present in low concentrations in plasma, and its study can be optimized 
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by choosing a biological sample closer to the disease process, especially in the discovery 
phase, where a great number of identified biomarkers can suggest relevant conditions 
and pathways involved in the studied diseases (10). 
Urine is the second most studied biological sample for metabolomic assays; it is easy 
to obtain, noninvasive and, like blood, an integrative biofluid. However, the profiling of 
urine is challenging overall with a wide-ranging variation in metabolite concentrations and 
fluctuating dilutions due to urine volume alterations. Implementing appropriate statistical 
analysis methods are pivotal (28). 
There is an opportunity for specific metabolomic approaches to study changes in 
samples closer to diseases or samples clearly influenced by or specific to pregnancy. 
Vaginal secretions have been studied to understand markers of labor and preterm labor, 
considering that they can represent changes occurring in the vagina, cervix and adjacent 
overlying fetal membranes (10, 29). There are still challenges in choosing the best way to 
collect samples and in considering the influences of individual characteristics, protein 
variations and contamination from previous intercourse or bleeding. 
Amniotic fluid (AF) is another potential target for studying metabolomics during 
pregnancy. Collection of AF depends on an invasive and specialized procedure early during 
gestation, with potential risks of miscarriage, infection, preterm labor, or bleeding; 
however, AF is considered to have the best predictive value of metabolic profiling for 
malformed fetuses (10, 30-32). It can also be obtained during labor or prior to delivery, 
and the discoveries arising could justify and overcome potential risks (33). The use of cord 
blood has mostly been addressed in neonatal research, with great potential in perinatal 
asphyxia as a noninvasive method to investigate and understand different conditions in 
the neonate after delivery (34). 
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A very important limitation on the use of plasma and most other biofluids is that the 
metabolites found are greatly dynamic and influenced by diet and immune status; 
furthermore, one isolated sample may not reflect the actual profile. There are standard 
procedures for sample collection and storage that need to be respected to guarantee 
accurate results, and immediate processing and freezing are mandatory (3, 35, 36). 
An additional source for metabolomic studies, considering pregnancy and childbirth, is 
the placenta. There are, however, important considerations regarding how to sample and 
peculiar difficulties in managing and controlling for confounding factors such as route of 
delivery, duration of labor, sex of the baby, and the time between delivery and sampling 
and storage for diverse assays (37). The study of the placenta may play a relevant role in 
the discovery phase and might help elucidate the involved mechanism and 
pathophysiology of conditions complicating pregnancy. 
The search for biomarkers that can possibly be identified in an easy source of tissue, 
with no risks during pregnancy, that are noninvasive to obtain and store and, most 
importantly, that are able to represent long-term metabolite profiles has motivated 
researchers over the years. Hair metabolomics can provide these advantages and has 
great potential, with recent interesting results for predicting FGR (22). 
Preterm birth 
PTB is defined as childbirth before 37 weeks of gestation, and the real mechanisms of the 
spontaneous onset of preterm labor/rupture of membranes involved in its occurrence are 
still unknown. Uterine distension, decidual hemorrhage, stress, autoimmune, infection, 
inflammation, environmental, behavioral and socioeconomic factors are some of the 
hypothetical remarkable conditions linked with PTB (38). The identification of risk factors 
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related to PTB has been studied for decades, but the complexity and dynamism of PTB 
development seem to require a multifactorial approach (4). The attempt to identify 
biological and sociodemographic markers capable of identifying high-risk pregnant 
women still has not achieved reasonable results. The only new screening and 
intervention-based recommendation for PTB prevention discovered in the last two 
decades is the second-trimester transvaginal measurement of cervical length and vaginal 
progesterone for women with a short cervix (39, 40). Further studies on cervical 
remodeling and associated biomechanical mechanisms must be performed (41). 
Compared to isolated biological markers, the metabolomic approach seems to be 
superior for demonstrating the organism function (3, 4, 24, 25, 38). In 2010, Romero and 
colleagues published a study evaluating metabolites from processed and stored AF (42). 
They identified women who had spontaneous preterm labor (PTL) with intact membranes 
and had been submitted to transabdominal amniocentesis to assess the microbial state 
of the amniotic cavity and/or fetal lung maturity in three facilities. According to their 
pregnancy outcomes, women were divided into three groups: 1) with PTL and delivery at 
term; 2) with PTL, with preterm delivery and without intra-amniotic 
inflammation/infection (IAI); 3) with PTL, preterm delivery and IAI. Using phase 1 to 
identify potential metabolites that could differ from subgroups and phase 2 to validate 
the results of discrimination, the authors demonstrated that the metabolic profile from 
AF achieved 96.3% and 88.5% accuracy for phase 1 and 2, respectively, to predict the 
subgroups. Moreover, they also showed differences in the presence of amino acids (AAs) 
and carbohydrates in the AF samples in the subgroups. The results can contribute to 
developing AF tests for PTB, to new interventions for high-risk populations or to 
understanding PTB syndrome. 
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Menon et al. selected 50 African American women who participated in the Nashville 
Birth Cohort and collected AF samples during labor: 25 with PTB (before 34 weeks, 
excluding pPROM) and 25 with full-term births (33). Approximately 350 metabolites were 
identified in the AF using LC/MS and GC/MS mass analyzers. The metabolites were 
categorized following their participation in different biochemical pathways, such as 
histidine, steroids, xanthine, acetaminophen, bile acids, fatty acids, detoxification of 
xenobiotics and cosmetic-formulation chemical metabolism. The mean predictive 
accuracy to discriminate PTB from full term was 90%, with 14.2% false negatives. Although 
the predictive performance of this set of metabolites deserves additional validation, 
valuable information regarding the possible relationship between maternal liver function 
and PTB was reported. 
 In general, the collection of AF is an invasive procedure, and its use for metabolomic 
analysis is usually reserved when amniocentesis is indicated for another purpose, 
especially in women with higher risk for spontaneous onset of preterm labor. The reasons 
must be taken into account to avoid sampling bias, such as risk for fetal malformation or 
intra-amniotic cavity infection. Graça et al. and Diaz et al. conducted metabolomic studies 
related to maternal and fetal outcomes, such as GDM, fetal malformations/chromosomal 
disorders, PTB and pPROM (32, 43). Urine, blood and AF samples were collected from 
women at high risk for fetal malformations/chromosomal disorders. Therefore, the 
different concentrations of allantoin, myo-inositol, alanine, citrate and 2-
hydroxyisobutyrate identified in the PTB group might not be generalized. 
More recently, Ghartey et al. conducted a nested case-control study inside a 
prospective cohort to identify cervicovaginal (CV) biomarkers related to spontaneous PTB 
(29). CV samples were collected at 20 weeks – 23 weeks + 6 days (first visit - V1) and 24 
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weeks – 27 weeks + 6 days (second visit – V2) gestational age intervals. The CV 
metabolome was analyzed from 10 women who had spontaneous PTB and 10 women 
who had term births using ultra-performance liquid chromatography-tandem mass 
spectrometry (UPLC/MS) and GC/MS. More than 300 metabolites were identified in the 
CV samples, and women with PTB had a distinct CV metabolome compared with that in 
samples of women with term birth. Considering V1 samples, more than half of the 
identified AAs were decreased in PTB samples, and methyl-4-hydroxybenzoate, an 
antimicrobial agent, was increased in the CV samples of women with term birth. Thus, an 
increased presence of sialic acid in CV samples of PTB women in V2 samples and 
downregulation of carbohydrates were identified. Sialic acid plays a role in immune 
function, specifically on viral entry into the cell. Therefore, there were remarkable 
differences in CV metabolic markers in women with PTB, enabling the study of some 
metabolic pathways related to PTB occurrences, such as cervicovaginal protein hydrolysis, 
inflammation, carbohydrate metabolism and viral/bacterial infection modulation. 
Metabolomic analyses can be performed using different technical approaches depending 
on the spectrum of metabolites to be identified. These differences can modify the 
sensitivity of metabolite identification. Thomas and colleagues conducted a metabolomic 
analysis to identify discriminatory metabolites in CV fluid in women with PTB and term 
birth (44). In this study, the identification of AAs, organic acids and fatty acids was 
prioritized, but the number of metabolites identified was much less than that in Ghartey’s 
study. No significant difference was noticed between the CV metabolites of women with 
PTB and term birth (44). 
Nonetheless, the collection of AF during preterm and term labor brings up a discussion 
of what benefits each period of sample collection during pregnancy may provide and the 
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possible confounders. There are insufficient data to clarify if different metabolomic 
profiles during preterm labor are related to the mechanisms of preterm labor 
determinism or to the proper maternal and/or fetal metabolism that is characteristic of 
each gestational age period (45, 46). A longitudinal targeted metabolomic profile 
conducted by Lindsay and colleagues showed AAs, nonesterified fatty acids, polar lipids, 
tricarboxylic acid cycle intermediate metabolic changes in healthy pregnancies (47). HPLC-
MS, LC-MS and flow-injection mass spectrometry analyses of plasma samples 
demonstrated the variance in amino acid concentrations across three set points of 
pregnancy (at the first, second and third trimester). The sum of the nonbranched chain 
essential AAs and tricarboxylic acid cycle intermediates increases from the first to the 
third trimester, whereas free carnitine and acetylcarnitine decrease. The findings seem to 
be consistent with placental and fetal mediation of AAs during pregnancy, with energetic 
synthesis and nitrogen cycle changes due to anabolic and catabolic phenomena. 
There are complex metabolic cycles mediating fetal development, pregnancy 
homeostasis, autoimmune regulation, and placental multiple functions. There are many 
options of samples, a period of collection and metabolomic analyzers to study preterm 
syndrome, and each one might result in innovative contributions (3, 4). The collection of 
samples during the preclinical phase (asymptomatic women) may provide early 
identification of higher-risk women as well as lightening trigger mechanisms of preterm 
labor. Another way to elucidate those triggering mechanisms is collecting samples during 
labor or from the neonates, demonstrating the resulting PTB metabolic profile (48-50). 
Multiethnic validation of current findings is required to move forward on preterm 
prediction and prevention. Therefore, international collaborative studies are essential, 
shortening the time and financial resources (38). 
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Fetal growth restriction 
Intrauterine growth restriction is an obstetric disorder characterized by the failure of a 
fetus to achieve its growth potential (51). It has a multivariate etiology, which includes 
genetic factors, infections, or uteroplacental insufficiency (52, 53). This pathological 
condition is part of a broad spectrum, composed of “Small for Gestational Age” (SGA) 
fetuses, which includes all fetuses whose weight is below the 10th percentile for 
gestational age from the reference ranges applied to the specific population or based on 
customized charts (51, 54). Some of them are physiologically small (constitutional) and 
therefore are not associated with adverse outcomes (52, 53). The incidence of FGR is 
approximately 4 - 8% in industrialized countries and 6 - 30% in low- and middle-income 
countries (55). 
FGR is associated with perinatal complications such as prematurity, fetal death and 
chronic metabolic disease in adulthood, such as diabetes mellitus type 2, hypertension 
and metabolic syndrome (56). The prenatal detection of fetuses with FGR is still a 
challenge in daily obstetric practice, and among low-risk pregnancies, the detection rate 
is approximately 15% (56). Whereas birth weight is a determinant of mortality and 
neonatal morbidity, much interest has been raised by research on new and effective 
means for the early diagnosis and/or prediction of FGR and the improvement of the 
clinical management (53). 
Some single parameters have been tested or, when combined, compose a 
multifactorial model. The isolated analysis of serum adiponectin in pregnant women 
between 11 and 13 weeks, performed by Nanda and colleagues in 2011, revealed the 
inability of that factor to predict FGR because the concentration of adiponectin was the 
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same in both the group with and the group without FGR (57). In an analysis of a 
multifactorial model, a group in the United Kingdom tested the association of mean 
maternal blood pressure, nuchal translucency, chorionic gonadotropin, serum pregnancy-
associated plasma protein (PAPP-A), pulsatility index of the uterine arteries, placental 
growth factor (PlGF), placental protein 13, and disintegrin and metalloprotease 12 
(ADAM12). This model showed a 73% detection rate for FGR, with a false positive rate of 
10% (58). In a second analysis, associating the pulsatility index of the uterine arteries, 
average maternal blood pressure, PAPP-A, and PlGF, the group achieved a 52.3% 
detection rate of FGR, with 10% false positives (59). However, the main challenge of this 
analysis is the great influence imposed by the frequent coexistence between preeclampsia 
and FGR in their results (60). 
More recently, a meta-analysis evaluating the predictive ability of uterine artery 
Doppler performed in the first trimester achieved a sensitivity of 39.2% for cases of FGR 
established early (61). In this search for effective screening tools to accurately identify 
women at the highest risk of FGR, metabolomics has emerged as a new science, seeking 
biomarkers that can compose a predictive model, which could provide early diagnosis of 
FGR, with a reduction in morbidity and neonatal mortality. These studies have evaluated 
the metabolomes of biofluids (urine and blood) or hair for comparison between fetuses 
with FGR and fetuses with adequate weight for gestational age. 
In 2010, Horgan and colleagues studied venous cord blood from women exhibiting the 
delivery of a healthy singleton fetus and from women with a suspected diagnosis of SGA 
(birth weight below the 10th percentile for gestational age) (62). Parallel to this analysis, 
women at 15 weeks of gestation underwent the analysis of plasma samples. Forty women 
who delivered SGA babies were matched to 40 controls who had uncomplicated 
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pregnancies. The metabolomics of both analyses showed 29 metabolites in very different 
concentrations between the comparison groups (adequate for gestational age vs SGA). Of 
these, 19 metabolites were identified as predictors of the model and applied to analyses 
of cord blood and maternal peripheral blood. In the latter case, the predictive model 
showed an area under the curve (AUC) of 0.9, which represents a robust predictive model 
of presymptomatic SGA (62). 
Dessi and colleagues studied the urine metabolic profiles of neonates with FGR and 
compared them with controls to define the metabolic patterns associated with this 
pathological condition. They observed a higher concentration of metabolites such as myo-
inositol (also found by Barberini et al. (63)), sarcosine, creatine, and creatinine in FGR 
neonates. An increase in these metabolites in the urine is observed in states of 
hypercatabolism, as is the case with fasting, and there is a lower level of protein synthesis 
(64). On the other hand, Maitre and colleagues found decreased levels of tyrosine, 
acetate, trimethylamine, and formate in maternal urine samples of the late first trimester 
(65). These molecules can play a role in carbohydrate and fat metabolism (acetate), 
function as precursors of neurotransmitters (tyrosine), act as mediators of cell death due 
to enhanced levels of reactive oxygen species (formate), or simply be markers of 
vegetable intake (trimethylamine). These findings highlight the complexity of FGR 
pathogenesis and provide some clues that metabolic changes can take place as soon as 
11 weeks of gestation. Recently, Sulek and colleagues evaluated the metabolome of hair 
collected between 26 and 28 weeks from 41 healthy pregnant women whose fetuses 
developed FGR (birth weight below the 10th percentile for gestational age) and 42 women 
whose fetuses had adequate birthweight for gestational age. Thirty-two discriminatory 
metabolites were found, mostly AAs and fatty acids. Five of these metabolites composed 
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a predictive model, which showed an extremely high AUC of 0.998 (22). However, the 
most severe cases of FGR can be diagnosed as early at 26 weeks of pregnancy, and 
perhaps 26-28 weeks would not be a suitable interval to screen for FGR in some women. 
FGR has a multifactorial etiology, apparently resulting from the interaction between 
a complex biochemical profile and impaired placental perfusion, which negatively impacts 
the function of transporting nutrients. The knowledge of metabolism for this condition is 
still scarce. Therefore, metabolomics could contribute to a better understanding of the 
pathophysiology of FGR and to a more precise definition of this syndrome. An early 
detection of fetuses at a higher risk for truly pathological growth restriction or a diagnosis 
of FGR among pregnant women could improve perinatal outcomes if appropriate 
interventions can be implemented during prenatal care. 
Pregnancy hypertensive disorders 
Preeclampsia (PE) is still a challenging condition in obstetrics practice, involving different 
clinical manifestations (i.e., early- and late-onset PE) that share the physiopathological 
aspect of inadequate trophoblast invasion of the maternal vasculature early in pregnancy. 
There are already known clinical (66) and ultrasonographic risk factors (67): the former 
can be identified at booking, and the latter can be better screened at the 2nd trimester 
(uterine artery waveform). Although easily and almost universally accessible, the 
strongest clinical risk factor history of preeclampsia cannot be applied to nulliparous 
women, which is a target group for PE (68). In addition, the good performance of uterine 
artery Doppler velocimetry requires availability of equipment and operator expertise (69). 
Therefore, great effort has been made to identify biomarkers that could be applied to 
diagnostic, prediction, or prognostic factors (i.e., soluble endoglin, PIGF and pregnancy-
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associated plasma protein-A PAPP-A) (70). However, these biomarkers still are not fully 
and easily available for clinical practice and some of them can only be evaluated at the 2nd 
or 3rd trimester when there are few therapeutic alternatives for these women. 
Considering poor placentation and systemic endothelial activation in PE (71), some 
authors have been searching for metabolites that could explain the pathogenesis of the 
disease. Kenny et al. found increased levels of uric acid, which is related to ischemic 
conditions, and 2-oxoglutarate, or α-ketoglutaric acid, an intermediate of the citric acid 
cycle (or tricarboxylic acid cycle), which is increased with limited oxidative capacity (72). 
These metabolites could reinforce the hypothesis of placental hypoxia in preeclampsia, 
and low levels of taurine could be a marker of defective trophoblast invasion in early-
onset PE (71, 73). 
It is interesting to note that alanine and glutamic acid levels are increased in women 
already diagnosed with PE (72) and early in pregnancy (74). Both alanine and glutamic acid 
are nonessential AAs and neurotransmitters. It seems that α-glutamate excitatory effects 
play an important role in membrane depolarization observed in epileptic seizures (75), 
which sheds light on the understanding of eclampsia. Alanine represents the main muscle 
energy source and has an inhibitory action in the brain, as does taurine (75). Renal 
function may also be affected in PE (76), and augmented levels of creatinine have been 
observed, either in the 1st (77) or in the 3rd trimester (72). 
Omics studies have found many metabolic disturbances in preeclamptic women, such 
as disorders in carnitine, AAs, carbohydrate or fatty acid pathways, by diverse platforms. 
However, the available studies have used small sample sizes and do not control for 
pregnancy complications, such as SGA infants (78), fetal malformations or PTB (31), which 
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can also show metabolic profile alterations. Additionally, it would be enlightening if 
longitudinal studies could perform data collection at different gestational ages. 
On the other hand, it is notable that the AUC, sensitivity, and specificity of predicting 
early or late PE (71, 77) can be improved when regression models mix metabolites with 
clinical factors, including weight, ethnicity, and mean arterial blood pressure. A first-
trimester predictive model that showed promising results, with an AUC of 0.835 in a 
validation study, enrolled 50 women with early preeclampsia and 108 matched controls 
(79), which is still a modest number of participants. Therefore, it is fundamental, in the 
near future, to perform a study involving a heterogeneous group of nulliparous low-risk 
pregnant women, taking into account that this is the set with the highest risk of 
preeclampsia. The understanding of the metabolome profile of preeclampsia may 
contribute not only to prediction but also to improving the knowledge regarding cellular 
and molecular pathophysiology, providing better management of preeclampsia and, 
ultimately, better maternal and perinatal outcomes. 
Gestational diabetes mellitus 
Gestational diabetes mellitus (GDM) is diabetes that is first diagnosed in the second or 
third trimester of pregnancy that is not clearly either preexisting type 1 or type 2 diabetes, 
according to the American Diabetes Association (80). It is related to important maternal, 
fetal, and neonatal outcomes and is a high-risk factor for diabetes mellitus later in life 
(80). There are still controversies regarding diagnostic criteria, treatment and monitoring 
of GDM, but recent advances in omics studies can provide clues about the maternal 
metabolic profile in normal and diabetic affected pregnancies and may be helpful in 
understanding and predicting the disease. 
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Normal pregnancy is characterized by progressive insulin resistance (81) and increased 
levels of lipoproteins and lipoprotein-cholesterol (82), and both phenomena increase 
glucose levels. Fat stores can be used as an energy source by the mother, so glucose can 
reach the fetus, which is the main energy source of the fetal unit and is easily transported 
through the placenta by facilitated diffusion (81, 82). GDM, however, seems to promote 
a shift from gluconeogenesis to ketone body production, which is probably why fasting 
acylcarnitine ester levels are lower and 3-hydroxybutyrate are higher in diabetic 
compared to normal pregnancies (83). 
In urine samples of 2nd-trimester diabetic pregnancies, Diaz et al. (2011) found 
increased levels of 2-hydroxyisobutyrate (43). This observation reinforces the association 
between GDM and type 2 diabetes (81), since this biomarker has also been identified in 
diabetic patients, reflecting disturbances in free fatty acid metabolism (84). Urinary 
excretion of 3-hydroxyisovalerate also appears to be increased in GDM (43) and reflects 
the reduced activity of β-methylcrotonyl-CoA carboxylase, a biotin-dependent enzyme 
(85). It is important to consider the (1) relationship between previous diabetes and 
congenital malformation (80) and (2) the possible teratogenic effect of biotin deficiency 
(85). This finding requires further investigation and may be helpful to improve the 
diagnostic criteria and follow-up of GDM. 
Using proton nuclear magnetic resonance (1H-NMR) spectroscopy to study urine 
samples of 1st and 2nd-trimester pregnancies, Sachse et al. (2012) have shown that urine 
citrate increases with higher degrees of hyperglycemia (86). However, they did not find 
any difference in the metabolomic profile between normal and affected women, 
regardless of the diagnostic criteria of GDM, even after normalizing the results to the 
creatinine level or considering that the urine metabolomic profile is influenced by the 
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immediate lifestyle and diet and less by the genetic background. On the other hand, UPLC-
MS identified slightly increased levels of choline in urine in the 2nd trimester of 
prediagnostic GDM women (31). However, as choline was also altered in fetal 
malformations and plays a role in fetal brain development, it seems to be nonspecific for 
GDM (43). 
Hair metabolomics was also investigated as a potential marker for GDM. Baker and 
colleagues analyzed hair metabolites in two different cohorts using samples of women 
who developed GDM matched by BMI to controls with uncomplicated pregnancies. 
Analyzing hair samples collected at the time of oral glucose tolerance testing (24-28 weeks 
of gestation) of 47 Chinese women in each group, the authors found one metabolite 
(adipic acid) that differs significantly between groups and might be potential 
discriminatory (87). Using hair samples collected earlier in pregnancy (at 20 weeks) of 
women who participated in the SCOPE study, two metabolites (itaconic acid and cis-
aconitate) had significantly different levels between groups (20 women with GDM and 26 
controls) (88). Although the results are from pilot studies, new potential approaches 
demand investigations in larger datasets. 
Studies have used various metabolomic technologies, in either AF, maternal plasma, 
serum, hair, or urine samples, at various times during pregnancy. Each technique and 
biological sample has distinct properties of sensitivity, specificity, and power to detect 
metabolic changes that affect GDM, and findings are still inconclusive (89). A 
comprehensive overview of this condition could be approached by studies involving 
several biological fluids in different gestational ages and taking into account dietary intake 
and treatment options (89). GDM is a worldwide problem, and its assessment during 
pregnancy can improve gestational and perinatal outcomes. More research is needed to 
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identify metabolites that could be used as biomarkers of disease and to better define this 
condition. 
Maternal and fetal infections 
Metabolomics has also been used for translational research in infectious diseases during 
pregnancy. The possibility of identifying a pattern of metabolites related to the more 
severe condition or to the development of fetal/neonatal sequelae, confirming a 
maternal-fetal transmission and recognizing potential pathological conditions of the fetus 
is a worthy approach, especially when current diagnostics tests are not sufficiently 
sensitive and specific. The current spread of Zika virus infection is a very recent example 
of how challenging the identification of pathophysiological mechanisms and the creation 
of reliable serological tests in some infectious diseases can be. The laboratory testing for 
Zika virus infection guidelines of the WHO demonstrates the difficulty in confirming 
maternal infection for suspected cases with more than one week after onset of symptoms 
or with a fetal diagnosis of neurological impairment in asymptomatic women (90). The 
CDC diagnostic testing recommendations highlight the common cross-reaction with other 
related flaviviruses, such as dengue, chikungunya, and yellow fever viruses (91), calling 
attention to the importance of more reliable tests. 
Recently, Zhou and colleagues demonstrated dynamic changes in the metabolomic 
profile of mice during Toxoplasma gondii infection (92). The authors showed that a set of 
metabolites could discriminate infected samples from controls, showing an AUC of 0.996. 
Fanos and colleagues conducted a metabolomic approach using urinary samples of 
newborns infected by cytomegalovirus and controls (10). The preliminary investigation 
showed that the abundance of a set of metabolites was significantly different between 
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the groups. Various studies related to nonpregnancy infections, such as Haemophilus 
influenzae, dengue, malaria, tuberculosis, and Clostridium difficile, have already 
demonstrated the potential contribution of metabolomics to the pathogenesis, 
mechanisms of adaptation, severity, host response and impairment (93-96). 
Another potential applicability for metabolomic studies is chorioamnionitis, an infection 
that can present not only as a subclinical condition with minimum consequences for 
women or fetuses/newborns but also as a severe infection leading to sepsis and severe 
maternal and neonatal morbidity and mortality (97-101). Chorioamnionitis is a major 
cause of mortality in many countries and lacks reliable markers for early diagnosis (97, 
102, 103). For instance, women with PROM, especially if preterm, are at higher risk for 
infection, and currently available markers collected from blood, vaginal secretions or AF 
have not proven to be highly accurate in the prediction or early diagnosis of 
chorioamnionitis (97, 102, 104-108). In this case, a false positive test for infection can lead 
to unnecessary interventions, such as prematurity, and a false negative test might 
determine the development of neonatal sepsis. Therefore, not only a timely identification 
of infection but a more accurate diagnosis is crucial to prevent severe adverse outcomes. 
A few metabolomic studies have been conducted to address the early identification of 
women with amniotic infection. A metabolomic analysis of AF from 40 women with 
rupture of membranes or preterm labor was performed, and the results were compared 
according to the microbiological/histological status of infection and neonatal outcomes 
(infection and perinatal brain injury) (109). Several metabolites of more than 8 metabolic 
pathways were identified as potential markers of chorioamnionitis. The sphingolipid 
metabolic pathway was the most important group of metabolites, showing the strongest 
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discriminant power with an AUC of >0.99% and >0.95% to discriminate cases with and 
without brain injuries in chorioamnionitis cases, respectively. The authors presented a set 
of metabolites as potential best biomarker candidates, discussing many possible 
correlations and underlying mechanisms related to chorioamnionitis. However, they also 
clarified that the external validation of findings is limited due to the use of specific 
methodology, excluding some phenotypes of women and newborns to create a more 
homogenous comparison analysis. According to the authors, this homogeneity of 
outcomes is not what is found “in real life”. 
A study from Romero and colleagues also demonstrated that metabolomic profiling is 
useful for discriminating cases of preterm delivery with and without intra-amniotic 
infection (42). Another case-control study, this time using lipidomic analysis of the AF, also 
identified potential markers for amniotic infection (110, 111). Both findings still require 
further validation. 
Metabolomic studies assessing potential makers for chorioamnionitis usually use AF 
samples collected after the rupturing of membranes through amniocentesis in sites where 
this invasive procedure is generally standard to address amniotic infection. The AF is a key 
tissue for maternal and perinatal research, considering its interactions with the placenta, 
mother, and fetal tissues, providing RNA, DNA and metabolites of all three components 
(24, 112). Nevertheless, more studies using blood, urine, hair, or vaginal secretion markers 
might be important to develop a more reproducible and less invasive method to 
investigate chorioamnionitis. 
Severe maternal morbidity and other conditions 
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Maternal complications during pregnancy, childbirth and postpartum periods are part of 
a continuum or spectrum of morbidity classified from mild to severe. Depending on the 
severity, the morbidity can be potentially life-threatening and put women at risk for 
“maternal near miss” or maternal death. Pragmatically, maternal near miss is defined as 
an experience of near death that can be identified considering aspects of clinical, 
laboratory and management-based criteria, according to the World Health Organization 
(113). 
Delays in preventing, diagnosing, or treating maternal complications are related to 
poorer maternal outcomes (114). Therefore, the early identification of severe maternal 
morbidity might provide a window of opportunity to save mothers from short- and long-
term adverse outcomes. The main causes of maternal mortality are related to 
hemorrhage and hypertensive complications (101), followed by sepsis, abortion, 
embolism, and other indirect causes. Clinical tools are being studied to identify, measure, 
and monitor maternal morbidity (113, 115, 116). Ordinarily, the clinical tools are 
composed of maternal symptoms and signs and clinical support characteristics. This 
means that the diagnosis of maternal morbidity occurs in an advanced stage of severity. 
Despite being a great advance, the use of the definition of potentially life-threatening 
conditions and maternal near miss would be even more useful to prevent maternal death 
and short- and long-term adverse consequences, with earlier diagnoses. 
The clinical tool called the Sequential Organ Failure Assessment (SOFA) can be used to 
identify severe maternal morbidity. However, even this well-known and widely used tool 
demands a certain degree of organ dysfunction as a proxy for prediction. Metabolomic 
analyses could be an interesting approach to early identify severe maternal morbidity 
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(life-threatening conditions and maternal near miss). The identification of common 
pathways of preclinical disorders related to maternal morbidity could be useful, widening 
the window of opportunity to act before severe organ dysfunction. Some studies have 
already described altered metabolomic profiles related to acute heart failure induced by 
shock, severe sepsis, and septic and hemorrhagic shock (117-119). The results show that 
metabolomic profiles can discriminate degrees of severity and may be used for early 
diagnosis. Therefore, such profiles might be useful to predict organ failure or systemic 
inflammatory response syndrome in pregnant women as well, independent of the cause 
of morbidity. 
Based on the same idea, the identification of a metabolomic pattern directly related to 
the main causes of severe maternal morbidity, hypertensive and hemorrhage disorders 
seems to be tangible. Aberrant placentation, for instance, is related to hypertensive and 
hemorrhagic complications during pregnancy. The abnormal remodeling of spiral arteries 
leads to ischemic placental disease mediated by many inflammatory, immunologic, and 
oxidative stress pathways (120, 121). A discovery of metabolomic analyses using samples 
from women with potentially life-threatening conditions, maternal near miss, and non-
complicated pregnancies might demonstrate whether it is possible to identify common 
metabolites related to maternal morbidity. 
Discussion 
The 21st century has had remarkable innovations in technology, especially in service 
industries, such as communication and informatics involving smartphones and high-
quality wireless networks, changing the way people live and interact. Modification is 
usually required by the need for new ways to deal with a competitive routine and a large 
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amount of information in different parts of the globe, all of which is part of the new era 
of globalization phenomena. There is a classic theory about innovations and economic 
growth based on creative destruction (122). Briefly, one of the bases of this theory is the 
stationary state, which is the gap period between the development of new research and, 
consequently, new innovations. This state can lead to innovation mostly depending on the 
rate of interest and the number and impact of available innovations. Translating this 
concept to our area of interest, we could say that research on maternal and perinatal 
health urges innovation. 
Maternal and child health are priority topics of the third sustainable development goal 
(2). Obstetric complications, such as PE, PTB, FGR, and GDM, have a major impact on 
maternal and perinatal health because they can lead to short- and long-term 
consequences for women or newborns, from childhood to adulthood. Biological 
biomarkers seem to be essential for the development of predictive models because they 
play an important role in the pathophysiology, whether in cause or in consequence 
mechanisms. The integrated study of the biological interactions in an organism (systems 
biology) has led to omics-based research, which has been demonstrated to be a promising 
and useful approach to assess such complex syndromes (3, 38). To yield reliable and 
reproducible information, samples must follow the specific and detailed methodology for 
processing and storage, and data on these details are key to allow comparisons between 
studies and advances in metabolomic research in maternal-fetal medicine. 
Metabolomics seems to be the most reasonable approach to studying the majority 
of obstetrical syndromes, considering the costs, confounders, analytical techniques, 
output data generation and the possibility of addressing final pathways for the underlying 
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mechanisms involved in the occurrence of each complication. Metabolomic studies have 
generated optimistic results so far, widening the opportunity to explore new 
methodologies for sample collection, preparation, and analysis. Apart from that, the 
technique requires validation of the initial findings of pilot studies in larger datasets, using 
numerous multiethnic population cohorts. Thus, metabolomics might be a sensible way 
to move forward in the prediction and prevention of maternal complications, achieving a 
significant impact on people’s lives as the 21st-century technology revolution may have 
done. 
The current review aimed to present how metabolomics has become a promising 
approach for maternal and perinatal health research in recent years, showing (especially 
for a nonexpert audience) the rationale behind this high-technology method in the omics 
science perspective and its potential translational application. The main maternal 
complications during pregnancy, such as preeclampsia, PTB, FGR and GDM, have 
multifactor complex etiologies, and certainly, an expressive number of unknown 
underlying factors, but the pathways related to the occurrence of these complications are 
not yet clarified. Such complexity makes their prediction extremely challenging also 
considering that the pathophysiology might involve genetic and environmental adaptive 
mechanisms from maternal and fetal components. Metabolomics is the study of the 
metabolites in a given sample, and it is the closest correspondent to the cell, tissue or 
organism function compared to other omics sciences, such as genomics, transcriptomics 
or proteomics. Metabolomic studies of maternal complications during pregnancy can be 
a valuable method to explore biomarkers in different sources of samples, although 
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advances in reproducible analytical procedures and external validations in larger datasets 
are still necessary. 
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Figure 2. Mass spectometry spectrum-scheme of metabolites output data 
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ABSTRACT 
Introduction: Preterm birth (PTB) is the leading cause of neonatal mortality and short- 
and long-term morbidity. The aetiology and pathophysiology of spontaneous PTB are still 
unclear, which makes the identification of reliable and accurate predictor markers more 
difficult, particularly for unscreened or asymptomatic women. Metabolomics biomarkers 
have been demonstrated to be potentially accurate biomarkers for many disorders with 
complex mechanisms such as PTB. Therefore, we aim to perform a systematic review of 
metabolomics markers associated with spontaneous PTB. Our research question is “What 
is the performance of metabolomics for predicting spontaneous preterm birth in 
asymptomatic pregnant women?” 
Methods and analysis: We will focus on studies assessing metabolomics techniques for 
predicting spontaneous preterm birth in asymptomatic pregnant women. We will conduct 
a comprehensive systematic review of the literature from the last 10 years. Only 
observational cohort and case-control studies will be included. Our search strategy will be 
carried out by two independent reviewers, who will scan title and abstract before carrying 
out a full review of the article. The scientific databases to be explored include PubMed, 
MedLine, ScieLo, EMBASE, LILACS, Web of Science, Scopus, and others.  
Ethics and dissemination: This systematic review protocol does not require ethical 
approval. 
We intend to disseminate our findings in scientific peer-reviewed journal, the Preterm 
SAMBA study open access website, specialists’ conferences, and to our funding agencies. 
Registration details: This protocol is registered in PROSPERO platform (code 
CRD42018100172). 
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Keywords: preterm birth, spontaneous preterm birth, metabolomics, biomarkers, 
prediction, metabolome. 
Strengths and limitations of this study 
 This systematic review protocol takes into account some important aspects 
regarding conducting a systematic review about spontaneous preterm birth and 
metabolomics such as the criteria used for defining spontaneous preterm birth, 
different population risk stratification, method used to estimate gestational age, 
and metabolomics techniques details. 
 Two independent reviewers are responsible for searching and selecting studies, as 
also extracting data, and a third reviewer will resolve any disagreement. 
 If possible, proper statistical methods will be applied to investigate metabolomics 
accuracy in predicting spontaneous preterm birth. 
 Possible limitations to this review include the different criteria applied for defining 
spontaneous preterm birth, and the diverse population risk stratification. 
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INTRODUCTION 
Spontaneous preterm birth (sPTB) is the leading cause of perinatal mortality and short- 
and long-term morbidity [1,2]. It is defined as birth that occurs before 37 weeks gestation 
due to spontaneous onset of labour or preterm premature rupture of membranes 
(pPROM) [3,4]. Several pathways and mechanisms linked with preterm birth have been 
proposed including, neuroendocrine, vascular, immune-inflammatory, and behavioural 
processes [5]. More specifically, several markers associated with uterine 
distension/contraction, decidual inflammation/infection and activation of hypothalamic–
pituitary–adrenal axis had been studied in the past decades [5,6]. However, no single 
marker or combination of markers has been found to be accurate enough for predicting 
sPTB [7–10]. History of previous preterm birth, cervical length at second trimester and 
cervico-vaginal fetal fibronectin are the most promising clinical tests for predicting 
spontaneous preterm, but they seem not to be clinically useful for asymptomatic women. 
Sensitivity of short cervical length (<25mm) and high cervico-vaginal fFN (>50ng/ml) are 
around 33-36% and 46%, respectively [11–13]. 
Preterm birth is a complex and multifactorial syndrome that possibly has a long pre-
clinical phase, maternal and fetal interactions, genetic and environmental influences, and 
adaptive mechanisms [14,15]. These challenging aspects, and the presence of still 
unknown underlying mechanisms, are the main limitations for the identification of an 
accurate predictor for sPTB [16–18]. None of the predictors used in clinical practice, such 
as previous history of preterm birth, infection (vaginal and urinary contaminants), 
fibronectin and transvaginal ultrasonography cervical length demonstrated exceptional 
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accuracy for predicting spontaneous preterm birth [7]. An exploration of innovative 
approaches is urgently required. 
Metabolomics is the study of metabolites, through identification and quantification of 
low-weight molecular particles, i.e. tens to hundreds thousands of intermediate products 
and substrates of systems biology chemical reactions [19,20]. This novel approach has 
been applied for identifying biomarkers and underlying biochemical pathways associated 
with complex obstetrical syndromes as preeclampsia, fetal growth restriction, gestational 
diabetes and preterm birth. In contrast to other “Omics Sciences” techniques, 
metabolomics is more closely associated with the phenotype of the disease and might 
thus identify a more robust and reliable set of predictors [21]. Importantly, implementing 
an adequate Omics experimental design is crucial for metabolomics studies. Using 
different baseline population (asymptomatic vs symptomatic or low- vs high-risk women 
for developing sPTB), study designs (prospective cohorts, case-control or cross sectional 
studies), sources of samples (amniotic fluid, vaginal fluid, blood, urine, hair, etc) and the 
timing of sample collection each have significant effects on study findings and the 
consequent interpretation and contribution to the current gap of knowledge [19].  
Different reviews collating scientific knowledge regarding preterm birth 
biomarkers/predictors has been conducted. Different methodology approaches has been 
applied so far, including narrative, systematic and umbrella reviews, a more 
comprehensive review that includes not only original studies but also other reviews [7,22–
24]. At the best of our knowledge, there is no systematic review on metabolomics 
markers. Therefore, we aim to conduct a systematic review of original studies 
investigating the use of metabolomics biomarkers for predicting spontaneous preterm 
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birth in asymptomatic pregnant women. This protocol describes the methods that will be 
applied in our systematic review. 
METHODS AND ANALYSIS 
The current systematic review proposal will be conducted, written and published 
following the Preferred Reporting Items for Systematics Reviews and Meta-Analyses 
(PRISMA-P) recommendations [25].  Also, it is properly registered at PROSPERO platform 
– code CRD42018100172. 
Review question 
What is the performance of metabolomics for predicting spontaneous preterm birth in 
asymptomatic pregnant women? 
Eligibility Criteria 
Original cohort or case-control studies involving asymptomatic pregnant women at the 
moment of sample collection (exposure) and with samples analysed using metabolomics 
techniques. Studies will be excluded if (1) they are cross-sectional studies, clinical trials, 
editorials, letter to editors, case reports, expert opinions, commentaries, or any type of 
review; (2) they describes only experimental studies with animals; or (3) they are 
duplicated data (e.g. data published in conferences proceedings and, then, published 
again in scientific journals). In this case, only the most complete publication will be 
considered, after comparing and confirming that the same technique and metabolites 
were explored. Studies published from 2008 to 2018 will be considered, and there will be 
no language restriction. Before submitting this systematic review for publication, we will 
rerun the search strategy to identify new studies that have been published after 
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performing the first round of search. 
Participants 
The current review is interested in evaluating the performance of metabolomics 
biomarkers for spontaneous preterm birth in asymptomatic pregnant women, which may 
contribute to clinical practice, potentially providing information regarding onset of 
preterm labour. Nevertheless, we aim to identify studies addressing only early predictors 
collected from women who are in an early preclinical stage, which might contribute to a 
wider window of opportunity for interventions and also to develop a widely reproducible 
screening test. Asymptomatic pregnant women should not have regular uterine 
tightening/contractions or signs of rupture of membranes (i.e. watery discharge). In 
addition, the study should preferably have a standardized definition of spontaneous 
preterm birth, the outcome of interest. 
Information Sources 
The search will be held in the following databases: PubMed, EMBASE, Scopus, CINAHL, 
and Web of Science, BVS/BIREME, which includes the Latin American and Caribbean 
Health Sciences Literature (LILACS), Medline and the Scientific Electronic Library Online 
(Scielo). In addition, secondary sources of original studies will be explored such as Google 
Scholar, hand-held searching of the reference list of eligible studies, conference 
proceedings, and contact with authors when necessary. 
Search Strategy 
The following terms will be used in our search strategy for the different scientific 
databases: (preterm birth, premature birth, premature infant, premature labor, 
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extremely premature infant, premature obstetric labor, spontaneous preterm birth, 
extreme preterm birth, late preterm birth, moderate preterm birth, preterm premature 
rupture of membranes, preterm delivery, PROM, sPTB, preterm PROM, pPROM, p-PROM) 
AND (metabolomic*, metabonomic*, metabolit*, lipidomic*, H NMR, proton NMR, 
proton nuclear magnetic resonance, liquid chromatogra*, gas chromatogra*, UPLC, ultra-
performance liquid chromatograph*, ultra-performance liquid chromatograph*, HPLC, 
high performance liquid chrormatograph*, high-performance liquid chrormatograph*) 
AND (pregnan*, antenat*, ante nat*, prenat*, pre nat*) (Supplementary Material). 
Respective adaptations in the syntax of search for each database will be applied 
accordingly. No filters - such as “research in animal’s models” and “reviews” - will be used 
in our search strategy, as it will be excluded according to eligibility criteria. The complete 
search strategy, including Boolean terms, is provided as Supplementary Material. 
Data Management 
We will export search results to a reference manager (Mendeley®). Then, the following 
information will be collected from each study using an appropriate form, which will be 
entered in an Excel® spreadsheet: author’s name, year of publication, country, study 
design, number of participants with and without spontaneous preterm birth, type of 
metabolomics analysis technique (liquid or gas chromatography, nuclear resonance), 
laboratory methods for metabolites data acquiring (targeted or untargeted techniques, 
etc), subtype of preterm birth (spontaneous preterm labour or pPROM), number of 
fetuses (singleton vs multiple), gestational age when samples were collected, source of 
samples (type/site of tissue), low or high-risk for preterm birth (authors criteria used to 
define the population will be collected) and method applied to estimate gestational age. 
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If possible, additional variables related to spontaneous preterm birth categories (delivery 
before 28 weeks and before 34 weeks) will be recorded for secondary analyses. Original 
authors will be contacted to clarify data, when needed. Finally, we will check the 
biochemical class of identified metabolites in Human Metabolome Database (HMDB, 
version 4.0) to explore and synthetize whether there are common biological pathways 
associated with spontaneous preterm birth [20].  
Selection Process 
Two independent reviewers (RTS and RBFG) will be responsible for screening and selecting 
studies initially according to title or abstract. Both researchers will read the full text of 
non-excluded studies to discriminate eligibility. A third reviewer (DFBL) will consider any 
disagreement; additional reviewers (RPJ, PNB and JGC) will be responsible for supervising 
all steps and approving data extraction.  
Data Collection Process 
We will extract search results to a reference manager where all studies will be stored. 
Then, included studies will be placed in a new folder. Finally, we will manually extract data 
of interest from these included studies to an Excel® file. Each reviewer will have their own 
reference manager account, file and folder and discrepant results will be discussed 
together with the third reviewer. 
Outcomes and Prioritization 
The primary outcome is spontaneous preterm birth, defined as any birth occurred before 
37 weeks of gestation due to spontaneous onset of labor or preterm premature rupture 
of membranes. Secondary outcomes are: 
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1. Spontaneous preterm birth before 28 weeks; 
2. Spontaneous preterm birth before 32 weeks; 
3. Spontaneous preterm birth before 34 weeks; 
The capacity to predict different degrees of sPTB (categories of gestational age) is 
important as the extreme (<28wks), moderate (<32 weeks) and non-late preterm 
(<34wks) newborns have different adverse outcomes compared to non-extreme 
(≥28wks); non-moderate (≥32wks) or late (≥34 wks) preterm newborns. 
Ideally, the method of gestational age estimation should be clearly reported. For instance, 
it can be reported as estimated by last menstrual period (LMP) and confirmed by an early 
ultrasound or only by an early ultrasound when LMP is unknown/uncertain. 
Index test 
Metabolomics techniques to predict spontaneous preterm birth is the diagnostic test of 
interest. Metabolomics is a technique to identify and quantify metabolites from biological 
samples using different type of platforms/equipment. The most common platforms 
include gas, liquid chromatography or ultra-performance liquid chromatography coupled 
to a mass spectrometer or a proton nuclear magnetic resonance [26]. The performance 
of the different thresholds of each metabolite will be compared and summarized through 
hierarchical summary receiver operator characteristic curve (HSROC) (meta-analysis) 
according to the subgroups described above. Considering that the raw data is not available 
in the majority of the diagnostic test accuracy studies [27] and that metabolites levels are 
usually reported as continuous variables, we intend to use a meta-analysis model based 
on ROC curves [28]. Briefly, a two-parameter model, based on the estimation of α and β 
parameters (using standard errors or maximum likelihood), will be applied as reported by 
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Kester & Buntinx [28]. Therefore, pooled ROC curves can be converted to an estimated 
ROC curve with 95% confidence interval. This method can also be applied in categorical-
ordinal variables tests. 
Risk of Bias in individual Studies 
We will apply the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool [29] 
to assess the risk of bias and applicability of primary diagnostic accuracy studies. Each 
study will be classified as “low”, “high” or “unclear” regarding risk of bias for each of the 
four domains of QUADAS tool: Patient Selection, Index Test (metabolomics), Reference 
Standard (occurrence of preterm birth), and Flow and Timing of participant’s inclusion and 
follow-up. For example, studies will be labelled as “low” risk of bias for Reference 
Standard when definition of spontaneous preterm birth and gestational age estimation 
are clear; “high” risk of bias would be considered when the moment of sample collection 
is not well described. 
Data Synthesis 
We will report details of identification, screening, eligibility and included studies using a 
flow diagram, according to PRISMA recommendations [25]. Data from included studies 
will be synthetized into tables according to the variables of interest. If possible, we will 
present data meta-analysis according to study design, metabolomics technique and type 
of samples analysed. We intend to perform subgroup analysis according to: 
● Different metabolomics methods applied: gas or liquid chromatography coupled 
with mass spectrometry or proton nuclear magnetic resonance; 
● Singleton and multiple pregnancies; 
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● Low-risk and high-risk women for developing preterm birth; 
● Subtype of preterm birth: Spontaneous preterm birth exclusively due to 
spontaneous onset of labour with intact membranes or sPTB due to premature 
rupture of membranes. 
● Gestational age interval when samples were collected: 1st trimester, 2nd trimester 
and 3rd trimester. 
Heterogeneity will be assessed by Cochran’s Q, Hotelling’s T-squared (τ²) and I2 tests. 
Funnel plots and sensitivity and cumulative analyses will be applied for detection of 
temporal trends and publication bias.  
Potential anticipated limitations to this review 
Firstly, although we have not considered any language restriction, we consider that there 
might be a limitation in studies published entirely in non-English language. However, in 
the last decade, more than 95% of scientific biomedical literature has been published in 
English [30], then we consider this a minor selection bias. Secondly, we intend to stratify 
the groups according to population risk. However, the characterization of low- or high-
risk for spontaneous preterm birth is controversial and lacks standardization, which might 
limit data comparison and subgroup analysis. Finally, categorization of sPTB into 
spontaneous onset of labour or pPROM is another topic of potential limitation - the 
recognition of the main initial mechanism for preterm delivery might not always be 
possible. Even when specified, it might provoke uncertainty and could limit further 
considerations regarding preterm phenotypes. In addition, another limitation is that 
individual patient data will not be collected. 
Patient and Public Involvement 
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Patients will not be directly involved in the study and no experience or direct impact from 
their perspective can be discussed. 
 
ETHICS AND DISSEMINATION 
This systematic review does not require ethical approval from the Research Council or 
Ethics board. We intend to disseminate our findings in scientific peer-reviewed journal, 
general free access website of Preterm Screening and Metabolomics in Brazil and 
Auckland (Preterm SAMBA) study, specialists’ conferences, and to our funding agencies. 
DISCUSSION 
This systematic review will comprise current knowledge related with metabolomics in the 
context of preterm birth prediction. Metabolomics science, a resourceful innovative field 
that allows better understanding on pathophysiology of complex syndromes, may address 
the main compounds associated with the spontaneous preterm delivery and, therefore, 
motivate further researchers to validate early measurable predictors of preterm birth.  
Metabolomics performance for predicting sPTB remains unclear and standardized and 
high-quality studies are needed to clarify the clinical application of metabolites for 
predicting sPTB. Nevertheless, metabolomics discovery studies commonly requires 
further validation studies; reproducible methodology is crucial. This systematic review 
protocol will collate the main potential early biomarkers, subgroup analysis and 
standardized definition for spontaneous preterm birth to better understand 
metabolomics performance in predicting sPTB and also to show its heterogeneity in terms 
of methodology (samples used, metabolomics technique, definition of SPTB phenotype, 
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etc). High performing predictors of preterm birth will help combat this leading cause of 
neonatal mortality and morbidity. 
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Supplementary Material  
 
 
Seacrh strategy: #1 AND #2 AND #3
preterm birth
premature birth
premature infant
premature labor
extremely premature infant
premature obstetric labor
spontaneous preterm birth
extreme preterm birth
late preterm birth
moderate preterm birth
preterm premature rupture of membranes
preterm delivery
PROM
sPTB
preterm PROM
pPROM
p-PROM
metabolomic*
metabonomic*
metabolit*
lipidomic*
H NMR
proton NMR
proton nuclear magnetic resonance
liquid chromatogra*
UPLC
ultra-performance liquid chromatograph*
ultra performance liquid chromatograph*
HPLC
high performance liquid chromatograph*
high-performance liquid chromatograph*
pregnan*
antenat*
ante nat*
prenat*
pre nat*
1 (OR for each 
term)
2 (OR for each 
term)
3 (OR for each 
term)
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Supplementary Material  
 
Search strategy according to literature database 
 
PUBMED, CINAHL, SCOPUS 
“preterm birth” OR “premature birth” OR “premature infant” OR “premature labor” OR 
“extremely premature infant” OR “premature obstetric labor” OR “spontaneous preterm 
birth” OR “extreme preterm birth” OR “late preterm birth” OR “moderate preterm birth” 
OR “preterm premature rupture of membranes” OR “preterm delivery” OR PROM OR 
sPTB OR “preterm PROM” OR pPROM OR p-PROM 
AND 
metabolomic* OR metabonomic* OR metabolit* OR lipidomic* OR “H NMR” OR 
“proton NMR” OR “proton nuclear magnetic resonance” OR “liquid chromatogra*” OR 
UPLC OR “ultra-performance liquid chromatograph*” OR “ultra performance liquid 
chromatograph*” OR HPLC OR “high performance liquid chromatograph*” OR “high-
performance liquid chromatograph*” 
AND 
pregnan* OR antenat* OR “ante nat*” OR prenat* OR “pre nat*” 
 
EMBASE 
‘preterm birth’ OR ‘premature birth’ OR ‘premature infant’ OR ‘premature labor’ OR 
‘extremely premature infant’ OR ‘premature obstetric labor’ OR ‘spontaneous preterm 
birth’ OR ‘extreme preterm birth’ OR ‘late preterm birth’ OR ‘moderate preterm birth’ 
OR ‘preterm premature rupture of membranes’ OR ‘preterm delivery’ OR PROM OR 
sPTB OR ‘preterm PROM’ OR pPROM OR p-PROM 
AND 
metabolomic* OR metabonomic* OR metabolit* OR lipidomic* OR ‘H NMR’ OR 
‘proton NMR’ OR ‘proton nuclear magnetic resonance’ OR ‘liquid chromatogra*’ OR 
UPLC OR ‘ultra-performance liquid chromatograph*’ OR ‘ultra performance liquid 
chromatograph*’ OR HPLC OR ‘high performance liquid chromatograph*’ OR ‘high-
performance liquid chromatograph*’ 
AND 
pregnan* OR antenat* OR ‘ante nat*’ OR prenat* OR ‘pre nat*’ 
 
BVS/BIREME 
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("preterm birth" OR "premature birth" OR "premature infant" OR "premature labor" OR 
"extremely premature infant" OR "premature obstetric labor" OR "spontaneous preterm 
birth" OR "extreme preterm birt" OR "late preterm birth" OR "moderate preterm birth" 
OR "preterm premature rupture of membranes" OR "preterm delivery" OR prom OR sptb 
OR "preterm PROM" OR pprom OR "p-PROM") 
AND  
(metabolomic* OR metabonomic* OR metabolit* OR lipidomic* OR h nmr OR "proton 
NMR" OR "proton nuclear magnetic resonance" OR "liquid chromatogra*" OR uplc OR 
"ultra-performance liquid chromatograph*" OR "ultra performance liquid 
chromatograph*" OR hplc OR "high performance liquid chromatograph*" OR "high-
performance liquid chromatograph*")  
AND  
(pregnan* OR antenat* OR "ante nat*" OR prenat* OR "pre nat*") AND 
(instance:"regional") AND ( year_cluster:("2015" OR "2011" OR "2016" OR "2014" OR 
"2013" OR "2012" OR "2009" OR "2017" OR "2010" OR "2008" OR "2018")) 
 
Web of Science 
preterm birth OR premature birth OR premature infant OR premature labor OR extremely 
premature infant OR premature obstetric labor OR spontaneous preterm birth OR extreme 
preterm birth OR late preterm birth OR moderate preterm birth OR preterm premature 
rupture of membranes OR preterm delivery OR PROM OR sPTB OR preterm PROM OR 
pPROM OR p-PROM 
AND 
metabolomic* OR metabonomic* OR metabolit* OR lipidomic* OR H NMR OR proton 
NMR OR proton nuclear magnetic resonance OR liquid chromatogra* OR UPLC OR 
ultra-performance liquid chromatograph* OR ultra performance liquid chromatograph* 
OR HPLC OR high performance liquid chromatograph* OR high-performance liquid 
chromatograph* 
AND 
pregnan* OR antenat* OR ante nat* OR prenat* OR pre nat* 
 
SCIELO 
("preterm birth" OR "premature birth" OR "premature infant" OR "premature labor" OR 
"extremely premature infant" OR "premature obstetric labor" OR "spontaneous preterm 
birth" OR "extreme preterm birth" OR "late preterm birth" OR "moderate preterm birth" 
OR "preterm premature rupture of membranes" OR "preterm delivery" OR PROM OR 
sPTB OR "preterm PROM" OR pPROM OR "p-PROM") 
AND 
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(metabolomic* OR metabonomic* OR metabolit* OR lipidomic* OR H NMR OR 
"proton NMR" OR "proton nuclear magnetic resonance" OR "liquid chromatogra*" OR 
UPLC OR "ultra-performance liquid chromatograph*" OR "ultra performance liquid 
chromatograph*" OR HPLC OR "high performance liquid chromatograph*" OR "high-
performance liquid chromatograph*") 
AND 
(pregnan* OR antenat* OR "ante nat*" OR prenat* OR "pre nat*") 
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4.5. Artigo Use of metabolomics for the identification and validation of clinical 
biomarkers for preterm birth: Preterm SAMBA 
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4.6. Artigo Planning, implementing and running a multicentre preterm birth 
study with biobank resources in Brazil: the Preterm SAMBA study 
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4.7. Artigo Trace biomarkers associated with spontaneous preterm birth from 
the maternal serum metabolome of asymptomatic nulliparous women – 
parallel case-control studies from the SCOPE cohort 
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Abstract 
Prediction of spontaneous preterm birth (sPTB) in asymptomatic women remains a great 
challenge; accurate and reproducible screening tools are still not available in clinical 
practice. We aimed to investigate whether the maternal serum metabolome together with 
clinical factors could be used to identify asymptomatic women at risk of sPTB. We 
conducted two case-control studies using gas chromatography-mass spectrometry to 
analyse maternal serum samples collected at 15- and 20-weeks’ gestation from 164 
nulliparous women from Cork, and 157 from Auckland. Smoking and vaginal bleeding 
before 15 weeks were the only significant clinical predictors of sPTB for Auckland and 
Cork subsets, respectively. Decane, undecane, and dodecane were significantly associated 
with sPTB (FDR <0.05) in the Cork subset. The odds ratio associated with a 1 sd increase 
in log (undecane) in a multiple logistic regression also including vaginal bleeding was 1.9. 
In summary, elevated serum levels of the alkanes decane, undecane, and dodecane were 
associated with sPTB in asymptomatic nulliparous women from Cork, but not in the 
Auckland cohort. The association is not strong enough to be a useful clinical predictor, but 
suggests that further investigation of the association between oxidative stress processes and 
sPTB risk is warranted.   
Keywords: preterm birth, spontaneous preterm birth, metabolomics, prediction, 
biomarker, metabolites, mechanism, maternal serum, decane, dodecane, undecane, alkanes. 
Funding: This study was jointly supported by the Brazilian National Research Council 
(CNPq) (Award 401636/2013-5), and the Bill and Melinda Gates Foundation (Award 
OPP1107597- Grand Challenges Brazil: Reducing the burden of preterm birth). 
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Introduction 
Spontaneous preterm birth (sPTB) due to spontaneous onset of labour or premature rupture 
of membranes (PROM) is a major cause of neonatal mortality and morbidity1-3. Although 
sPTB is prevalent in both high and low/middle-income countries, the major burden of sPTB 
is concentrated in Asian and African countries where about 85% of preterm births occur 
1,4,5. Short- and long-term consequences of preterm birth include bronchopulmonary 
dysplasia, neurodevelopment and cognitive impairment, retinopathy, as well as substantial 
impact on the functional, mental and social health of the infant and its family 6-8. Despite 
an increase in the research conducted into sPTB and advancements in the implementation 
of management and prevention strategies, significant reductions of sPTB have not been 
achieved9,10. 
Natural progesterone (oral or vaginal), 17α-hydroxyprogesterone (intra-muscular), pessary 
and/or cervical cerclage have been variously recommended to prevent sPTB in some 
guidelines 11-14, but their benefits are disputed. According to systematic reviews and meta-
analyses, the use of such interventions in selected women can reduce the risk for sPTB, but 
they are less likely to reduce the risk for perinatal morbidity 15-19. The identification of a 
more accurate screening tool to predict which women are most at risk of sPTB could 
improve the selection of women that would benefit from interventions, increasing the 
likelihood of success and reducing the costs to the healthcare system. However, current 
screening tools used to identify women at risk of developing sPTB fail to accurately predict 
preterm birth in asymptomatic women.  
Cervical length is possibly the most employed indicator for sPTB risk in clinical practice. 
While there is evidence for an increased risk of sPTB in women with a shortened cervix 
11,12, approximately 2/3 of women with short cervical length will have a term birth 20,21. 
Chemical biomarkers for sPTB have also been sought, with fetal fibronectin (fFN), insulin-
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like growth factor-binding protein 1 (IGFPB-1), and interleukin-6 (IL-6) 22-27 among the 
most studied. A systematic review of sPTB biomarkers found more than 200 studies 
published between 1965 and 2008, reporting more than 100 potential biomarkers 27. 
However, no single biomarker has proven to be a reliable predictor of sPTB. The authors 
of the systematic review concluded that there are many heterogeneities between the studies 
in terms of their experimental study design, timepoint of sample collection, and sample 
processing methods. One of the largest prospective cohort studies to date evaluated the 
performance of serial transvaginal cervical length measurements and quantitative vaginal 
fFN levels for predicting sPTB in a sample of approximately 10,000 nulliparous women 
with singleton pregnancies 28. Despite determination of cervical length and fibronectin 
levels at three different gestations, the model still showed low predictive accuracy for 
sPTB.  
sPTB is a condition with a multifactorial aetiology, a long pre-clinical phase, and adaptive 
mechanisms during pregnancy 29. For instance, the cervical remodelling process, which 
involves softening and ripening of the cervix, invariably occurs in the spontaneous onset 
of labour and is considered its endpoint 30. However, it does not occur in the same period 
of pregnancy for all women, which limits its potential as a marker for the prediction of 
sPTB 31. The underlying complexity of the drivers of sPTB demands a robust analytical 
technique capable of taking into consideration the multiple pathways potentially affected 
in the development of sPTB.  
Metabolomics, the study of low molecular weight compounds in a biological system, has 
previously been used to successfully investigate pregnancy complications such as fetal 
growth restriction, preeclampsia, and gestational diabetes mellitus 32-35. Metabolomic 
measurements provide a biochemical snapshot of the physiological state of the organism 
36; their close relationship with the biological phenotype means they have the potential to 
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reveal underlying mechanisms of disease. Due to the biochemical complexity of the 
metabolome, hyphenated analytical techniques are used. This involves subjecting sample 
extracts to a high-resolution separation technique such as gas chromatography (GC), high-
pressure liquid chromatography (HPLC), or capillary electrophoresis (CE). Identification 
is then carried out using mass spectrometry (MS), or nuclear magnetic resonance (NMR). 
The Preterm SAMBA study (Preterm Screening and Metabolomics in Brazil and Auckland) 
has been established to identify and validate metabolomic biomarkers for sPTB 37, in 
collaboration with the SCOPE (Screening for Pregnancy Endpoints) study. SCOPE was an 
international multicentre prospective cohort study that collected standardized data and 
samples from more than 5,690 low-risk pregnant women 38-40. The main objective of 
SCOPE was to develop a robust database and biobank to identify predictors and develop 
screening tests for preeclampsia, sPTB and small-for-gestational-age newborns. The 
current study describes the results of Preterm SAMBA phase 1, which used the SCOPE 
biobank to investigate the metabolomic profile, at 15- and 20-weeks’ gestation, amongst 
SCOPE participants who went on to have sPTB, when compared to matched controls. 
Parallel analyses were performed using participants from the Irish and New Zealand´s 
centres of the SCOPE study. 
Methods 
Study design and participants 
Two case-control studies were conducted, using a sub-set of women from the Auckland, 
New Zealand and Cork, Ireland centres of the Screening for Pregnancy Endpoints (SCOPE) 
study 41.  
The SCOPE study recruited 5,690 nulliparous low-risk women with a singleton pregnancy 
from New Zealand, Australia, Ireland and the United Kingdom between November 2004 
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and August 2008. Ethical approval was obtained from the local ethics committees in both 
Ireland and New Zealand (Cork: study number ECM5 (10) 05/02/08, Clinical Research 
Ethics Committee of the Cork Teaching Hospitals; New Zealand: study number 
AKX/02/00/364, Northern X Reginal Ethics Committee) and all participants gave their 
written informed consent. Details on enrolment and inclusion criteria for the SCOPE study 
have been published elsewhere 38-40. Collection of data and biological samples complied 
with standardized procedures in all participating centres and was conducted in accordance 
with the principles of the Declaration of Helsinki.  Cases of sPTB were defined as those 
women who delivered before 37 weeks’ gestation, and controls as those who delivered at 
or after 37 weeks’ gestation.  
a) Cork, Ireland  
The subset of SCOPE participants included in this study from the Cork, Ireland centre 
consisted of 55 cases of sPTB and 102 controls, matched to cases according to maternal 
age (± 3 years) and maternal body mass index (BMI; ± 5 kg/m2)*. 
b) Auckland, New Zealand  
The subset of SCOPE participants included in this study from the Auckland, New Zealand 
centre consisted of 55 cases of sPTB and 109 controls, comprising 56 controls matched to 
cases according to maternal age (± 3 years), and 53 controls matched to cases according to 
both maternal age (± 3 years) and BMI (± 5 kg/m2)*. 
(* Our intention was to match each case to two controls, however, in Cork eight control 
subjects were excluded due to misclassification or lack of data; in Auckland one maternal 
age and BMI control was reclassified to a maternal age control and another was excluded 
due to technical difficulties). 
189 
 
 
Data collection 
Demographic information including maternal age and BMI was collected at the time of 
recruitment (15 ±1 weeks’ gestation), along with information on family medical history. 
History of vaginal bleeding and any infections during the pregnancy were also recorded at 
the initial visit. The infant characteristics were recorded at birth and included birth weight, 
customised birth weight centile, and whether the infant was small, normal, or large for 
gestational age.  
Outcome 
Spontaneous preterm birth was defined as any birth that occurred before 37 weeks due to 
spontaneous onset of labour or premature rupture of membranes. Gestational age (GA) was 
estimated by last menstrual period (LMP) and confirmed by an ultrasound dating before 16 
weeks of gestation. A discordance of seven or more days between LMP and ultrasound 
dating or an unsure LMP led to the estimation of GA exclusively by early ultrasound 
parameters. Term birth for the control group was determined as delivery after 37 weeks of 
gestation. Early sPTB before 34 weeks was considered for subgroup analysis. 
Sample collection and storage 
Maternal blood samples were collected in two 6 mL vacutainers by venepuncture at 15 and 
20 weeks (± 1 week). Following clot formation, the vacutainers were centrifuged at 3,000 
rpm for 10 min at 4οC, followed by a second centrifugation at 4,000 rpm for 10 min at 4οC. 
After centrifugation, the resulting serum (supernatant) was pipetted into a sterile tube and 
aliquots of 250 µL were dispensed into cryotubes. All samples were stored at -80οC. The 
study followed standard best practice procedures for repositories in all steps of sample 
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collection and storage, registering all SPREC (Standard PREanalytical Coding) data 
accordingly in an online database 42.  
For this study, two 250 µL maternal serum samples were obtained from the biobank for 
each participant, one from each time point; 15- and 20-weeks’ gestation (± 1 week). 
Sample preparation and extraction 
The serum samples underwent extraction and derivatization procedures based on the 2010 
protocol of Smart et al. 43. Briefly, samples were thawed on ice at 4ºC and transferred from 
cryotubes to 1.5 mL microcentrifuge tubes. An internal standard (IS; 20 µL of 10 mM L-
Alanine-2,3,3,4-d4) was added to all samples and the sample-IS mix was vortexed for 1 
min. Samples were dried for 4h at 0.8 HPa in a centrifugal vacuum concentrator with a -
104°C refrigerated vapour trap (Thermo Fisher Scientific Savant SC250EXP SpeedVac 
Concentrator with Savant SP5121P Refrigerated Vapour trap). Metabolites were extracted 
using 50% and 80% cold methanol-water solution (-20ºC, v/v). Specifically, 500 µL of 
50% cold methanol-water solution was added to all samples, followed by vortexing for 1 
min and centrifugation at 3,000 rpm for 5 min at -4°C. After centrifugation, the supernatant 
was transferred to a fresh chilled microcentrifuge tube (kept on dry ice). Then, 500 µL of 
80% methanol-water solution was added to the pellet and this was centrifuged at 3,000 rpm 
for 5 min at -4°C. The supernatants obtained from both extraction steps were combined and 
dried in the centrifugal vacuum concentrator for 4 hours at 0.8 HPa, with a -104ºC 
refrigerated vapour trap. Dried extracted samples were stored at -80°C prior to 
derivatisation. 
Negative controls were produced by subjecting an empty microcentrifuge tube to the same 
processing as the samples. Pooled quality control samples (QC) were produced by pooling 
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a small amount from every sample, mixing, and then making aliquots of the same volume 
as the samples.  
Derivatization was carried out using methyl chloroformate (MCF). Samples were 
derivatised in batches of 18-24, on the same day that they were analysed on the GC-MS. 
Samples were re-suspended with 400 µL of 1 M sodium hydroxide and were transferred to 
silanised glass tubes, followed by addition of 334 µL of methanol and 68 µL of pyridine. 
The sample was placed on a vortexer for the remainder of the derivatization process at 
~1,500 rpm. The rate limiting step began from the addition of 40 µL of MCF. A second 
addition of 40 µL of MCF was made, 30 sec later. After another 30 sec, 400 µL of 
chloroform was added to extract the alkylated derivatives from the reaction mixture. After 
10 sec, 400 µL of sodium bicarbonate (50 mM) was added. Centrifugation was used to 
separate the aqueous layer from the chloroform layer. After centrifugation, the aqueous 
layer was removed and the remaining chloroform extract was dehydrated by the addition 
of sodium sulphate (~0.3g). The remaining liquid was then transferred to an amber glass 
GC-MS vial with a glass 33 µL insert.  
Gas chromatography – mass spectrometry (GC-MS) analysis 
The GC-MS instrument parameters were based on Smart et al. 43, with modifications. One 
microliter of sample was injected for analysis. The injector was set to 290 °C in splitless 
mode. The column flow was maintained at 1.0 mL min-1 in constant flow mode. The 
column was a fused silica ZB-1701 30 m long, 0.25 mm inside diameters, with a 0.15 µm 
stationary phase constituting of 86% dimethylpolysiloxane and 14% cyanopropylphenyl 
(Phenomenex). Instrument grade helium (> 99.99 %, BOC) was used as the carrier gas for 
the analysis. The detector was run in positive-ion, electron-impact ionisation mode, at 70eV 
electron energy. Identification of compounds was carried out using mass spectra acquired 
192 
 
 
in scan mode from 38 to 550 atomic mass units. The Cork samples were analysed on an 
Agilent 7890A gas chromatograph coupled to an 5975C inert mass spectrometer. The 
Auckland samples were analysed on a Thermo Scientific Trace GC Ultra gas 
chromatograph coupled to an ISQ mass spectrometer. 
Data extraction and compound identification 
Data processing was semi-automated. The raw files obtained from the GC-MS were 
converted into common data form (cdf) format for analysis and were deconvoluted and 
identified using the Automated Mass Spectral Deconvolution and Identification System 
(AMDIS - http://www.amdis.net/) from an in-house mass spectral library for MCF-
derivatised metabolites (~210 compounds) developed by Silas Villas-Boas (SVB). The 
library contained mass spectra predominantly from certified reference standards. In 
addition to the in-house library, the National Institute of Standards and Technology (NIST) 
mass spectral library (NIST14, 163,198 compounds) was also used to identify peaks in the 
raw chromatograms. Since AMDIS is not able to batch deconvolute with the entire NIST 
library, a NIST subset library was constructed employing a method developed by Elizabeth 
McKenzie using pooled quality controls. 
The NIST subset was produced using the top five results for each feature from the Agilent 
Chemstation PBM (Probability Based Matching) deconvolution program. MassOmics 
(version 2.3) was used to create the subset library. MassOmics is an R script based on the 
XCMS R package, with a Windows graphic user interface (GUI) developed by Ting-Li 
Han. MassOmics used XCMS and the AMDIS report to integrate the peak areas for each 
of the identified metabolites. The summary report obtained from running the MassOmics 
script was then checked, and peaks with low ID hits, or with large retention time shift, and 
laboratory contaminants were removed. 
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Data was checked against negative controls to identify and remove background 
contaminants. Peaks that were not extracted correctly with XCMS were integrated 
separately using the Ion Extractor feature in MassOmics. Co-eluting peaks underwent 
manual integration. The relative abundance obtained for each metabolite was normalised 
to the internal standard (Alanine-d4). After internal standard normalisation, the remaining 
technical variation was corrected for by analytical batch median centering using the 
samples. An analytical batch was defined as ~25 injections, comprising ~18 samples, 4 
QC´s, one Alkane series, one negative control, and one standard mixture. 
Statistical analysis 
Statistical analysis of the normalised mass spectral data was performed using R 3.4.3 44 
(https://www.R-project.org). Data was analysed separately for each site. Clinical predictors 
in Table 2 were analysed for univariate associations with preterm birth, and a multivariate 
logistic regression model predicting preterm birth with these predictors was selected using 
stepwise logistic regression with AIC, starting from an intercept only model, followed by 
backward elimination of variables with multivariate p> 0.05. Mann-Whitney tests were 
used to analyse the difference in metabolite levels between cases and controls; ratios 
between the 15 and 20-week levels of each metabolite were also assessed in this way. To 
adjust for multiple comparison testing, false discovery rates (FDR) were calculated for each 
comparison using the Benjamini-Hochberg procedure 45. Metabolites with an estimated 
FDR < 0.05 are reported. We then assessed whether a logistic regression model including 
these metabolites, individually or in combination, improved the area under the receiver 
operator characteristic curve compared to the model based on clinical predictors alone 46,47. 
To assess whether a more complex model might improve prediction, the sparse partial least 
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squares discriminant analysis (PLS-DA) method from the mixOmics package was 
employed 48. 
The clinical variables, log transformed 15 and 20-week metabolite intensities, and 15 to 
20-weeks ratios were used as candidate predictors. Up to three components with five 
predictors each were used. The number of components was selected based on the 
Malhalanobis distance balanced error rate using 10-fold cross validation, averaged over 10 
repeats. The significance of this model was assessed by a permutation test. Specifically, the 
balanced error rate estimated by cross validation was compared between the actual data, 
and data where the response category was permuted to destroy any true association with 
the predictors. The error rate was computed for 1000 permutations; the model was 
considered significantly better than random if the balanced error rate for the real data was 
better than 95% of the permuted replicates (p < 0.05). 
The above procedures were repeated for comparing preterm birth <34 weeks to the entire 
control group.  
Results 
Participants 
Participant demographic and outcome characteristics are shown in Table 1. These show the 
success of the matching strategy (similar BMI and age in case and control groups) and the 
expected association between birthweight and gestational age category. Potential clinical 
predictors are shown in Table 2. For Auckland data, smoking was the only significant 
clinical predictor in univariate models, and the multivariate model selection also chose a 
model with smoking only (odds ratio = 4.9; p-value = 0.03). When considering preterm 
birth <34 weeks, smoking was no longer a significant predictor comparing preterm cases 
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<34 weeks to the entire control group. For the Cork data, having vaginal bleeding before 
15 weeks’ was the only significant univariate predictor of sPTB (<37weeks); multivariate 
model selection again chose a model with this variable only (odds ratio = 2.8; p-value = 
0.006). The selected multivariate model for preterm birth <34 weeks included vaginal 
bleeding, smoking, and history of miscarriage (Table 4). 
Metabolites identified 
In the Cork samples, 176 compounds were detected. Of these, 77 were identified using an 
in-house library of reference standards and the remaining compounds were identified using 
mass spectrum alone (NIST 2014 mass spectral library). Of the in-house library matches, 
61 were putatively identified (80-100% match to a reference standard) and 15 were 
tentatively identified (60-79% mass spectral match). Of the NIST14 library identifications, 
25 were putatively identified (80-100% mass spectral match), 58 were tentatively identified 
(60-79% mass spectral match), and three were unknown (< 60% mass spectral match).  
In the Auckland samples, 142 compounds were detected. Of these, 50 were identified using 
an in-house library of reference standards and the remaining compounds were identified 
using mass spectrum alone (NIST 2014). Of the in-house library matches, 41 were 
identified, eight were tentatively identified, and one was unknown. Of the NIST14 library 
identifications, 51 were putatively identified, 34 were tentatively identified, and seven were 
unknown.  
Metabolites and performance of predictive models  
Table 3 shows the metabolites associated with preterm birth < 37 weeks’ and preterm birth 
< 34 weeks’, at each location and at each gestational time point (15 weeks or 20 weeks); 
ratios between the 15 and 20 week values were also assessed. Three metabolites detected 
at 20 weeks of gestation in the Cork subset were found to be significantly associated with 
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sPTB (FDR < 0.05) when compared to term births: undecane, dodecane and decane. All 
three were found to have higher abundance in sPTB cases. Adding the natural log intensity 
of undecane to the clinical predictors in a logistic regression model increased the area under 
the curve from 0.60 to 0.73 (Fig. 1), significantly improving the model (p=0.0007). This 
model estimates an odds ratio of 1.9 for a 1 standard deviation increase in log (undecane). 
The other metabolites were correlated with undecane (Pearson´s correlation for log 
intensities r=0.87 decane, r=0.89 dodecane). Consequently, results were similar for the 
other metabolites added individually to the model but adding multiple metabolites did not 
improve the model further. Fig. 1 shows the receiver operating characteristic curves for the 
clinical model only, and the clinical model with the addition of undecane. Sparse PLS-DA 
also produced a 1-component model for the Cork preterm birth data with an error rate that 
was significantly better than error rates produced for random permutations (p=0.01). This 
model again included undecane, dodecane, decane, and vaginal bleeding. A fifth predictor, 
stearic acid measured at 15 weeks’ gestation, was present; however, its loading was small, 
and incorporating it into the logistic regression did not significantly improve the area under 
the curve (p=0.37).  
No metabolites or 15-20 week ratios met the false discovery rate threshold for the Cork 
<34 weeks data, for either preterm <37 weeks or <34 weeks in the Auckland data, nor were 
the sparse PLS-DA models significant (p = 0.07, preterm birth <37 weeks; p= 0.48 preterm 
birth <34 weeks).  
Discussion 
We have analysed potential predictors of sPTB using serum samples and clinical data from 
Cork and Auckland participants of the SCOPE study, an international cohort of low-risk 
nulliparous women. An untargeted metabolomics approach was applied to serum samples 
collected at 15 and 20 weeks of gestation. More than one hundred metabolites were 
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identified in each subset (Cork and Auckland), but only three metabolites from the 20-week 
serum of Cork participants were found to be significantly associated with sPTB. As 
expected for the metabolomics method employed, the most common classes of metabolites 
were fatty acids, followed by amino acids. Vaginal bleeding before 15 weeks’ and smoking 
during pregnancy were the only clinical factors associated with sPTB in Cork and Auckland 
subsets, respectively. In the Cork cohort, adding undecane to a multivariate logistic 
regression model for predicting sPTB improved its performance over a model with vaginal 
bleeding alone. We note that, as depicted in Fig. 1, there are clear average differences in 
undecane levels between case and control groups, but also substantial overlap, limiting the 
utility of the metabolite measurements in clinical practice.  
There is a biologically plausible explanation for observing elevated alkanes (decane, 
undecane, dodecane) in the serum of mothers who had sPTB. Oxidative stress may lead to 
degradation of cell membranes by lipid peroxidation, followed by conversion of 
polyunsaturated fatty acids to volatile alkanes. The association of several oxidative stress-
associated processes and sPTB have been previously reported 49-51, and oxidative stress has 
been associated with elevated alkane levels in gastroenteric disease, lung disease, and other 
chronic diseases of metabolism 52-54. Glutathione, an important intracellular antioxidant, 
has been found to be decreased in maternal and umbilical cord blood of very low preterm 
neonates and their mothers 55. Preterm birth seems to be associated with depletion of 
glutathione, reinforcing a possible increased oxidative status and lower antioxidant 
capacity. However, failure to demonstrate elevated alkanes among sPTB cases in the 
Auckland cohort limits our confidence, and there was no evidence these alkanes were 
associated with early sPTB (<34 weeks) at either study site. In addition, hypotheses 
describing the role of reactive oxygen species generation, metabolic and inflammatory 
imbalance and many other downstream mechanisms (telomerase reduction, cell apoptosis 
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and senescence, etc.) caused by oxidative stress activation 49 do not clarify whether those 
mechanisms are trigger factors or consequences of underlying conditions/alterations 
resulting in preterm PROM and/or spontaneous onset of preterm labour.   
The differences across study sites in the associations between sPTB and clinical factors 
such as smoking and vaginal bleeding in this case-control analysis also suggest that there 
are differences in the Cork and Auckland populations. The alkanes elevated in the Cork 
preterm birth group are present in outdoor and indoor air contaminants, which could 
potentially differ across study sites, providing an alternative explanation for the 
observation. Association of environmental exposures with maternal and perinatal health 
have been reported for many years but are not yet well established 56,57. Further 
investigation of individual pollutant exposure would be necessary to confirm whether 
elevated alkanes are associated with environmental exposure. It is also possible that 
technical rather than biological variability accounts for some of the differences observed 
across sites. Samples from the different sites, while analysed using the same protocols, 
were run on different platforms by different technical personnel. Thirty-four fewer 
metabolite species were detected in the Auckland samples, suggesting reduced sensitivity.  
We also examined prediction of very preterm birth (<34 weeks). While no clinical 
predictors were significant in the Auckland cohort, the selected multivariate model for Cork 
included vaginal bleeding, smoking, and previous miscarriage. While caution is needed 
because of the small sample size, 14 out of the 16 cases of early sPTB from Cork had at 
least one of these risk factors.  
To the best of our knowledge, there are few studies in the literature applying metabolomics 
techniques to understand sPTB in asymptomatic pregnant women 33,58-60. Previous studies 
have used between 20 and 70 samples of a variety of biofluids (amniotic and cervicovaginal 
fluid, as well as serum), equally divided between cases and controls. There is also a 
199 
 
 
diversity of pregnancy stages and analytical techniques, so it is not surprising that there is 
little overlap in the specific compounds identified. However, Virgiliou et al. also suggested 
that the changes in amino acids and lipids they observed could be related to oxidative stress 
60.  
Our study has strengths and limitations. Cases and controls were selected from a large 
cohort comprised of low-risk nulliparous women enrolled in early pregnancy and 
containing a high standard biobank. Several procedures were employed to assure data, 
sample, and analysis compliance and reliability according to Standard Operating Protocols. 
Shortcomings of our study include lack of data regarding cervical length, a previously 
reported risk factor, and assaying of the metabolome of the two cohorts at different times 
on different equipment. In addition, we have not investigated predictive metabolites for the 
different preterm birth subtypes (spontaneous onset of preterm labour or preterm premature 
rupture of membranes), focusing instead on an early sPTB (<34 weeks) subgroup, due to 
the increased morbidity in this specific group. Using data and samples from women of 
different populations (Cork, Ireland; Auckland, New Zealand), enabled us to compare 
reproducibility of our technique and also to discuss possible local drivers for sPTB (Alkane 
pollutants in Cork, Ireland, for instance). Cork and Auckland samples were analysed by 
different laboratory experts and instruments and as such, the reproducibility and sensitivity 
differed across the sites.  
While our finding of an association between elevated alkanes and sPTB at the Cork site is 
preliminary, it raises several interesting questions to pursue in the future. What differences 
are typical or expected across geographically distant study sites? What role might exposure 
to exogenous pollution sources, including alkanes, play in preterm birth?  And finally, how 
might oxidative stress trigger, or be triggered by, processes leading to spontaneous preterm 
birth?  
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Figure Legends  
Figure 1. Prediction model for sPTB <37 weeks: Comparison of ROC curves using 
clinical predictors only (vaginal bleeding) and clinical predictors with log undecane 
intensity for the Cork cohort; with comparison of log2 intensity for undecane across case 
(Preterm Birth <37w) and control (Term birth) individuals. 
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Table 1. Medians (Lower and Upper Quartiles) or Counts (%) for Matching and Outcome Variables  
  Cork Auckland 
 Term Birth 
N= 109 
Spontaneous 
Preterm Birth 
N= 55 
Term Birth 
N=102 
Spontaneous 
Preterm Birth 
N=55 
Maternal BMI 23.4 (21.8, 25.8) 24.0 (21.6, 26.3) 23.5 (21.7, 26.0) 23.5 (21.5,27.0) 
Maternal Age (years) 30 (27, 32) 30 (27, 34) 31 (28, 33) 32 (29, 34) 
Birthweight (g) 3600 (3350, 3830) 2520 (2045, 2795) 3560 (3320, 3884) 2540 (2173, 2995) 
Gestational age at delivery 
(weeks) 
40.6 (39.9, 41.3) 35.3 (33.7, 36.4) 40.4 (39.3, 41.1) 35.7 (34, 36.4) 
Gestational age at delivery     
< 28 weeks N/A 3 (6%) N/A 3 (6%) 
28-32 weeks  4 (7%)  2 (4%) 
32-34 weeks  9 (16%)  8 (15%) 
34-37 weeks  39 (71%)  42 (76%) 
Preterm Premature Rupture of 
Membranes 
    
Yes N/A 29 (53%) N/A 25 (45%) 
No  26 (47%)  30 (55%) 
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Table 2. Medians (Lower and Upper Quartiles) or Counts (%) for potential clinical predictors for sPTB <37 weeks and <34weeks 
P-values are from tests of case-control differences using the Mann-Whitney test (Continuous variables), Chi-squared test (categorical variables with adequate counts) or 
Fisher’s exact test (*). § p-value for the three categories. ⱡ p-value for current smoker vs no smoking in pregnancy. aAny infection during pregnancy means upper 
respiratory or urinary tract infection, pyelonephritis, gastrointestinal infection, vaginal candidiasis or other infections.  
 
 
Cork Auckland 
 Term Birth 
N= 109 
Spontaneous 
Preterm Birth 
<37w 
N= 55 
p-value 
<37w 
vs term 
Spontaneous 
Preterm Birth 
<34w 
N=16 
p-value 
<34w 
vs term 
Term Birth 
N=102 
Spontaneous 
Preterm Birth 
<37w 
N=55 
p-value 
<37w vs 
term 
Spontaneous 
Preterm Birth 
<34w 
N=13 
p-value 
<34w 
vs term 
Maternal height (cm) 165 (161, 168) 165 (160, 168) 0.99 
167 (160, 169) 
0.48 
165 (161, 
169) 
165 (162, 168) 0.80 164 (162, 168) 0.53 
Infant sex           
Female 
Male 
47 (43%) 24 (44%) >0.99 7 (44%) 1 * 47 (46%) 24 (44%) 0.90 4 (31%) 0.38* 
62 (57%) 31 (56%)  9 (56%)  55 (54%) 31 (56%)  9 (69%)  
Smoking in pregnancy           
no smoking 
quit 
current smoker 
82 (75%) 
17 (16%) 
10 (9%) 
40 (72%) 
8 (15%) 
7 (13%) 
0.78 § 
0.66 ⱡ 
10 (62%) 
3 (19%) 
3 (19%) 
0.33* 
92 (90%) 
7 (7%) 
3 (3%) 
44 (80%) 
4 (7%) 
7 (13%) 
0.06* § 
0.03* ⱡ 
12 (92%) 
1 (8%) 
0 
1 *§ 
Fertility Treatment 7 (6%) 2 (4%) 0.72* 2 (13%) 0.32* 11 (11%) 7 (13%) 0.92 2 (15%) 0.64* 
Previous Miscarriage 15 (14%) 10 (18%) 0.61 4 (25%) 0.26* 15 (15%) 6 (11%) 0.67 2 (15%) 1 * 
Gravidity           
1 
2 
3 or more 
91 (83%) 
13 (12%) 
5 (5%) 
43 (78%) 
10 (18%) 
2 (4%) 
0.55* 
12 (75%) 
2 (13%) 
2 (13%) 
0.39* 
73 (72%) 
23 (23%) 
6 (6%) 
37 (67%) 
11 (20%) 
7 (13%) 
0.36* 
8 (62%) 
3 (23%) 
2 (15%) 
0.35* 
Vaginal bleeding 
before 15 w visit 
23 (21%) 23 (42%) 0.01 9 (56%) 0.01* 22 (22%) 14 (25%) 0.72 3 (23%) 1 * 
Any infection before 15 
w visita 
26 (24%) 11 (20%) 0.72 5 (31%) 0.54* 45 (44%) 24 (44%) >0.99 6 (46%) 1* 
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Table 3. Metabolites significantly associated with sPTB <37 weeks and <34 weeks 
SCOPE site 
Gestational age at sample 
collection 
Metabolite CAS number P-Value* FDR 
Direction of association and 
PTB category 
Auckland 15 weeks None - - - - 
Auckland 20 weeks None - - - - 
Auckland 
Ratio between 15 and 20 
weeks’ gestation 
None - - - - 
Cork 15 weeks None - - - - 
Cork 20 weeks 
Undecane 
Dodecane 
Decane 
1120-21-4 
112-40-3 
124-18-5 
3.73E-05 
8.11E-05 
7.06E-04 
0.007 
0.007 
0.040 
Higher in sPTB <37weeks 
Higher in sPTB <37weeks 
Higher in sPTB <37weeks 
Cork 
Ratio between 15 and 20 
weeks’ gestation 
None - - - - 
* Mann Whitney U test  
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Table 4. Clinical predictors of preterm birth <34 weeks in the Cork data, compared to controls (n=124) 
Variables Odds Ratio P-value 
Vaginal Bleeding 9.17 0.002 
Smoking—current 9.47 0.015 
Any miscarriage 4.54 0.047 
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4.8. Artigo Clinical and epidemiological factors associated with spontaneous 
preterm birth: a multicentre cohort of low risk nulliparous women 
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Abstract  
Objective: Determine incidence and risk factors associated with spontaneous preterm birth 
(sPTB). 
Design: Prospective multicentre cohort. 
Setting: Five Brazilian referral maternity hospitals. 
Population: Nulliparous low-risk women. 
Methods: Women enrolled at 19-21 weeks. Comprehensive maternal data collected during 
three study visits, addressed as potentially associated factors for sPTB. Bivariate and 
multivariate analysis estimated risk ratios.  
Main outcomes measures: Birth before 37 weeks due to spontaneous preterm labour or 
premature rupture of membranes (sPTB). Control group were women with term birth 
(≥37weeks). 
Results: Outcome data was available for 1,165 women, 6.7% of whom had sPTB, around 16% 
had consumed alcohol and about 5% had used other illicit drugs during the first half of 
pregnancy. Current drinking at 19-21 weeks (RR 3.96 95% CI [1.04-15.05]) and a short cervix 
from 18-24 weeks (RR 4.52 95% CI [1.08-19.01]) correlated with sPTB on bivariate analysis. 
Increased incidence of sPTB occurred in underweight women gaining weight below quartile 
1 (14.8%), obese women gaining weight above quartile 3 (14.3%), women with a short cervix 
(<25 mm) at 18-24 weeks (31.2%) and those with a short cervix and vaginal bleeding in the 
first half of pregnancy (40%). Cervical length (RRadj 0.93 95% CI [0.92-0.94]) and current 
drinking (RRadj 6.61 95% CI [1.04-15.05]) correlated independently with sPTB. 
Conclusion: The incidence of sPTB increased in some maternal phenotypes, representing 
potential groups of interest, the focus of preventive strategies. Similarly, targeted 
interventions for nulliparous women with a short cervix in the second trimester and alcohol 
use prevention during pregnancy require further exploration. 
Funding: The Brazilian National Research Council (CNPq) (Award 401636/2013-5) and Bill 
and Melinda Gates Foundation (grant OPP1107597). Funders played no role in study design, 
data collection/analysis, decision to publish or manuscript preparation. 
Tweetable abstract: Short cervix and alcohol use correlated with higher risk for spontaneous 
preterm birth in nulliparous women. 
Keywords: preterm birth, risk factor, alcohol, cervical length, phenotype. 
214 
 
 
 
Intoduction 
Spontaneous preterm birth (sPTB) is a common major maternal complication leading to 
perinatal morbidity and mortality as well as short- and long-term sequelae (1–3). Around two-
thirds of deliveries that occur before 37 weeks are due to spontaneous preterm labour or 
preterm premature rupture of membranes (pPROM) and its pathophysiology remains unclear 
(3). The two main known risk factors for preterm birth (PTB) are a previous history of preterm 
birth and multiple pregnancies (1,3,4). These factors are highly associated with preterm birth, 
although they cannot be applied to all women, such as nulliparous with singleton 
pregnancies.  
Several biophysical, biological and clinical markers have been studied to identify women at 
high risk in a timely manner. Assessment is aimed at providing a more specialized prenatal 
care in referral centres capable of optimizing preventive interventions such as progesterone, 
pessary or cerclage (5–8). Women with a short cervix in the second trimester, defined as a 
cervical length ≤ 25mm measured by transvaginal ultrasound between 18 to 24 weeks of 
gestation (9), are four to five times more likely to have a spontaneous preterm birth than 
women with a normal cervix (> 25mm) (10,11). Nevertheless, cervical length (CL) seems to 
vary according to ethnicity and parity (10,12), and possibly has a different impact on distinct 
populations.  
Routine universal screening of cervical length remains controversial and it is not widely 
recommended (13,14). Nevertheless, determining its association with sPTB in different 
populations may be significant for a better investigation of appropriate preventive 
interventions in targeted subgroups of women at higher risk. Since sPTB is a multifactorial 
complex disease, other clinical risk factors for sPTB also remain controversial; initial or 
pre/pregnancy body mass index (BMI), weight gain during pregnancy and sociodemographic 
factors are lacking in consistency (15–17). 
Therefore, our aim is to assess the incidence and clinical/ epidemiological risk factors 
associated with sPTB in nulliparous women in Brazil. The determination of risk factors is an 
important strategy to identify women at higher risk for this important complication which 
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represents a great burden for maternal and perinatal health. Earlier identification of women 
at increased risk is crucial for implementation of preventive strategies and planning adequate 
prenatal/childbirth care. 
Methods 
We conducted a nested case-control analysis derived from the Preterm-SAMBA study, a 
longitudinal multicentre cohort from July 2015 to July 2018 in five Brazilian obstetric centres 
located in three regions of Brazil. The research protocol and other methodological details 
were previously published (18,19). Briefly, the study was developed to identify clinical and 
biological predictors of sPTB, applying metabolomics techniques in maternal blood samples. 
The Brazilian cohort is the validation phase of the Preterm SAMBA study to assess the 
performance of a potential prediction model developed, using another international 
multicentre cohort – the SCOPE study (20). The study protocol was approved by the 
Institutional Review Board (IRB) of each centre and endorsed by the Brazilian National 
Committee for Ethics in Research (CONEP). This manuscript follows the Strengthening the 
Reporting of Observational studies in Epidemiology (STROBE) Statement. 
Participants and settings 
Nulliparous low-risk women with a singleton pregnancy between 19 and 21 weeks of 
gestation were the inclusion criteria. Exclusion criteria included 3 or more previous abortions; 
cervical suture; fetal malformation; chronic hypertension requiring antihypertensive drugs 
and/or diabetes and/or renal disease; arterial blood pressure above 160x100 mmHg on 
enrolment; Systemic Lupus Erythematosus and/or antiphospholipid syndrome; sickle cell 
disease; HIV infection; Müllerian anomalies; history of cervical knife cone biopsy; chronic use 
of corticosteroids, aspirin, calcium, fish oil, vitamin C, vitamin E or heparin. Participating 
centres were five referral maternity hospitals from the Brazilian Network for Studies on 
Reproductive and Perinatal Health from the northeastern, southern and southeastern regions 
of Brazil. Nevertheless, eligible women underwent surveillance not only in maternity 
outpatient clinics but also in neighbouring primary healthcare units and private clinics. 
Sample Size Estimation  
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The sample size for the Preterm SAMBA cohort was calculated taking into account the 
primary outcome - spontaneous preterm birth. Assuming a type I error of 5% and accuracy 
for the test by the area under the ROC curve of at least 0.68, and to test the hypotheses with 
adequate power (80% of power, β = 0.2), the required sample size should be near 80 sPTB 
cases. The expected minimum prevalence of this outcome in Brazil is 7%, resulting in a sample 
size calculation of   1,150 women for the cohort. 
Procedures and data management 
All steps of the clinical study have been previously described (18). Briefly, data were collected 
on three study visits. During the first visit, between 19 and 21 weeks of gestation, blood and 
hair samples were collected and stored appropriately for metabolomic assay and other 
possible future measurements. A comprehensive assessment was conducted to gather 
information on sociodemographic characteristics, reproductive family history, current or 
previous diseases, and habits, with a complete follow-up until delivery and immediate 
postpartum period. During the interview, data were entered on an internet-accessed central 
database with a complete audit trail (MedSciNet®). Anthropometric measurements of 
maternal body mass index (BMI), height, weight, head circumference, arm circumference and 
triceps, biceps, subscapular, suprailiac skinfolds plus a nutritional assessment based on a 24-
hour diet recall were performed according to standardized methods described in the SOP. 
Between 27-29 weeks and between 37-39 weeks, women underwent the same evaluation, 
except for blood and sample collection performed only on the first visit.  Late pregnancy and 
postpartum data were collected through medical records and prenatal chart review, or 
alternatively by personal interviews or phone calls in cases where childbirth occurred outside 
the five hospitals. 
Outcome and variables 
Spontaneous preterm birth was the main outcome, defined as any delivery before 37 weeks 
of gestation due to spontaneous onset of labour or preterm premature rupture of 
membranes (pPROM). Gestational age (GA) was estimated by the last menstrual period (LMP) 
and/or ultrasound (US) before 20 weeks of gestation. If discordance between LMP and US 
was below 7 days, GA was estimated by LMP. US was the preferred method for GA estimation 
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when discordance was above 7 days. The control group was comprised of women who had 
term birth, defined as any delivery ≥37 weeks of gestation. 
Potential factors associated with sPTB included sociodemographic data, smoking, alcohol 
(self-reported and recorded if drinking or not: 3 months before pregnancy and during 
pregnancy until the first visit) and drug use (marijuana, cocaine, etc.;  reported and recorded 
similarly to  alcohol consumption),  history of preterm birth of study participant’s mother or 
sisters, sPTB or low birth weight reported by study participant, body mass index on the first 
visit, weight gain per week between the first and second visits, cervical length  recorded by 
transvaginal ultrasound between 18 and 24 weeks of gestation, maternal conditions (self-
reported anemia, depression or chronic hypertension), complications and infections during 
pregnancy, including asymptomatic bacteriuria and vaginal bleeding before the first visit 
(until 19-21 weeks). Maternal clinical phenotype was defined by the association with some 
maternal characteristics including maternal BMI, family income, weight gain, vaginal 
bleeding, urinary infection, short cervical length (<25mm, measured at 18-24 weeks of 
gestation), ethnicity and schooling level. The proportion of women in each quartile (below 
Q1, Q1-Q2, Q2-Q3 and above Q3) and percentile category (<p10, p10-p90, and >p90) of 
weight gain per week between the first and second visits were also addressed for both 
preterm and term groups.  
Statistical analysis 
We determined the general incidence of sPTB in the cohort and each gestational category 
according to the severity of prematurity: late sPTB (34-36weeks), moderate sPTB (32-
33weeks), very sPTB (28-32weeks) and extreme sPTB (<28 weeks). Bivariate analysis was 
performed to assess potential factors associated with sPTB, calculating risk ratios (RR) and 
95% confidence interval (CI). The incidence of sPTB and respective 95% CI were calculated for 
each clinical phenotype. We conducted a non-conditional logistic regression analysis to 
identify factors independently associated with sPTB using adjusted RR and 95% CI. Only 
variables with a p-value <0.25 entered the multivariate analysis model. Statistical analysis was 
performed using Stata v. 7.0 (StataCorp) and SPSS v. 20.0 (IBM). All analyses were adjusted 
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for the primary sampling unit (PSU) considering the heterogeneity of the five participating 
centres. 
Results 
In total, 1,373 nulliparous pregnant women were assessed for eligibility. Of these, 1,181 were 
included in the Preterm SAMBA study and had the first visit (Figure 1). Outcome data were 
available for 1,165 participants, 78 of whom had a spontaneous preterm birth (6.7%) and 
1,040 had a term birth (89.3%). The overall preterm birth incidence, including provider-
initiated preterm birth (pi-PTB) was 10.7% (Supplementary S1). The incidence of sPTB in the 
Northeastern and Southern/Southeastern centres was 6.0% and 7.3%, respectively, although 
this difference was not statistically different (p-value 0.387). The proportions of late, 
moderate, very and extreme sPTB were 70.5%, 12.8%, 10.3% and 6.4%, respectively 
(Supplementary S1). In around 98% of pregnancies, gestational age was estimated or 
confirmed before 20 weeks by ultrasound (Supplementary S2).  
Table 1 shows that none of the assessed maternal socio-demographic characteristics was 
associated with sPTB. The majority of participating women were aged 20-34 years (69.2% 
sPTB women; 67.8% term birth women), non–white (59% sPTB; 60% term birth), had less than 
12 years of schooling (66.7% sPTB; 67.9% term birth) and their annual family income was 
3,000 to 12,000 US$ or more. Adolescents comprised 23.1% and 25.9% in sPTB and term 
births groups, respectively. More than 85% of participating women received prenatal care 
exclusively from the public health care system. 
Table 2 shows that on the first visit, current drinking was almost four times more frequent in 
women who had sPTB than in those who had term births (RR 3.96, 95% CI [1.04-15.05]). On 
the first visit, 6.4% and 7.5% of women who had sPTB and term births, respectively, were 
current smokers or had ceased smoking during the first half of pregnancy. Around 16% of 
participants consumed alcohol in the first half of pregnancy and approximately 5% had used 
illegal drugs. Table 3 shows that 41.1% and 43.1% of women were overweight or obese in 
sPTB and term birth groups, respectively. Cervical length below 25 mm from 18 to 24 weeks 
was associated with a higher incidence of sPTB (RR 4.52, 95% CI [1.08-19.01]). However, the 
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mean cervical length of women who had sPTB (33.1mm ±9.96) or term birth (36.9mm ±6.35) 
was not statistically different (weighted mean difference of 3.76, 95% CI [(-2.17)-(9.69)]). 
Other maternal conditions evaluated were not associated with a higher risk for sPTB.  
The incidence of sPTB in groups of women with clinical phenotypes including mixed maternal 
characteristics is shown in Table 4. Some of these women had a higher incidence of sPTB than 
the general study population. Examples were underweight women whose weight gain was 
below Q1 (14.8%), obese women with weight gain >Q3 (14.3%), women with a short cervical 
length (31.2%) and women with a short cervix that had vaginal bleeding in the first half of 
pregnancy (40%). None of the maternal phenotypes such as ethnicity, family income or 
schooling level showed a higher incidence of sPTB. 
Cervical length (mm) measured between 18 and 24 weeks of gestation and alcohol use on 
the first visit were independently associated with sPTB on multivariate analysis (adjusted RR 
0.93, 95%CI [0.92-0.94] and 6.61 [2.83-15.46], respectively) (Supplementary S3). Each 
increase of 1mm in cervical length decreases the risk of sPTB by 7%. Ethnicity and more than 
3 days of vaginal bleeding in the first half of pregnancy were the only significantly different 
maternal characteristics among groups of women with varying cervical lengths (≤25 mm, 26-
25 mm and >35 mm) (Supplementary S4). The proportion of white ethnicity and more than 3 
days of vaginal bleeding in women with a cervix >35mm and <25mm were 47.7% and 36.8%, 
and 5.8% and 0%, respectively. 
Discussion 
Main Findings 
The Preterm SAMBA multicentre cohort study found an overall PTB rate of 10.4%, where sPTB 
accounted for 62.4% of PTB cases (6.7% of all births). In addition, sPTB was highly associated 
with alcohol consumption and a short cervix at mid-pregnancy. 
Strengths and limitations 
We conducted a prospective multicentre cohort study of nulliparous women from five 
obstetric maternities in Brazil, representing a multi-regional and mixed population in an 
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upper-middle income country. Our study has some limitations: 1) the initial/pre-pregnancy 
weight was not recorded; 2) transvaginal ultrasound was recorded as ultrasound report or 
prenatal chart and not all participating women were offered the exam; 3) we did not use a 
standard instrument to address alcohol use during pregnancy. In addition to these limitations, 
our study represents local protocols and the reality of obstetric referral centres. Furthermore, 
a larger sample is presumed to confer more power to the study and other potential risk 
factors could be identified as significant. 
Interpretations 
The PTB rate was slightly lower in our study than in the general female Brazilian population. 
According to the EMIP study, a multicenter cross-sectional study that provided surveillance 
for over 33,700 births from 2011 to 2012 in 20 referral Brazilian maternity hospitals, the 
overall prevalence of PTB was 12.7% (4). sPTB was responsible for 65% of all PTB. The 2016 
official data from SINASC, the national live birth information system, shows a PTB rate of 
11.3% (21). Unfortunately, Brazilian official data does not distinguish PTB rates according to 
subtypes. A considerable proportion of women in our study, although classified as low-risk, 
were overweight or obese (291/1,165 - 41%) on the first visit (19-21 weeks), had previous 
chronic medical conditions including anemia, depression or chronic hypertension (145/1,165 
- 12.4%), had an annual family income lower than 12,000 US$ (654/1,165 - 56.1%) and had 
less than 12 years of schooling (785/1,165 – 65.0%). Considering the characteristic of our 
population, the concept of “low-risk” pregnancy here may be controversial. The sampled 
population reflects the Brazilian population and is no different from another multicentre 
study in Brazil (4). In addition, we focused on nulliparous women to avoid confounders 
related to a previous history of preterm birth, because it is applicable to every woman (at 
least once). 
A short cervix, defined as a cervical length below 25mm on second-trimester transvaginal 
ultrasound, is a significant risk factor for preterm birth. Since the ’90s, a growing body of 
evidence supports its association with PTB (10,22–24). Cervical lengths of nulliparous women 
seem to be statistically, but not clinically, different from cervical lengths of multiparous 
women. Iams et al. evaluating almost 3,000 North-American women, showed that median 
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cervical lengths were 34.0 mm and 36.1mm, respectively (10). More recently, van der Ven et 
al investigating over 11,000 Dutch women, reported that mean cervical lengths of nulliparous 
and multiparous were 43.1 mm and 45.1 mm, respectively (12). In our study, mean cervical 
lengths were 33.1 mm and 36.9 mm in women who had sPTB and term birth, respectively. 
Cervical length may not clinically differ according to parity, but this seems to vary widely 
among the population studied. We established 25mm as a cut-off point for women 
potentially at higher risk for sPTB. However, the distribution of cervical length in Brazilian 
women, including the 10th percentile, remains undetermined. It is required for clarification of 
population characteristics and related adaptations to identify women at higher risk for sPTB. 
Alcohol consumption during pregnancy is known to be associated with adverse maternal and 
perinatal outcomes, including preterm birth, small for gestational age infants and fetal 
alcohol spectrum disorder (FASD) (25–28). However, it is controversial whether there is a safe 
level of alcohol consumption during pregnancy and whether low alcohol intake could protect 
against PTB (26,28). Observational and experimental animal studies showed that ethanol 
seems to decrease oxytocin release in the neurohypophysis (29,30). A study on alcohol intake 
in nine large European cohorts showed that the proportion of women drinking alcohol during 
pregnancy decreased from 2000-04 (39%) to 2005-11 (14%) (31). Greater awareness of the 
harmful effects of alcohol and lower self-reporting are primary reasons for this decrease (31). 
Maternal alcohol use during pregnancy is a context-specific cultural challenge that needs to 
be confronted. In a meta-analysis by Larsen et al, over 90% of women were from Nordic 
countries (31). A systematic review with meta-analysis of studies from Latin American and 
Caribbean countries estimated that 15.2% of pregnant women in Brazil consume alcohol 
during pregnancy (32). Cuba and Mexico have prevalence rates of 4.8% and 1.2% respectively. 
Local and regional Brazilian studies showed that tobacco and illegal drug use, mental health 
disorders, low schooling, non-white race and lack of a partner are factors associated with 
alcohol consumption during pregnancy (33–37). Nevertheless, we did not find any Brazilian 
studies that comprehensively addressed maternal characteristics, lifestyle and other factors 
associated with alcohol use during pregnancy, specifically in nulliparous women. 
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Amelioration of preventive actions to avoid alcohol use in this specific maternal group is a 
key strategy. 
Recently, a group of experts proposed a new conceptual framework for the study of preterm 
birth, using maternal clinical phenotypes (38). A clinical phenotype is characterized by a group 
of common clinical characteristics observed during pregnancy that is potentially associated 
with an outcome. Rather than separate women by outcome, the clinical phenotype intends 
to address the incidence and associated adverse outcomes in women who have common 
characteristics during pregnancy. It may improve recognition of groups at higher risk for 
adverse outcomes and enable implementation of targeted interventions for each specific 
group. We found four maternal phenotypes with at least double the incidence of sPTb 
compared to the overall population. These phenotypes were based on maternal BMI, weight 
gain from 20-27 weeks of gestation, cervical length, and vaginal bleeding in the first half of 
pregnancy. All these characteristics can be easily identified during pregnancy, especially in 
referral obstetric units where well-trained specialists perform transvaginal ultrasound. A 
standard threshold for weight gain during pregnancy, dependent on the initial or pre-
pregnancy BMI, was not used in this study, since it was not available. More importantly, 
existing literature supports our findings. Obese women with higher weight gain and 
underweight women with lower weight gain are at increased risk for sPTB (39). Although each 
clinical phenotype was composed of a low number of women, these results are still useful for 
indicating groups of women that may benefit from further study and are also considered at 
higher risk for sPTB.  
 
Conclusion 
Our study reinforces that cervical length is a remarkable biophysical risk factor for sPTB. 
However, instead of routine screening for low-risk nulliparous women, we first suggest a 
better investigation of the benefits of preventive interventions for this population with a 
short cervix in the second trimester. In addition, subgroups that have a higher incidence of 
sPTB should also be further evaluated to find associated factors, perinatal related outcomes, 
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and preventive strategies. Alcohol use during pregnancy is known to be harmful. Strategies 
to identify and prevent alcohol consumption should be better explored in our context, 
especially in nulliparous women.  
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Table 1. Unadjusted risks for sPTB according to some socio-demographic characteristics 
Characteristics sPTB  Term Births RR [95%CI] 
Region    
Northeast 34 (43.6%) 506 (48.7%) Ref. 
South and Southeast 44 (56.4%) 534 (51.3%) 1.21 [0.69-2.12] 
Maternal age (years)    
≤19 18 (23.1%) 269 (25.9%) 0.88 [0.55-1.42] 
20-34 54 (69.2%) 705 (67.8%) Ref. 
≥35 6 (7.7%) 66 (6.3%) 1.17 [0.27-5.15] 
Ethnicity    
White 32 (41.0%) 416 (40.0%) Ref. 
Non-white  46 (59%.0) 624 (60.0%) 0.96 [0.40-2.30] 
Marital status     
With partner  52 (66.7%) 762 (73.3%) Ref. 
Without partner  26 (33.3%) 278 (26.7%) 1.34 [0.99-1,81] 
Maternal Occupation     
Paid work  41 (52.6%) 512 (49.2%) 1.11 [0.74-1.66] 
Housewife 13 (16.7%) 192 (18.5%) 0.95 [0.36-2.54] 
Not working* 24 (30.7%) 360 (32.2%) Ref. 
Schooling (years)     
< 12  52 (66.7%) 706 (67.9%) Ref. 
≥ 12  26 (33.3%) 334 (32.1%) 1.05 [0.46-2.39] 
Annual Family Income (US$)     
Up to 3,000  2 (2.6%) 48 (4.6%) 0.53 [0.21-1.32] 
3,000 to 12,000  41 (52.5%) 563 (54.1%) 0.90 [0.55-1.47] 
Above 12,000  35 (44.9%) 429 (41.3%) Ref. 
Source of prenatal care     
Entirely public  67 (85.9%) 899 (86.4%) 0.96 [0.54-1.70] 
Private/insurance/mixed  11 (14.1%) 141 (13.6%) Ref. 
Total 78 1,040  
*students, unemployed and licensed. 
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Table 2. Unadjusted risks for sPTB according to some maternal medical history and habits 
Characteristics sPTB Controls RR (95%CI) 
Smoking     
No smoking 73 (93.6%) 962 (92.5%) Ref. 
Ceased during pregnancy or smoker 5 (6.4%) 78 (7.5%) 0.85 [0.23-3.23] 
Alcohol drinking a    
No alcohol  56 (83.6%) 757 (83.5%) Ref. 
Ceased before 1st visit  8 (11.9%) 142 (15.7%) 0.77 [0.34-1.75] 
Current drinker at 1st visit  3 (4.5%) 8 (0.9%) 3.96 [1.04-15.05] 
Other Drugs b     
Never  61 (95.3%) 839 (94.6%) Ref. 
Ceased before 1st visit  1 (1.6%) 39 (4.4%) 0.37 [0.03-5.18] 
Current user at 1st visit  2 (3.1%) 9 (1.0%) 2.68 [0.86-8.33] 
Previous maternal conditions    
Yes  15 (19.2%) 130 (12.5%) 1.60 [0.89-2.86] 
No  63 (80.8%) 910 (87.5%) Ref. 
Previous abortion     
Yes  9 (11.5%) 117 (11.3%) 1.03 [0.33-3.19] 
No  69 (88.5%) 923 (88.7%) Ref. 
Mother’s History of PTB c    
Yes  8 (11.0%) 98 (9.9%) 1.11 [0.24-5.18] 
No  65 (89.0%) 890 (90.1%) Ref. 
Mother’s History of LBW d    
Yes5 5 (7.2%) 111 (11.7%) 0.61 [0.17-2.20] 
No 64 (92.8%) 839 (88.3%) Ref. 
Sister’s History of PTB e    
Yes  4 (12.5%) 22 (7.3%) 1.69 [0.52-5.48] 
No  28 (87.5%) 279 (92.7%) Ref. 
Sister’s History of LBW e    
Yes  4 (12.5%) 32 (10.6%) 1.18 [0.16-8.91] 
No  28 (87.5%) 269 (89.4%) Ref. 
Total 78 1,040  
Missing information for: a) 144; b) 167; c) 57; d) 99; e) 17.  
LBW: low birth weight; PTB: preterm birth. Values in bold mean they are statistically significant. 
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Table 3. Unadjusted risks for sPTB according to some maternal medical conditions during pregnancy 
Characteristics sPTB  Controls RR [95%CI] 
Body Mass Index* at first visit (19-21weeks) a     
Underweight (<21.5kg/m2) 14 (17.9%) 181 (17.4%) 0.99 [0.28-3.55] 
Normal weight (21.5-26.2 kg/m2) 32 (41.0%) 410 (39.5%) Ref. 
Overweight (26.3-30.9 kg/m2)  21 (26.9%) 270 (26.0%) 1.00 [0.54-1.85] 
Obesity (>30.9 kg/m2)  11 (14.2%) 178 (17.1%) 0.80 [0.52-1.23] 
Quartile of weight gain rate per week 
(kg/week) b  
   
≤Q1 (≤0.33) 15 (27.3%) 211 (24.9%) 1.01 [0.47-2.20] 
Q1-Q2 (0.34-0.49) 14 (25.5%) 200 (23.5%) Ref. 
Q2-Q3 (0.50-0.66) 15 (27.3%) 216 (25.5%) 0.99 [0.43-2.30] 
≥Q3 (≥0.67) 11 (20.1%) 221 (26.1%) 0.72 [0.25-2.08] 
Percentile of weight gain rate per week 
(kg/weeks) b 
   
<p10 (<0.18) 6 (10.9%) 85 (10.0%) 1.15 [0.60-2.23] 
p10-p90 (0.18-0.82) 41 (74.5%) 675 (79.6%) Ref. 
>p90 (>0.82) 8 (14.5%) 88 (10.4%) 1.46 [0.97-2.17] 
Cervical length from 18 to 24 weeks c    
Mean ±SD 33.1 ±9.96 36.9 ±6.35 3.76 [(-2.17)-(9.69)]# 
≤ 25mm  5 (13.5%) 11 (2.5%) 4.52 [1.08-19.01] 
> 25mm  32 (86.5%) 431 (97.5%) Ref. 
Urinary tract infection in the first half of 
pregnancy d 
   
Yes 8 (13.1%) 198 (25.6%) 0.46 [0.20-1.04] 
No  53 (86.9%) 574 (74.4%) Ref. 
Asymptomatic bacteriuria in the first half of 
pregnancy e 
   
Yes  2 (3.5%) 69 (9.5%) 0.36 [0.04-3.25] 
No  55 (96.5%) 654 (90.5%) Ref. 
Recurrence of any infection§ f    
Yes 6 (10.9%) 119 (14.0%) 0.76 [0.27-2.16] 
No 49 (89.1%) 730 (86.0%) Ref. 
Vaginal bleeding in the first half of pregnancy     
Yes  24 (30.8%) 193 (18.6%) 1.85 [0.89-3.84] 
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No  54 (69.2%) 847 (81.4%) Ref. 
Number of days with vaginal bleeding in the 
first half of pregnancy 
   
1-3 days  14 (58.3%) 156 (80.8%) Ref. 
>3 days 10 (41.7%) 37 (19.2%) 2.58 [0.62-10.74] 
Total 78 1,040  
*According to Atalah body mass index categories at 19weeks (Atalah E, Castillo C, Castro R, Aldea A. Rev Med 
Chil. 1997 Dec;125(12):1429-36) §Women who had any infection before first visit (19-21 weeks) and another any 
infection between first and second visits (between 19-21 weeks and 27-29 weeks); only calculated for women who 
attended both visits. Missing information for: a) 1; b) 215; c) 639; d) 285; e) 338; f) 32. #WMD, weighted mean 
difference [95% CI]. 
Values in bold mean they are statistically significant. 
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Table 4. Incidence of preterm birth according to some maternal clinical phenotypes 
Maternal clinical phenotypes 
Incidence of sPTB 
n/N (%) 
[95% CI] 
Underweight on enrolment (<21.5kg/m2)* and Weight 
gain rate per week <Q1  
4/27 (14.8%) [0.0 – 34.7] 
Underweight on enrolment (<21.5kg/m2)* and Weight 
gain rate per week <Q2 
4/52 (7.7%) [0.0 – 18.7] 
Obesity (>30.9)* and Weight gain rate per week >Q3 3/21 (14.3%) [3.9 – 24.6] 
Overweight or Obese* and Weight gain rate per week 
>Q3 
6/76 (7.9%) [4.1 – 11.7] 
Obesity (>30.9)* and Weight gain rate per week >Q2  5/54 (9.3%) [0.8 – 17.7] 
Overweight or Obese* and Weight gain rate per week 
>Q2  
11/165 (6.7%) [3.6 – 9.7] 
Vaginal bleeding and urinary infection in the first half 
of pregnancy  
3/49 (6.1%) [0.0 – 15.1] 
Short Cervical Length from 18 to 24 weeks  5/16 (31.2%) [0.0-77.2] 
Short Cervical Length from 18 to 24 weeks and vaginal 
bleeding in the first half of pregnancy  
2/5 (40.0%) [0.0 – 91.6] 
Low family income and schooling levels  0/42 (0%) - 
Low family income and schooling levels  14/261 (5.4%) [2.6 – 8.1] 
White, low family income and schooling levels (a) 0/6 (0%) - 
White, low family income and schooling levels (b) 3/48 (6.3%) [0.0-12.5] 
Non-white, low family income and schooling levels (a) 0/36 (0%) - 
Non-white, low family income and schooling levels (b) 11/213 (5.2%) [2.0-8.3] 
White, high family income and schooling levels (a) 11/169 (6.5%) [3.4-9.7] 
White, high family income and schooling levels (b) 13/198 (6.6%) [3.9-9.2] 
Non-white, high family income and schooling levels (a) 5/77 (6.5%) [0.0-15.9] 
Non-white, high family income and schooling levels (b) 9/129 (7.0%) [0.0-14.8] 
General population of the study 78/1165 (6.7%) [4.7 – 8.7] 
(a) Low income defined as income up to 3,000 US$. High income when above 12,000 US$. (b) Low income 
defined as income up to 6,000 US$. High income when above 6,000 US$. *(Atalah E, Castillo C, Castro R, Aldea 
A. Rev Med Chil. 1997 Dec;125(12):1429-36)
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S1. Incidence of preterm birth in the Preterm SAMBA study 
Incidence n/N (%) 
Preterm birth (overall) 125/1,165 (10.7%) 
Spontaneous PTB 78/1,165 (6.7%) 
Provider-initiated PTB 47/1,165 (4.0%) 
sPTB by Region*  
Northeast (2 centres) 13/257 + 21/309 = 34/565 (6.0%) 
South and Southeast (3 centres) 12/139 + 14/143 + 18/318 = 44/600 (7.3%) 
sPTB categories/severity 78 (100%) 
Late preterm birth (34-36w) 55 (70.5%) 
Moderate PTB (32-33w) 10 (12.8%) 
Very PTB (28-31w) 8 (10.3%) 
Extreme PTB (<28w) 5 (6.4%) 
*p-value: 0.387 
PTB: preterm birth; sPTB: spontaneous preterm birth  
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S2. Methods for estimating gestational age in the Preterm SAMBA study 
Method* sPTB Term birth 
LMP only 1 (1.3%) 15 (1.4%) 
LMP and US (LMP) 32 (41.0%) 449 (43.2%) 
LMP and US (US) 21 (26.9%) 269 (25.9%) 
US only 24 (30.8%) 307 (29.5%) 
*p-value: 0.903 
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S3. Factors independently associated with sPTB: multivariate analyses by non-conditional logistic 
regression 
Variables RRadj 95% CI p-value 
Cervical Length from 18 to 24 weeks (mm) 0.93 0.92-0.94 <0.001 
Current drinker at 1st visit 6.61 2.83-15.46 0.004 
Variables included in the model: age (years); marital status; alcohol drinking; previous maternal conditions; 
initial BMI; Cervical length (mm); vaginal bleeding in the first half of pregnancy; urinary tract infection in the 
first half of pregnancy; weight gain rate per week (kg) 20-27 weeks >p90. 
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S4. Maternal characteristics according to transvaginal cervical length measured between 18-24 
weeks (n=497) 
Characteristics Cervical length 
≤25mm 
Cervical length 
26-35mm 
Cervical length 
>35mm 
p-value 
Maternal age (years)     0.125 
≤19 3 (15.8%) 53 (26.4%) 40 (14.4%)  
20-34 15 (78.9%) 128 (63.7%) 208 (75.1%)  
≥35 1 (5.3%) 20 (10.0%) 29 (10.5%)  
Ethnicity     0.034 
White 7 (36.8%) 78 (38.8%) 132 (47.7%)  
Non-white  12 (63.2%) 123 (61.2%) 145 (52.3%)  
Marital status     0.307 
With partner  16 (84.2%) 145 (72.1%) 212 (76.5%)  
Without partner  3 (15.8%) 56 (27.9%) 65 (23.5%)  
Maternal Occupation    0.079 
Paid work  13 (68.4%) 88 (43.8%) 166 (59.9%)  
Homemaker  4 (21.1%) 41 (20.4%) 47 (17.0%)  
Not working  2 (10.5%) 72 (35.8%) 64 (23.1%)  
Schooling (years)    0.768 
< 12  12 (63.2%) 127 (63.2%) 173 (55.4%)  
≥ 12  7 (36.8%) 74 (36.8%) 104 (37.5%)  
Annual Family Income (US$)    0.295 
Up to 3,000  0 (0%) 3 (1.5%) 5 (1.8%)  
3,000 to 12,000   7 (36.8%) 115 (57.2%) 122 (44.0%)  
Above 12,000 12 (63.2%) 83 (41.3%) 150 (54.2%)  
Source of prenatal care    0.500 
Entirely public  16 (84.2%) 164 (81.6%) 220 (79.4%)  
Private/insurance/mixed  3 (15.8%) 37 (18.4%) 57 (20.6%)  
Smoking     0.316 
No smoking  17 (89.5%) 188 (93.5%) 256 (92.4%)  
Ceased during pregnancy or smoker 2 (10.5%) 13 (6.5%) 21 (7.6%)  
Alcohol drinking a    0.571 
No alcohol 15 (83.3%) 147 (81.7%) 189 (79.4%)  
Ceased during pregnancy or drinker  3 (16.7%) 33 (18.3%) 49 (20.6%)  
Other Drugs b    0.109 
Never  16 (100%) 176 (95.7%) 245 (93.9%)  
Ceased during pregnancy or user  0 (0%) 8 (4.3%) 16 (6.1%)  
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Previous maternal conditions 2 (10.5%) 40 (19.9%) 41 (14.8%) 0.382 
Previous abortion 6 (31.6%) 31 (15.4%) 33 (11.9%) 0.142 
Mother’s History of PTB 29 1 (6.2%) 24 (12.9%) 38 (14.3%) 0.379 
Mother’s History of LBW c 2 (13.3%) 22 (12.6%) 36 (14.1%) 0.814 
Sister’s History of PTB 5 (100%) 63 (90%) 95 (88%) 0.502 
Sister’s History of LBW 5 (100%) 58 (82.9%) 91 (89.8%) 0.305 
Body Mass Index on enrolment d    0.563 
Underweight (<21.5kg/m2) 3 (15.8%) 35 (17.4%) 37 (13.4%)  
Normal weight (21.5-26.2) 6 (31.6%) 83 (41.3%) 118 (42.6%)  
Overweight (26.3-30.9) 6 (31.6%) 56 (27.9%) 69 (24.9%)  
Obesity (>30.9)  4 (21.0%) 27 (13.4%) 53 (19.1%)  
Quartiles of weight gain rate per week 
(kg) 20-27 weeks d 
   0.405 
≤0.33 (≤Q1)  5 (33.3%) 28 (15.3%) 57 (23.3%)  
0.34-0.49 (Q1-Q2)  4 (26.7%) 56 (30.8%) 60 (24.5%)  
0.50-0.66 (Q2-Q3)  3 (20.0%) 58 (31.9%) 70 (28.6%)  
≥0.67 (≥Q3)  3 (20.0%) 40 (22.0%) 58 (23.7%)  
Percentiles of weight gain rate per 
week (kg) 20-27 weeks  
   0.522 
<p10 (<0.18)  2 (13.3%) 12 (6.6%) 23 (9.4%)  
p10-p90 (0.18-0.82)  11 (73.4%) 151 (83.0%) 207 (84.5%)  
>p90 (>0.82) 2 (13.3%) 19 (10.4%) 15 (6.1%)  
Urinary infection in first the half of 
pregnancy e 
2 (14.3%) 45 (30%) 50 (23.5%) 0.203 
Asymptomatic Bacteriuria in the first 
half of pregnancy f 
12 (85.7%) 105 (70%) 163 (76.5%) 0.521 
Recurrence of any Infection§ 0 (0%) 17 (12.3%) 20 (9.8%) 0.534 
Vaginal bleeding in the first half of 
pregnancy 
6 (31.6%) 36 (17.9%) 55 (19.9%) 0.372 
Number of days with vaginal bleeding 
in the first half of pregnancy 
   <0.001 
1-3  6 (100%) 31 (86.1%) 39 (70.9%)  
>3 0 (0%) 5 (13.9%) 16 (29.1%)  
Total 19 201 277 497 
Missing information for: a) 61; b) 36; c) 51; d) 55; e) 120; f) 142. 
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4.9. Artigo Perinatal outcomes from preterm and early term birth in a multicenter 
cohort of low risk nulliparous women 
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Abstract 
Introduction: Preterm birth is the major contributor for neonatal and under-five years 
mortality rates and also accounts for a short- and long-term adverse consequences up to 
adulthood. Perinatal outcomes may vary according to lots of factors as preterm subtype, late 
prematurity, which account for the vast majority of cases, country and population 
characteristics. An under-recognition of the perinatal outcomes and its associated factors 
might have underpowered strategies to provide adequate care and prevent its occurrence.  
Objective: To determine the incidence of maternal and perinatal outcomes according to 
preterm birth subtypes, and late preterm and early term births. 
Methods: A multicentre prospective cohort in five maternities in Brazil between 2015 and 
2018. Nulliparous low-risk women with singletons were included. Comprehensive data were 
collected during three antenatal visits (at 19-21weeks, 27-29 weeks and 37-39 weeks). 
Maternal and perinatal outcomes were also collected according to maternal and neonatal 
medical records. Women who had spontaneous (sPTB) and provider-initiated (pi-PTB) 
preterm birth were compared to those who had term birth. Also, late preterm birth (after 34 
weeks), and early term (37-38 weeks) were compared to full term birth (39-40 weeks). 
Bivariate analysis estimated risk ratios for maternal and adverse outcomes. Finally, a 
multivariate analysis was conducted to address factors independently associated with any 
adverse perinatal outcome (APO).  
Results: In total, 1,165 women had outcome data available, from which 6.7% had sPTB, 4.0% 
had pi-PTB and 89.3% had a term birth. sPTB and pi-PTb were associated with poorer 
perinatal outcomes, as well as late sPTB, late pi-PTB and early term neonates. pi-PTB (RRadj 
8.12, 95% CI [2.54-25.93], p-value 0.007), maternal weight gain between 20 and 27 weeks 
<p10 (RRadj 2.04, 95% CI [1.23-3.38], p-value 0.018) and participants from the Northeast 
centres (RRadj 2.35, 95% CI [1.11-4.95], p-value 0.034) were independently associated with 
APO. 
Conclusion: sPTB and, especially, pi-PTB were associated with poorer perinatal outcomes in 
nulliparous low-risk women. Strategies to more accurately identify women at higher risk of 
PTB and to prevent perinatal adverse outcomes remain a great challenge in the Brazilian 
context, a middle-income country with perpetuated inequity in income, education and access 
to health care.  
Key words: perinatal outcomes, spontaneous, provider-initiated, preterm birth, adverse 
perinatal outcome, late preterm birth 
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Introduction 
Preterm birth (PTB) is associated with short- and long-term adverse outcomes for the 
neonate, including cerebral palsy. In addition, it is the leading cause of neonatal death and 
also a contributor to the under-five mortality rate (1–3). A secondary analysis of a World 
Health Organization study evaluating almost 300,000 deliveries in 29 countries showed that 
perinatal outcomes as stillbirth and early neonatal deaths vary according to the preterm birth 
subtypes (4). The rates are approximately 30% lower in spontaneous than in provider-
initiated preterm birth.  
Preterm birth subtype can be classified according to its motivation. Spontaneous preterm 
birth (sPTB) is defined as any preterm birth occurred due to spontaneous onset of labour or 
premature rupture of membranes (PROM) and provider-initiated preterm birth (pi-PTB) 
when preterm birth was indicated by health care providers due to maternal and/or fetal 
conditions (1). It can be also divided according to gestational age at delivery in extremely 
preterm (<28 weeks), very preterm (28-31 weeks), moderate preterm (32-33 weeks), and late 
preterm (34-36 weeks) (1,5). Not only preterm neonates are associated with adverse 
perinatal outcomes, but also early term neonates (37-38 weeks) (6–8). Both groups are close 
to 37 weeks and, because of that, related outcomes are usually underestimated, especially in 
provider-initiated deliveries. Neonatal and infant mortality rates are around 2 times higher in 
these groups compared to 39 weeks neonates (8). 
Secondary analyses of the Birth in Brazil study, a hospital-based cross-sectional study that 
included women from 266 hospitals from February 2011 to October 2012, confirm that PTB 
is the leading cause of neonatal mortality in Brazil (9). The factors associated with higher rates 
of neonatal mortality included peregrination, not using a partograph, delivering before 32 
weeks and delivering at a unit of the public unified health system (9). Less than 20% and 15% 
of the public and private maternities have an intensive care unit, respectively (10). In addition, 
67.1% in the public and 16.5% in private maternities have ambulances for neonates. 
Determining the incidence of perinatal and neonatal outcomes is important for allocating 
human and infrastructure resources to properly provide care for preterm neonates and 
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infants and planning adequate strategies to monitor PTB preventive interventions. We aim to 
address the incidence of maternal and perinatal outcomes in women with preterm and early 
term births. 
Methods 
We conducted a longitudinal multicentre cohort study in five referral obstetric centres in 
Brazil between July 2015 and July 2018, called Preterm SAMBA. The research protocol and 
others aspects of the study implementation and progress had already been detailed (11,12). 
In brief, the Preterm birth cohort was comprised of low-risk nulliparous women with 
singleton pregnancies. Exclusion criteria were repeated abortions (≥3), fetal major 
malformation, chronic hypertension (using antihypertensive drug or if moderate 
hypertension), diabetes type I or II, renal disease, HIV, sickle cell disease, uterine anomalies, 
history of cervical knife cone procedures, use of steroids (≥3 months), aspirin, calcium, fish 
oil, vitamin C or E or heparin. Participants were enrolled at 19-21 weeks of gestation. Then, 
antenatal visits were performed at 19-21 weeks, 27-29 weeks and 37-39 weeks. Data 
regarding sociodemographic characteristics, maternal and family medical history, habits, 
anthropometric measures, height, pregnancy characteristics, occurrence of complications 
and other maternal and fetal outcomes were collected and entered in an online database 
during the three study visits. Childbirth and postpartum data were retrospectively collected 
by reviewing maternal and neonatal medical records until discharge. Maternal weight gain 
rate per week (WGR) was calculated according to the difference of weight between the first 
two visits (19-21 weeks and 27-29 weeks). 
The study was approved by the Ethical Review Board of each participant centre and was 
endorsed by the Brazilian National Committee for Ethics in Research (CONEP). The study 
complies with the 1989 Declaration of Helsinki and the Brazilian national regulations for 
studies in human beings stated by the National Health Council (Resolution CNS 466/12). All 
participating women signed an informed consent form before enrolment. 
Outcomes and variables 
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Preterm birth was defined as any birth occurred before 37 weeks of gestation. A term birth 
group was comprised of all women who had birth ≥37 weeks of gestation. Then, three groups 
were established according to gestational age and preterm birth subtypes. Spontaneous 
preterm birth included women who had preterm birth due to spontaneous onset of labour 
or premature rupture of membranes. Provider-initiated preterm birth was defined as a 
preterm birth due to medical indication on account of maternal or fetal 
conditions/complications. In addition, neonatal outcomes from late sPTB, late pi-PTB (34-36 
weeks) and early term (37-38 weeks) and post term (41-42 weeks) cases were compared to 
full term cases (39-40 weeks). 
Maternal and neonatal outcomes included: onset of labour and mode of delivery; 
hyperglycaemia in pregnancy (HIP), defined by an initial fasting plasma glucose (FPM) ≥92 
mg/dL or altered 75g oral glucose tolerance test performed between 24 and 28 weeks of 
gestation that means FPG ≥92 mg/dL or 1h-postglucose load ≥180 mg/dL or 2h-postglucose 
load ≥153 mg/dL; preeclampsia, defined as having systolic blood pressure ≥140 or systolic 
blood pressure ≥ 90 mmHg after 20 weeks gestation on at least two occasions apart of 20 
min, and/or proteinuria (24-h urinary protein ≥ 300 mg or urine dipstick ≥ ++) and/or severe 
maternal complications; neonatal intensive care admission; phototherapy for jaundice; Apgar 
score <7 at 5 minutes; need of intubation after birth; length of maternal and NICU stay; fetal 
malformation diagnosed/confirmed after birth; neonatal sepsis (confirmed or suspected); 
adequacy of birthweight according to GROW customized birthweight centiles (13). A 
composite outcome “any adverse perinatal outcome” (APO) was operationally defined as one 
of the following adverse neonatal outcomes: NICU stay >7 days, intubation at birth, Apgar 
score<7 at 5 minutes, fetal or neonatal death, discharge home on oxygen, neonatal sepsis 
(early or late, suspected or confirmed), cyanosis, hypoglycaemia, birth asphyxia, respiratory 
distress or mechanical ventilation. Antenatal and peripartum management characteristics 
were also addressed, including vaginal progesterone (any dose), cerclage, pessary, steroids 
and tocolysis use. For mode of delivery, elective C-section was considered when it was 
indicated in women without labour, and also for women who failed induction (did not 
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initiated labour). Intrapartum C-section were considered when C-section was performed in 
women during labour, including women at any stage of labour following induction.  
Statistical analysis 
Maternal characteristics were compared between the sPTB, pi-PTB and term groups using 
chi-squared test (χ2). Only p-values <0.05 were considered statistically significant. Bivariate 
analyses were carried out to calculate the risk ratios and 95% CI for maternal and perinatal 
outcomes, including pregnancy management characteristics in sPTB, pi-PTB compared to 
term and also to late sPTB, late pi-PTB, and early term compared to full term.  
We used Stata v. 7.0 (StataCorp) and SPSS v. 20.0 (IBM SPSS Statistics, USA) to perform all 
statistical analysis. All the analyses (p-values and 95% CI of the RR) accounted for the primary 
sampling unit (PSU), i.e., they were design-based.  
Results 
Preterm SAMBA study included 1,181 participants, from which 1,165 were followed and had 
outcome data available (Figure 1). Preterm birth rate was 10.7% (n=125). From the 78 cases 
of sPTB and 47 of pi-PTB, 55 (70.5%) and 27 (57.4%) were late preterm births. From the 1,040 
term births, 354 (34.0%) were early term (37-38 weeks), 575 (55.3%) full term (39-40) and 
111 (10.6%) post-term (41-42 weeks). None of the studied maternal and sociodemographic 
characteristics were different between sPTB, pi-PTB and term births (Table 1). Before the 
admission when the birth occurred, women who had sPTB had significantly more cerclage 
(RR 3.62, 95% CI [1.07-12.22]), pessary use (RR 5.55, 95% CI [3.17-9.71]), history of preterm 
labour or pPROM (RR 8.27, 95% CI [3.70-18.51]), use of antenatal steroids (RR 9.45, 95% CI 
[7.19-12.42]) or tocolysis (RR 6.27, 95% CI [2.73-14.42]) compared to women who had term 
birth (Table 2). Women who had pi-PTB had pessary and antenatal steroids use approximately 
6 and 26 times more frequent, respectively, than women with term births. 
Table S1 shows that the frequency of use of antenatal steroids were 65.2% and 29.6% in 
women who had sPTB <34 weeks and 34-36 weeks, respectively. In pi-PTB, it was 73.7% and 
56.0% for <34 weeks and 34-36 weeks, respectively. Tocolysis was performed in 43.5% and 
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14% of cases of women who had a sPTB <34 weeks and 34-36 weeks (p-value 0.001), 
respectively. 
Table 3 shows maternal and neonatal outcomes according to sPTB, pi-PTB and term birth 
cases. All neonatal adverse outcomes were significantly more frequent in preterm birth 
groups than in term. In addition, pi-PTB showed higher risk for almost all adverse neonatal 
outcomes compared to sPTB, including APO (RR 6.17, 95% CI [3.72-10.22] for sPTB and RR 
25.39, 95% CI [10.08-63.96] for pi-PTB). pi-PTB cases had had 7 and 5 times more 
preeclampsia [95% CI 2.39-12.21] and small for gestational age neonates [95% CI 3.15-16.99], 
respectively, than women with term birth. 
Table 4 shows maternal and neonatal outcomes for late sPTB, late pi-PTB, and early and full-
term birth categories. Longer maternal postpartum hospitalization, NICU admission, 
phototherapy for jaundice and APO were more frequent in late sPTB and pi-PTB groups than 
full term birth. Women who had preeclampsia were more frequent in late pi-PTB (RR 7.5 
[2.48-22.67]) and early term birth cases (RR 1.7 [1.36-2.13]). There were no cases of fetal 
death in late sPTB, late pi-PTB, and term birth groups (data not shown). There were few cases 
of neonatal death (1 early term) and need for intubation after birth (1 late pi-PTB, 3 early 
term and 1 full term). 
Elective C-section was much more frequent in pi-PTB (89.4%) and late pi-PTB (88.9%) than in 
overall term births (24.1%) or full-term birth (19.7%). Overall C-section (including elective and 
intrapartum) were performed in 91.5% of pi-PTB cases, 47.9% of term births and 26.9% of 
spontaneous preterm birth. 
Table 5 shows that pi-PTB (RRadj 8.12, 95% CI [2.54-25.93], p-value 0.007), maternal WGR 
(RRadj 2.04, 95% CI [1.23-3.38], p-value 0.018) and women from the northeast participating 
centres (RRadj 2.35, 95% CI [1.11-4.95], p-value 0.034) were independently associated with 
any adverse perinatal outcomes.  
Discussion 
In the Preterm SAMBA multicentre cohort, maternal and neonatal outcomes from 1,165 
nulliparous low-risk women were evaluated. Spontaneous and, especially, provider-initiated 
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preterm neonates were associated with poorer short-term outcomes. Also, late preterm and 
early term were also associated with more adverse neonatal outcomes. pi-PTB, maternal 
weight gain rate between 20 and 27 weeks of gestation below the 10th percentile and women 
from the northeast centres were independently associated with any adverse perinatal 
outcome. 
Despite being considered at term, early term neonates present poorer adverse outcomes 
when compared to full term and caution with “liberalization” in pregnancy resolution in this 
pregnancy interval should be taken (14,15). Similarly to late preterm, early term neonates are 
associated with higher prevalence of NICU admission, need for oxygen therapy, 
hypoglycaemia, neonatal mortality and other neonatal morbidities when compared to full 
term neonates (14). Neonatal mortality is around 2.3 times higher in 37 weeks compared to 
39 weeks neonates (6). ACOG reinforced the importance of delaying, when possible, the 
elective resolution of pregnancy to after 39 weeks, rather than intervening at 37 or 38 weeks 
(7). In 2016, the Brazilian Federal Council of Medicine, an independent agency responsible 
for professional regulation of medical doctors, established a normative resolution 
establishing that elective C-section due to patient request should only be performed after 39 
weeks of gestation (16). The concept of “too much, too soon” and “too little, too late” can be 
properly applied in this discussion (17). Adequate management of obstetric interventions 
(induction of labour, C-section, recognition of maternal/fetal complication, etc.) during late 
preterm and early term is a complex challenge in the Brazilian context, where there are 
disparities in access to intensive maternal and neonatal care units (10,18,19) and high rates 
of preventable severe maternal morbidities such as preeclampsia/eclampsia (20,21). Brazil 
shows to be a country where over-medicalization and misuse of obstetric interventions walk 
together with a lack of well-trained multidisciplinary team of health care providers and 
insufficient equipment and resources. 
The use of tertiary preventive strategies such as antenatal corticosteroids (ACS) and tocolysis 
does not prevent preterm birth, but may improve associated neonatal outcomes (22–25). 
Around 65% of sPTB before 34 weeks and 30% of late sPTB used ACS. The EMIP study, a 
multicentre cross-sectional study in 20 referral maternities in Brazil, showed that ACS was 
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used in 54.0% of sPTB before 34 weeks and in 14.0% of late sPTB (26). In accordance with the 
evidence-based recommendation for using ACS between 34 and 36 weeks raised by ALPS 
study (27) in 2016 and by 2017 Cochrane Systematic review (22), an increase in the use of 
ACS can be observed between both Brazilian studies, EMIP (2011-2012) and Preterm SAMBA 
(2015-2018). In our study, half of women who had sPTB and around 70% who had pi-PTB had 
used ACS before the admission when birth occurred (Table S1). The effect of repeated doses 
and the benefits of ACS in low-resource settings remains controversial. The WHO reported 
that there is a need for further investigation of ACS effects in low-resource settings, where 
the estimate of gestational age may not be accurate enough (28). According to the Birth in 
Brazil study, information of an early ultrasound was available for only 44.5% of women (29). 
Women who had a pi-PTB were independently associated with perinatal adverse outcomes. 
The EMIP study, a cross-sectional study that carried out surveillance of preterm births in 20 
referral obstetric centres in Brazil, showed that hypertensive disorders motivated around 
90% of pi-PTB due to maternal conditions (30). This study also showed that the neonatal 
mortality of extreme and late pi-PTB neonates before discharge were 200 and 6 times higher, 
respectively, in comparison to term neonates. A pi-PTB is a medical intervention to improve 
maternal and perinatal health condition, but it requires an evidenced-based decision-making 
process in order to avoid unnecessary prematurity and, consequently, more adverse neonatal 
outcomes. The HYPITAT II clinical trial showed that labour induction between 34 and 37 
weeks of gestation in women with hypertensive disorders reduces adverse maternal 
complication (31). Respiratory distress, however, were more frequent in the intervention 
group (RR 3.3, 95% CI [1.4–8.2; p=0.005]). pi-PTB is associated with severe maternal morbidity 
and the decision-making process requires optimal resources to assure timely interventions, 
since any delay is also associated with more severe maternal outcomes (32,33). The evidence 
that maternal morbidity leads to such adverse perinatal outcomes related to preterm birth 
reinforces the need for monitoring the occurrence of maternal morbidity, maternal near miss 
and the effects of related interventions to reduce both maternal and perinatal adverse 
outcomes. 
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Maternal WGR between 20 and 27 weeks below the tenth percentile was independently 
associated with APO. The recommendations of gestational weight gain from the Institute of 
Medicine - 2009 remains controversial as it did not take into account different populations 
and the effect of weight gain to the different preterm birth subtypes (34). We did not use a 
standard definition for adequacy of weight gain as maternal early/pre-pregnancy body mass 
index was not available. Therefore, we addressed perinatal outcomes according to the 
different weight gain percentile and quintiles. We acknowledge the fact that 43% of women 
in Preterm SAMBA study were overweight or obese (data not shown) and only 39% were 
normal weight at 20 weeks according to the Atalah and cols´ reference ranges (35). Poor 
maternal weight gain during pregnancy has been associated with adverse perinatal outcomes 
such as small for gestational age and preterm birth. A study evaluating more than 500,000 
normal weight women and 230,000 overweight women showed that deviations of weight 
gain are associated with small for gestational age (36). This association depends on how the 
exposure variable will be applied (total weight, rate of weight gain or adequacy according to 
IOM recommendation). Further studies including Brazilian population is required to better 
explore the risks for maternal and perinatal outcomes. 
Although our findings are not innovative, we acknowledge the fact that it is a prospective 
low-risk nulliparous women cohort where, in theory, are expected to have low incidence of 
maternal and perinatal complications. Nevertheless, we have the opportunity to report 
important indicators as the real incidence of perinatal outcomes for this population, that can 
be used to plan and monitor strategies to ameliorate maternal and perinatal health care. For 
instance, almost 50% of women who delivered at term had a C-section. We did not evaluate 
the indication for elective or intrapartum C-section, but such high rates in this population 
(nulliparous women) requires a careful attention. There were only 12.8% of induction in pi-
PTB cases. C-section can be a life-saving procedure for both mother and fetus, and a balance 
between risk and benefits might be context specific (37). In Brazil, C-section rate is certainly 
unbalanced. 
A Cochrane systematic review showed that there are a plenty of non-clinical interventions to 
reduce unnecessary C-sections, including education programmes for women, training 
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programmes for professionals, implementation of midwifery-labourist care and clinical 
practice guidelines to better support its indication (38). The use of an institutional 
standardized classification of C-section to monitor its incidence is also a highly recommended 
approach (39,40). According to a systematic review, there are at least 27 classifications based 
on different factors including women´s characteristics, degree of urgency and indications 
(41). The Robson´s ten-group classification, based on obstetric characteristics as parity, 
previous C-section, preterm birth, onset of labour, fetal presentation and the number of 
fetuses, seems to be the most adequate (39,41); it can be easily implemented and used for 
longitudinal monitoring. A limitation is that the tenth group, comprised of all preterm birth 
cases, does not differentiate cases according to other obstetric characteristics (40). 
Nulliparous women is a priority group when avoiding unnecessary C-sections due to its 
consequences to the women´s reproductive and general health (42). 
The antenatal use of steroids, tocolysis, pessary and cerclage were much more frequent in 
women who had sPTB than who had term births. This groups of women also presented a 
higher frequency of history of preterm labour or pPROM before the admission when birth 
occurred and short cervix, what explains the higher frequency of such interventions. An 
accurate prediction of which women will have a preterm birth within 7 days when presenting 
a preterm labour would be very useful to plan which interventions would benefit the most. A 
systematic review with meta-analysis addressed the performance of placental alpha 
microglobulin-1 (PAMG-1), fetal fibronectin (fFN) and phosphorylated insulin-like growth 
factor-binding protein-1 (phIGFBP-1), proteins usually presented in the amniotic fluid and/or 
choriodecidual interface, in predicting preterm birth (43). The sensitivity and specificity of 
these biomarkers were 0.76 and 0.97 for PAMG-1, 0.58 and 0.84 for fFN, and 0.93 and 0.73 
for phIGFBP-1, respectively. However, the comparison of these biomarkers performance with 
already established clinical evaluation and procedures had not been already well explored. 
Another gap to be better explored is the cost-effectiveness when using such biomarkers in an 
upper-middle income country containing such inequalities and huge area and population as 
Brazil. 
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Participants from the Northeast centres were independently associated with APO. Our study 
was conducted in five referral obstetric facilities placed in four states of Brazil. The HDI in 
2010 were 0.783 and 0.746 from the South/Southeast states, and 0.673 and 0.682 from the 
Northeast states (44). According to a populaion-based study conducted in 2006 in Brazil, the 
proportion of women with inadequate prenatal care, low schooling and low income is higher 
in the Northeast when compared to the South/Southeast (18). A more recent study, hospital-
based comprising almost 24,000 women in Brazil, reinforced the existence of huge disparities 
in the different regions of Brazil (10,19). The Northeast lacks of adequate prenatal care and 
maternities´ human and equipment resources when compared to South/Southeast regions. 
Secondary analyses of the World Health Organization Multicountry Survey on Maternal and 
Newborn Health showed that the provision of care and maternal and perinatal outcomes vary 
according to the human development index (HDI) (4). As the HDI increase, the proportion of 
adverse perinatal outcomes seems to decrease and pi-PTB, on the contrary, to increase. Also, 
the accessibility to a preterm resolution of pregnancy when required is limited for younger 
women and for those with lower schooling (4).  
There are strengths and limitations in our study. Early term neonates had 2.6 times more risk 
for neonatal death and pi-PTB and early term neonates had approximately 11 and 2 times 
more risk, respectively, for need of intubation. Although remarkable, these findings should 
be interpreted with caution due to the low number of cases in each group. We only evaluated 
perinatal and short-term neonatal outcomes, before neonate’s and woman’s discharge. New 
hospital admissions or complications were not evaluated. Comprehensive multicentre studies 
evaluating long-term outcomes of preterm birth in low- and middle-income countries are of 
urge importance. Brazil is a huge country with regional and private/public system inequalities 
in maternal, perinatal an infant health care (10,19). Low resource settings have the highest 
rates of maternal and neonatal morbidity and mortality (45), and are the neediest places 
where improving quality of antenatal care, investments in preterm birth research and 
implementing maternal and perinatal high evidence-based care will impact the most.  
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Table 1. Maternal characteristics from women who had sPTB, pi-PTB and term births 
Characteristics sPTB  pi-PTB Term births p-value 
Region    0.329 
Northeast 34 (43.6%) 25 (53.2%) 506 (48.7%)  
South and Southeast 44 (56.4%) 22 (46.8%) 534 (51.3%)  
Maternal age (years)    0.137 
≤19 18 (23.1%) 4 (8.5%) 269 (25.9%)  
20-34 54 (69.2%) 37 (78.7%) 705 (67.8%)  
≥35 6 (7.7%) 6 (12.8%) 66 (6.3%)  
Ethnicity    0.429 
White 32 (41.0%) 14 (29.8%) 416 (40.0%)  
Non-white  46 (59%.0) 33 (70.2%) 624 (60.0%)  
Marital status     0.127 
With partner  52 (66.7%) 39 (83.0%) 762 (73.3%)  
Without partner  26 (33.3%) 8 (17.0%) 278 (26.7%)  
Maternal Occupation     0.085 
Paid work  41 (52.6%) 32 (68.1%) 512 (49.2%)  
Housewife 13 (16.7%) 6 (12.8%) 192 (18.5%)  
Not working  24 (30.7%) 9 (19.1%) 360 (32.2%)  
Schooling (years)     0.883 
< 12  52 (66.7%) 33 (70.2%) 706 (67.9%)  
≥ 12  26 (33.3%) 14 (29.8%) 334 (32.1%)  
Annual Family Income (US$)     0.511 
Up to 3,000  2 (2.6%) 2 (4.3%) 48 (4.6%)  
3,000 to 12,000  41 (52.5%) 29 (61.7%) 563 (54.1%)  
Above 12,000  35 (44.9%) 16 (34.0%) 429 (41.3%)  
Source of prenatal care     0.602 
Entirely public  67 (85.9%) 42 (89.4%) 899 (86.4%)  
Private/insurance/mixed  11 (14.1%) 5 (10.6%) 141 (13.6%)  
Total 78 47 1,040  
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Table 2. Antenatal and peripartum management characteristics of sPTB, pi-PTB and term births 
Characteristics sPTB RR (95%CI) pi-PTB RR (95%CI) Term births 
Use of vaginal 
progesterone *a 
     
None 62 (80.5%) Ref. 42 (91.4%) Ref. 987 (96%) 
1 Trimester only  6 (7.8%) 3.76 [078-18.01] 2 (4.3%) 2.13 [0.24-18.96] 21 (2%) 
1st, 2nd and/or 3rd 
trimesters  
9 (11.7%) 5.08 [1.76-14.66] 2 (4.3%) 2.13 [0.42-10.74] 21 (2%) 
Cerclage       
Yes  1 (1.3%) 3.62 [1.07-12.22] 0 (0%) - 4 (0.3%) 
No  77 (98.7%) Ref. 47 (100%) Ref. 1,161 (99.7%) 
Pessary       
Yes  3 (3.8%) 5.55 [3.17-9.71] 2 (4.3%) 6.86 [3.39-13.88] 5 (0.5%) 
No  75 (96.2%) Ref. 45 (95.7%) Ref. 1,035 (99.5%) 
History of preterm labor 
or pPROM # 
     
Yes  24 (30.8%) 8.27 [3.70-18.51] 1 (2.1%) 0.67 [0.02-19.09] 33 (3.2%) 
No 54 (69.2%) Ref. 46 (97.9%) Ref. 1,007 (96.8%) 
Antenatal Steroids #a      
Yes 33 (50%) 9.45 [7.19-12.42] 31 (73.8%) 26.53 [7.97-88.32] 51 (6.3%) 
No 33 (50%) Ref. 11 (26.2%) Ref. 761 (93.7%) 
Tocolysis #       
Yes  8 (10.3%) 6.27 [2.73-14.42] 2 (4.3%) 3.41 [0.23-51.27] 12 (1.2%) 
No  70 (89.7%) Ref. 45 (95.7%) Ref. 1,028 (98.8%) 
*Initiated until 28 weeks. #before the admission when the birth occurred. Missing information for: a:13.
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Table 3. Maternal and neonatal outcomes of sPTB and pi-PTB compared to full term births 
Characteristics sPTB RR [95% CI] pi-PTB RR [95% CI] 
Term 
Births 
Onset of labor      
Spontaneous labour 65 (83.3%) Ref. 0 (0%) Ref. 617 (59.3%) 
PROM + induction 9 (11.5%) 1.66 [0.69-3.95] 0 (0%)  48 (4.6%) 
Induction intact membranes 0 (0%)  6 (12.8%)  184 (17.7%) 
Elective C-section 4 (5.2%) 0.22 [0.03-1.50] 41 (87.2%)  191 (18.4%) 
Mode of delivery      
Vaginal 57 (73.1%) Ref. 4 (8.5%) Ref. 556 (53.8%) 
Intrapartum C-section 5 (6.4%) 0.65 [0.36-1.16] 1 (2.1%) 0.56 [0.02-20.32] 277 (23.8%) 
Elective C-section 16 (20.5%) 0.23 [0.05-1.14] 42 (89.4%) 21.73 [2.60-181.80] 251 (24.1%) 
Length of maternal postpartum 
hospitalization a 
     
1-3 days 62 (79.5%) Ref. 28 (59.6%) Ref. 951 (91.5%) 
4-6 days 13 (16.7%) 2.44 [1.12-5.33] 13 (27.7%) 5.22 [1.05-25.89 74 (7.1%) 
≥ 7 days 3 (3.8%) 2.88 [0.64-12.90] 6 (12.8%) 10.49 [2.34-47.10] 14 (1.3%) 
Preeclampsia 2 (2.6%) 0.40 [0.07-2.18] 18 (38.3%) 7.32 [3.15-16.99] 67 (6.4%) 
HIP b 12 (16.9%) 1.15 [0.39-3.44] 5 (12.5%) 0.83 [0.27-2.51] 133 (14.8%) 
Mean (±SD) birthweight (g) c 2,253 ±666.9 1,002 [893.6-1111.0]# 1,824 ±845.7 1,431 [921.9-1940.0]# 3,255 ±422.3 
Adequacy of birthweight to GA c      
SGA (p< 10)  8 (10.2%) 0.94 [0.20-4.49] 45 (44.7%) 5.40 [2.39-12.21] 117 (11.4%) 
AGA (p10-90)  58 (74.4%) Ref. 23 (48.9%) Ref. 793 (77.2%) 
LGA (p>90) 12 (15.4%) 1.36 [0.48-3.86] 3 (6.4%) 0.89 [0.14-5.65] 117 (11.4%) 
Fetal death 1 (1.3%) 14.51 [10.63-19.79] 2 (4.3%) 24.11 [18.88-30.79] 0 (0%) 
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Neonatal death 2 (2.6%) 9.90 [5.08-19.32] 5 (10.6%) 22.48 [10.99-45.99] 1 (0.1%) 
Apgar score – 5th minute <7 d 5 (6.8%) 5.47 [2.46-12.15] 5 (11.1%) 9.04 [3.51-23.31] 9 (0.9%) 
Need of intubation after birth e 12 (15.4%) 12.42 [8.85-17.43] 10 (22.2%) 21.67 [11.79-39.85] 4 (0.4%) 
NICU admission 40(51.3%) 7.54 [3.65-15.58] 36 (76.6%) 23.47 [16.13-34.16] 97 (9.3%) 
Phototherapy for jaundice e 47 (61.0%) 7.08 [3.68-13.60] 31 (68.9%) 10.68 [5.66-20.14] 154 (14.9%) 
Length of NICU stay (days)      
1-3 days 4 (10.0%) Ref. 8 (22.2%) Ref. 59 (60.8%) 
4-6 days 5 (12.5%) 3.58 [0.54-23.81] 3 (8.3%) 1.26 [0.13-12.34] 17 (17.5%) 
≥ 7 days 31 (77.5%) 9.39 [1.73-51.06] 25 (69.4%) 4.55 [1.39-14.92] 21 (21.6%) 
Neonatal sepses f 14 (18.4%) 7.17 [4.54-11.33] 10 (21.7%) 9.76 [3.88-24.54] 20 (1.9%) 
APO* g 37 (50.0%) 7.17 [3.16-16.28] 38 (80.9%) 29.13 [18.07-46.98] 92 (9.4%) 
Total 78  47  1,040 
Missing information for: a) 1; b) 157; c) 13; d) 65; e) 11; f) 5; g) 64. #WMD, weighted mean difference [95% CI]. *APO: NICU stay >7 days or intubation 
at birth or Apgar score<7 at 5 minutes or fetal/neonatal death or discharge home on oxygen or neonatal sepsis or cyanosis or hypoglycaemia or birth 
asphyxia or respiratory distress or mechanical ventilation. 
264 
 
 
 
Table 4. Maternal and neonatal outcomes of late preterm birth and early and post term compared to full term births 
Characteristics 
Late 
sPTB 
34-36 
wks 
RR (95% CI) 
sPTB vs full 
term 
Late pi-
PTB 
34-36 
wks 
RR (95% CI) 
pi-PTB vs full 
term 
Early 
term 
37-38 
wks 
RR (95% CI) 
Early term vs 
full term 
Full term 
39-40 
wks 
Post 
term 
41-42 
wks 
RR (95% CI) 
Post term vs 
full term 
Onset of labor           
Spontaneous labour  
42 
(76.4%) 
Ref. 0 (0%) Ref. 
189 
(53.4%) 
Ref. 
375 
(65.2%) 
53 
(47.7%) 
Ref. 
PROM + induction  9 (16.4%) 
3.08 [1.45-
6.56] 
0 (0%)  24 (6.8%) 
1.63 [1.24-
2.14] 
20 (3.5%) 4 (3.6%) 1.35 [0.66-2.74] 
Induction intact membranes  0 (0%)  4 (6.8%)  
65 
(18.4%) 
1.32 [0.73-
2.40] 
82 
(14.3%) 
37 
(33.3%) 
2.51 [0.99-6.36] 
Elective C-section  4 (7.2%) 
0.39 [0.06-
2.50] 
23 
(85.2%) 
 
76 
(21.4%) 
1.30 [0.81-
2.11] 
98 
(17.0%) 
17 
(15.4%) 
1.19 [0.41-3.43] 
Mode of delivery           
Vaginal  
39 
(70.9%) 
Ref. 2 (7.4%) Ref. 
180 
(50.8%) 
Ref. 
330 
(57.3%) 
49 
(44.2%) 
Ref. 
Intrapartum C-section  
11 
(20.0%) 
0.73 [0.30-
1.77] 
1 (3.7%) 
1.25  [0.02-
74.28] 
81 
(22.9%) 
1.08 [0.82-
1.41] 
132 
(23.0%) 
38 
(34.2%) 
1.73 [1.25-2.40] 
Elective C-section  
 
5 (9.1%) 
0.40 [0.09-
1.72] 
24 
(88.9%) 
29.08 [1.34-
630.29] 
93 
(26.3%) 
1.28 [0.91-
1.79] 
113 
(19.7%) 
24 
(21.6%) 
1.35 [0.46-4.01] 
Length of maternal postpartum 
hospitalization a 
         
1-3 days  
40 
(72.7%)  
Ref. 
16 
(59.3%) 
Ref. 
318 
(90.1%) 
Ref. 
534 
(92.9%) 
99 
(89.2%) 
Ref. 
4-6 days  
12 
(21.8%) 
3.91 [1.57-
9.77] 
9 (33.3%) 
7.55 [0.86-
65.93] 
32 (9.1%) 
1.34 [0.68-
2.64] 
32 (5.6%) 10 (9.0%) 1.52 [0.41-5.61] 
≥ 7 days  3 (5.5%) 
3.59 [0.78-
16.40] 
2 (7.4%) 
6.25 [1.08-
36.13] 
3 (0.8%) 
0.67 [0.10-
4.46] 
9 (1.5%) 2 (1.8%) 1.16 [0.19-7.12] 
Preeclampsia 1 (1.8%) 
0.45 [0.05-
3.69] 
8 (29.6%) 
7.50 [2.48-
22.67] 
39 
(11.0%) 
1.70 [1.36-
2.13] 
24 (4.2%) 4 (3.6%) 0.88 [0.13-6.10] 
HIP*b 9 (18.8%) 
1.23 [0.33-
4.66] 
3 (13.0%) 0.83 [0.35-1.97] 
52 
(16.4%) 
1.04 [0.73-
1.47] 
76 
(15.5%) 
5 (5.7%) 0.37 [0.08-1.81] 
Mean (SD) birthweight (g) c 
2,533 
±457 
793.8 [649.7-
938.0]# 
2,403 
±520 
924.4 [622.4-
1,226.4]# 
3,059 
±390 
268.2 [214.7-
321.7]# 
3,327 
±388 
3,508 
±438 
-180.9 [(-
269.3)- (-
92.6)]# 
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Adequacy of birthweight to GA 
d 
         
SGA (p< 10)  6 (10.9%) 
1.11 [0.18-
6.74] 
7 (25.9%) 2.99 [1.08-8.32] 
43 
(12.2%) 
1.16 [0.82-
1.63] 
57 
(10.1%) 
17 
(15.3%) 
1.52 [0.73-3.14] 
AGA (p10-90)  
42 
(76.4%) 
Ref. 
17 
(63.0%) 
Ref. 
265 
(75.1%) 
Ref. 
448 
(79.6%) 
80 
(72.1%) 
Ref. 
LGA (p>90) 7 (12.7%) 
1.26 [0.36-
4.36] 
3 (11.1%) 1.35 [0.31-5.85] 
45 
(12.7%) 
1.18 [0.81-
1.70] 
58 
(10.3%) 
14 
(12.6%) 
1.28 [0.47-3.54] 
Neonatal death  0 (0%)  0 (0%)  1 (0.3%) 
2.63 [2.25-
3.08] 
0 (0%) 0 (0%)  
Apgar score – 5th minute <7e 1 (2.0%) 
1.95 [0.15-
24.90] 
2 (7.4%) 
6.40 [0.67-
60.70] 
4 (1.2%) 
1.16 [0.46-
2.97] 
5 (0.9%) 0 (0%) 
 
 
Need of intubation after birth f 0 (0%)  1 (3.7%) 
11.46 [6.60-
19.91] 
3 (0.9%) 
1.99 [1.07-
3.69] 
1 (0.2%) 0 (0%)  
NICU admission  
19 
(34.5%) 
4.16 [1.87-
9.23] 
18 
(66.7%) 
15.20 [10.80-
21.39] 
35 (9.9%) 
1.06 [0.89-
1.27] 
52 (9.0%) 10 (9.0%) 1.00 [0.84-1.18] 
Phototherapy for jaundice g 
29 
(52.7%) 
4.85 [2.90-
8.13] 
17 
(63.0%) 
7.98 [2.85-
22.39] 
54 
(15.3%) 
1.00 [0.87-
1.15] 
88 
(15.4%) 
12 
(11.0%) 
0.72 [0.33-1.58] 
Length of neonatal admission 
(days)  
         
1-3 days  3 (15.8%) Ref. 5 (27.8%) Ref. 
22 
(62.9%) 
Ref. 
31 
(59.6%) 
6 (60.0%) Ref. 
4-6 days  4 (21.1%) 
2.83 [0.22-
36.24] 
2 (11.1%) 1.03 [0.26-4.15] 3 (8.5%) 
0.48 [0.08-
3.03] 
12 
(23.1%) 
2 (20.0%) 
0.88 [0.04-
20.09] 
≥ 7 days  
12 
(63.1%) 
6.48 [1.00-
42.05] 
11 
(61.1%) 
3.96 [1.29-
12.13] 
10 
(28.6%) 
1.27 [0.94-
1.71] 
9 (17.3%) 2 (20.0%) 
1.12 [0.10-
12.30] 
Neonatal sepses h 3 (5.6%) 
2.58 [1.71-
3.90] 
1 (3.7%) 
1.89 [0.18-
19.88] 
6 (1.7%) 
0.93 [0.35-
2.42] 
11 (1.9%) 3 (2.7%) 1.33 [0.32-5.62] 
APO* i 
15 
(29.4%) 
3.37 [1.45-
7.84] 
18 
(66.7%) 
14.65 [9.50-
22.57] 
34 
(10.2%) 
1.07 [0.90-
1.26] 
50 (9.3%) 8 (7.4%) 0.81 [0.46-1.43] 
Total 55  27  354  575 111  
Missing information for: a) 1; b) 154; c) 1; d) 13; e) 62; f) 9; g) 8; h) 3; i) 64. *Hyperglycemia in pregnancy. #WMD, weighted mean difference 
[95% CI]. *APO (Any Adverse Perinatal outcome): NICU stay >7 days or intubation at birth or Apgar score<7 at 5 minutes or fetal/neonatal 
death or discharge home on oxygen or neonatal sepsis or cyanosis or hypoglycaemia or birth asphyxia or respiratory distress or mechanical 
ventilation. 
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Table 5: Factors independently associated with APO* among preterm neonates: multiple 
analyses by non-conditional logistic regression [n=837] 
Variables RRadj 95% CI p-value 
pi-PTB 8.12 2.54–25.93  0.007 
Maternal weight gain rate per week 20-27 weeks <p10 2.04 1.23–3.38 0.018 
Region (Northeast) 2.35 1.11–4.95 0.034 
Variables included in the model: Region; ethnicity; annual family income; source of prenatal care; smoking 
status; previous maternal condition; cervical length from 18 to 24 weeks <25mm; weight gain rate per week 
20-27 weeks <Q1; weight gain rate per week 20-27 weeks <Q2; weight gain rate per week 20-27 weeks <p10; 
weight gain rate per week 20-27 weeks >p90; sPTB; pi-PTB; gestational age at birth. *APO: NICU stay >7 days 
or intubation at birth or Apgar score<7 at 5 minutes or fetal/neonatal death or discharge home on oxygen or 
neonatal sepsis or cyanosis or hypoglycaemia or birth asphyxia or respiratory distress or mechanical ventilation. 
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S1. Peripartum management characteristics according to spontaneous and provider-initiated preterm birth categories 
Characteristics sPTB  pi-PTB  
 <34w 34-36w p-value <34w 34-36w p-value 
Tocolysis*a   0.001   - 
Yes  10 (43.5%) 7 (14.0%)  0 (0%) 0 (0%)  
No 13 (56.5%) 43 (86.0%)  15 (100%) 17 (100%)  
Antenatal Steroids*b   0.033   0.378 
Yes 15 (65.2%) 16 (29.6%)  14 (73.7%) 14 (56.0%)  
No 8 (34.8%) 37 (70.4%)  5 (26.3%) 11 (44.0%)  
*during admission when birth occurred. Missing information for sPTB and pi-PTB, respectively: a) 5 and 15; b) 2 and 3. 
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5. DISCUSSÃO GERAL 
O tópico prematuridade permanece sendo foco de novas pesquisas na área 
de saúde materna e perinatal ao longo de várias décadas. Isso porque trata-se de 
uma complicação de desenvolvimento complexo, de etiologia desconhecida, 
associada com desfechos adversos desde o início da vida e que pode 
corresponder à perda de qualidade de vida e sequelas a longo prazo, inclusive 
com possíveis repercussões em condições crônicas na vida adulta. Além disso, 
está associada a altos custos pela assistência aos indivíduos nascidos prematuros 
e a suas famílias, ao grande impacto mundial independentemente do nível 
socioeconômico da população ou de desenvolvimento do país (8,9).  
A abordagem aqui apresentada resume-se em tentar explorar alguns 
fatores clínico-epidemiológicos que, embora não completamente inovadores, 
foram abordados em contextos e utilizando-se de métodos que podem colaborar 
para o conhecimento científico. Além dos aspectos clínico-epidemiológicos, foram 
explorados também o desenvolvimento e implementação de uma abordagem 
inovadora para a identificação de marcadores de parto prematuro, a 
metabolômica. Nessa discussão geral, mantenho o foco nos aspectos gerais do 
desenvolvimento dos estudos e de seus resultados. A discussão mais detalhada 
dos resultados e seus impactos para o conhecimento e prática clínica foram 
abordados separadamente em cada artigo. O processo do desenvolvimento dos 
estudos científicos em prematuridade que compõem essa tese foram baseados 
em esforços coletivos que merecem uma reflexão contextualizada com a 
importância do tema, o seu desenvolvimento em nosso contexto no Brasil, o papel 
da Rede Brasileira de Estudos em Saúde Reprodutiva e Perinatal e as minhas 
atividades como pesquisador (coordenador nacional do estudo Preterm SAMBA) 
e como aluno de pós-graduação. 
Os dados oficiais sobre prematuridade no Brasil reportavam uma 
prevalência que não ultrapassava 7,5% de 2002 até 2010 (10). Embora aumentos 
sucessivos nas taxas e no número absoluto de nascidos prematuros tenham 
ocorrido nesse período, as estimativas de estudos internacionais apontavam para 
números quase 50% maiores dos que observados nos dados oficiais para esse 
período 2010 (9,11). A partir de 2010, com a mudança do formulário de coleta de 
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dados de nascidos vivos que abastece o SINASC e com o melhor registro dos 
casos, os números oficiais parecem ter encontrado seu nível real e a 
prematuridade começa a ter maior destaque no contexto de pesquisa na área de 
saúde materna e perinatal no Brasil.  
A Rede Brasileira de Estudos em Saúde Reprodutiva e Perinatal organiza-
se, então, para desenvolver os estudos EMIP (3) em 2011 e Preterm SAMBA (12) 
e P5 (Pessário e Progesterona para Prevenção de Prematuridade) em 2013. Os 
três estudos são multicêntricos envolvendo robusta estrutura de pesquisa, 
múltiplos profissionais da saúde, treinamento de recursos humanos e investimento 
em infraestrutura de pesquisa. Cabe dizer que, ainda quando residente em 
Ginecologia e Obstetrícia pela Universidade Federal do Paraná, fui colaborador 
na coleta de dados do estudo EMIP em todo o período do estudo, participando da 
reunião final do estudo realizada pelos pesquisadores do centro coordenador 
(Unicamp) em Campinas. Foi através dessa participação que se oportunizou meu 
envolvimento em outras atividades em pesquisa com a Unicamp e com a Rede. 
Em 2014, ingressei no programa de pós-graduação em Tocoginecologia da 
Faculdade de Ciências Médicas da Unicamp como aluno de mestrado e tive como 
objetivo da minha dissertação os dados do estudo EMIP. A partir de então, começa 
meu envolvimento com o tema prematuridade, iniciando uma “história natural” que 
se desenrolou desde a coleta de dados do EMIP, análise dos dados no mestrado 
até o desenvolvimento de novos projetos e metodologias nesse tópico. Esse 
processo de alguns anos retrata, sobretudo, a narrativa do pesquisador desde a 
elaboração do “problema” ou da pergunta de pesquisa, a escolha da abordagem 
metodológica, dos instrumentos de coleta de dados, das ferramentas analíticas 
apropriadas, até, enfim, as reflexões e decisões sobre o desenvolvimento do 
processo de pesquisa. Essa construção e envolvimento são produtos 
normalmente não mensurados ou avaliados no decorrer do desenvolvimento de 
uma tese ou projeto de pesquisa. Entretanto, foi e tem sido fundamental no 
contexto da formação e manutenção da Rede Brasileira de Estudos em Saúde 
Reprodutiva e Perinatal, que se baseia fundamentalmente em pessoas, 
pesquisadores jovens e seniors, no contexto da pesquisa em prematuridade, tema 
que, assim como muitos outros, necessita de experts que tenham grande 
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envolvimento nos processos de desenvolvimento de pesquisa para o advento de 
transformações e inovações.  
Aaron Cicourel (13) e Horward Becker (14), sociólogos americanos do 
século XX, tratam do desenvolvimento da pesquisa sociológica sob o ponto de 
vista do papel do indivíduo pesquisador, de suas perspectivas, vivências e 
percepções. E partir disso, vigora-se o papel do pesquisador a partir da construção 
de suas percepções do processo e das transformações que esse processo traz 
para ambos, pesquisador e pesquisa. Os planos de análises, a construção dos 
métodos e procedimentos de estudo, protocolos operacionais e discussão dos 
resultados e suas implicações tiveram influência e foram desenvolvidos através 
do meu envolvimento com a Rede Brasileira, com seus colaboradores e demais 
projetos em vigência, assim como com outras atividades correlatas em que tive a 
oportunidade de participar nas linhas de pesquisa de Fisiologia, patologia e 
epidemiologia das condições obstétricas, perinatais e do ciclo-gravídico-puerperal 
e de Morbidade Materna Grave (NEAR MISS) e Mortalidade Materna. Durante o 
curso tive a oportunidade de participar: da consolidação e análise de consistência 
dos dados de projetos como o COMMAG (15), CIPHER (16); da proposição de 
análises secundárias do Fetal Growth Study (17), um estudo da Organização 
Mundial da Saúde, do grupo de trabalho em morbidade materna da OMS (Maternal 
Morbidity Working Group) (18–20); de reuniões dos programas de pós-graduação 
da área de Medicina III da Capes, desenvolvendo um tutorial para o 
preenchimento da Plataforma Sucupira (21), seguindo os preceitos específicos 
dos avaliadores e do documento de área e de dois artigos sobre as atividades de 
pesquisa do nosso programa de Tocoginecologia (2,22); do desenvolvimento de 
um tutorial prático para pesquisadores utilizarem o sistema Importa Fácil Ciência, 
programa prestado pelos Correios para a importação de itens de pesquisa (23); 
de realizar seis meses de interstício pelo programa de doutorado sanduíche no 
exterior financiado pela CAPES, realizado na Universidade de Leicester, 
Leicester, Reino Unido, desenvolvendo atividades correlatas ao projeto Preterm 
SAMBA e em outros projetos como o estudo CLIMB (Complex Lipids In Mother 
and Babies), participando de artigos ainda não publicados desse ensaio clínico de 
suplementação materna de gangliosídeos e do desenvolvimento de projeto de 
pesquisa e cursos, conforme relatório do orientador no exterior apresentado à 
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Capes (Anexo 4); da participação por um ano e meio no Programa de Estágio 
Docente (PED) da Faculdade de Ciências Médicas da Unicamp, em que 
desenvolvi atividades de ensino supervisionada com os alunos do quarto ano em 
unidade de atenção primária em saúde; da apresentação de aulas em congressos 
acadêmicos regionais e estaduais em Recife, Fortaleza, São Paulo; de reuniões 
com parceiros internacionais como a organizada pela Universidade de Harvard em 
Uganda para discussão de programas de mentoring entre pesquisadores e 
instituições e um workshop da Fundação Bill e Melinda Gates em Nova Déli, para 
qualificar pesquisadores na implementação de intervenções através da mudança 
de hábitos. Essa inserção foi muito importante, não só para o desenvolvimento 
dos projetos apresentados nessa tese, mas também para o desenvolvimento 
atividades em diferentes etapas do processo de pesquisa e obtenção de produtos 
que foram fundamentais para a minha qualificação.  Esse envolvimento, relatado 
por Howard e Becker como o papel social do pesquisador na “história natural” da 
pesquisa e, principalmente, o processo de profissionalização da formação de 
pesquisadores, são fundamentais para a transposição de barreiras na pesquisa 
na área de saúde materna e perinatal, especialmente em temas complexos e que 
envolvem múltiplas abordagens metodológicas (24). Segundo o IOM, a dificuldade 
na formação/treinamento, na manutenção no mesmo campo de pesquisa, são 
alguns dos grandes desafios para avançar na pesquisa em prematuridade e suas 
consequências (24). 
O Sistema Único de Saúde (SUS), serviço de acesso universal com 
princípios de equidade e resolutividade, organiza-se através de diferentes níveis 
de atenção (primário ao quaternário) para atender as demandas de tratamentos e 
promoção à saúde (25). Apesar de alguns estudos mostrarem que o Brasil tem 
assistência pré-natal com boa cobertura, infraestrutura e disponibilidade de 
serviços como vacinação, consultas e internação (26,27), ainda existem 
inequidades regionais ou até mesmo interinstitucionais relacionadas 
principalmente à qualidade do serviço e cuidados clínicos oferecidos (25,28,29). 
O programa Rede Cegonha, programa lançado pelo Ministério da Saúde em 2011 
(30), foi instituído no âmbito do SUS visando garantir o acesso e qualidade a 
diversos serviços de saúde à mulher. Entretanto, exceto pela proposição de 
melhoria global ao atendimento pré-natal e do parto, nenhum planejamento 
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específico para identificação, prevenção ou atendimento ao parto prematuro foi 
proposto. Não necessariamente por negligência, mas por falta de novos 
programas com evidência científica de benefício na prevenção. Essa dificuldade e 
escassez de programas específicos é realidade também de países com outros 
contextos de assistência à saúde e de renda (alta ou baixa) (31,32). 
O investimento em identificação de fatores de risco e modelos preditores se 
justifica, pois objetivam auxiliar a organização do sistema de saúde e 
desenvolvimento de intervenções preventivas mais eficazes. Nossos resultados 
na análise secundária dos dados do EMIP sobre ganho de peso e IMC inicial, por 
exemplo, não permitem recomendar restrição de ganho de peso a mulheres com 
categorias específicas de IMC ao início do pré-natal. Entretanto, mostra evidências 
para novos estudos que objetivem desenvolver intervenções correlatas, já que o 
IMC inicial e o ganho de peso podem ter diferentes impactos nos diferentes 
subtipos de prematuridade e, como fatores modificáveis, poderiam ser melhor 
explorados. Além disso, a análise de cluster, também dos dados do EMIP, 
demonstram que parcela significativa das mulheres com parto prematuro não 
apresenta condições predisponentes facilmente identificáveis, corroborando a 
necessidade de investirmos em outros marcadores e modelos de identificação que 
não clínico-epidemiológicos. Nossos resultados com o estudo em marcadores 
metabolômicos, por sua vez, traz resultados razoáveis quando mostra um modelo 
preditor com área de curva ROC acima de 0,70 para predição de parto prematuro 
espontâneo, por exemplo. Esplin e colaboradores (33) mostraram que a 
fibronectina fetal e medida do colo uterino por ultrassonografia transvaginal 
tiveram resultados inferiores na predição do parto prematuro espontâneo em 
nulíparas (área sob curva ROC de 0,67 [IC 95%, 0,64 - 0,70]). Entretanto, nossos 
resultados devem ser fruto de cautelosa interpretação, pois não parecem ser 
resultados de provável reprodutibilidade e validação, uma vez que foram 
identificados em apenas uma das subpopulações estudadas. De qualquer forma, 
a expertise adquirida e os marcadores identificados servirão de base para 
desenvolver novas análises, podendo-se explorar o biobanco contendo milhares 
de amostras de soro, plasma e cabelo de mulheres brasileiras para estudos de 
validação ou novas fases de identificação. 
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De forma geral, a literatura converge na ideia de que dificilmente um único 
marcador será capaz de compor um modelo preditor para prematuridade com boa 
performance. Apesar de ainda não bem elucidada, a fisiopatologia do parto 
prematuro espontâneo parece ser um processo dinâmico ao longo da gestação e 
que, por isso, estaria associado a múltiplos fatores que interagem por semanas ou 
dias, e talvez até por poucas horas, para desencadear o processo clínico de 
esvaecimento do colo, contrações e/ou ruptura de membranas ovulares. Os 
fatores envolvidos precocemente nesses múltiplos processos têm sido alvo dos 
estudos de potenciais marcadores.  
A predição é um grande desafio do desenvolvimento tecnológico e a 
interpretação do conceito e método aplicados em diferentes áreas do 
conhecimento podem ser úteis no avanço das técnicas e abordagens, 
principalmente na de epidemiologia. Predizer ciclones tropicais, por exemplo, é de 
grande interesse para a sociedade, principalmente para que se minimizem as 
catástrofes causadas por esses fenômenos da natureza (34). Modelos complexos 
e avançados envolvendo ferramentas estatísticas são empregados para obter 
melhores resultados na predição desse evento, com especial interesse em 
predizê-lo o mais precocemente possível (35,36). Entretanto, as condições do 
tempo e suas variáveis envolvidas podem mudar (para melhor ou pior) e o modelo 
precisa levar em consideração não só essa mudança, mas também a 
probabilidade de que elas venham a ocorrer. Muitos anos de pesquisa coletando 
informações sobre essas variáveis como velocidade do vento, altitude, pressão 
atmosférica, umidade do ar, direção do vento, entre muitas outras, foram 
necessárias para entender o processo a ponto de produzir modelos preditores de 
utilidade prática. Algumas reflexões importantes a serem destacadas dessa 
analogia: um ciclone pode ocorrer com diferentes velocidades do vento, pressões 
atmosféricas ou graus de umidade do ar; o evento pode ocorrer com diferentes 
interações dessas variáveis, ou seja, menor grau de umidade do ar com maior 
pressão atmosférica ou vice e versa, a depender das condições das várias outras. 
Voltando ao parto prematuro espontâneo, ficam evidentes as limitações do uso de 
variáveis dicotômicas na avaliação de risco e predição, muito provavelmente 
porque elas não levam em consideração toda essa possível dinâmica. Nossos 
resultados mostraram que o parto prematuro espontâneo pode ocorrer havendo 
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ou não um histórico de parto prematuro anterior, episódios de sangramento na 
primeira metade da gestação, infecções genitourinárias, história de tabagismo, ou 
ainda colo curto ao ultrassom transvaginal no segundo trimestre, por exemplo. 
Provavelmente o risco individual muda na presença ou ausência de cada fator, 
diferentemente para cada interação. As limitações nos nossos resultados 
utilizando avaliações clínico-epidemiológicas vão ao encontro da teoria proposta 
por Menon (37) ou Behrman (38) e seus colaboradores:  há que se levar em 
consideração as interações dos fatores genéticos, epigenéticos, metabólicos, 
sociais, ambientais, nutricionais, geográficos, comportamentais, étnicos, etc., na 
avaliação de risco ou predição do parto prematuro espontâneo.  
Apesar das limitações na performance da medida do colo uterino na 
identificação de risco ou predição de parto prematuro, esse se confirma como um 
importante marcador clínico identificável durante a gestação. E, segundo nossos 
achados, também está associado a eventos adversos perinatais. Sua importância 
se dá, sobretudo porque é um dos únicos marcadores que possuem tal força de 
associação isoladamente e pode ser identificado em qualquer mulher durante o 
segundo trimestre de gestação. Faço aqui, então, essa importante ressalva para 
mostrar que há um papel importante da medida do colo uterino no rastreamento 
de parto prematuro. Há, de fato, algumas limitações na sua utilização prática que 
incluem o fato de o exame requerer profissional médico ultrassonografista com 
adequado treinamento das técnicas para avaliação transvaginal do colo uterino, 
que o exame seja realizado em intervalo específico na gestação (entre 18 a 24 
semanas, preferencialmente) e de ainda não haver evidência sobre qual é sua 
validade em mulheres que foram submetidas a procedimentos cirúrgicos no colo 
uterino, como, por exemplo, cirurgia de alta frequência (CAF ou LEEP, Loop 
electrosurgical excision procedure). O que se observa na prática é que apesar das 
limitações e baixa acurácia na identificação de mulheres sob risco de parto 
prematuro, intervenções como o rastreamento de parto prematuro através da 
medida do colo durante o pré-natal são adotadas por serem o que “se têm em 
mãos”. Na ausência de outras boas alternativas, torna-se essa o centro das 
atenções. A Federação Brasileira das Associações de Ginecologia e Obstetrícia 
(FEBRASGO), por exemplo, recomenda em seus manuais de Manual de 
Gestação de Alto Risco (2010) e de Manual de Perinatologia (2013) que sejam 
276 
 
 
 
realizados, entre outras medidas, o rastreamento através da medição do colo 
uterino por ultrassom transvaginal e progesterona vaginal para aquelas com colo 
curto (39,40).  
Entretanto, ainda temos que avançar no conhecimento científico acerca da 
utilização do rastreamento do colo uterino e medida preventivas correlatas aos 
achados do rastreamento (progesterona e/ou pessário, por exemplo), sobretudo 
sobre qual o ponto de corte para mulheres brasileiras, que outros marcadores 
podem ser associados ao modelo de rastreamento, qual a evidência em mulheres 
sem parto prematuro anterior, porque ainda temos falso negativos e positivos e o 
que podemos aprender com esses casos. Alguns autores, experts em 
prematuridade, alertam para o fato de termos, desde os anos 2000, mais de 790 
publicações sobre o tópico colo curto e progesterona (41) e que precisamos 
avançar urgentemente em alternativas a essa proposta (41,42). Algumas 
estratégias poderiam encurtar o tempo na busca de evidência científica, com 
menor uso de recursos em novos ensaios clínicos. A Meta-análises com uso de 
dados individuais de pacientes (IPD meta-analysis, individual patient data), a rede 
de colaboração de pesquisadores e experts estabelecendo padronização de 
variáveis e a metanálise em rede (Network meta-analsyis) poderiam algumas das 
estratégias a serem considerada avançar nesse tópico A metanálise em rede é 
capaz de realizar comparações diretas e indiretas sobre a eficácia de diferentes 
intervenções em grupos e subgrupos de mulheres de diferentes ensaios clínicos 
(43,44). 
A metabolômica mostra-se como uma das técnicas que é capaz de abordar 
vários desses aspectos, uma vez que, em teoria, avalia o resultado final dessas 
interações (45–47). Na avaliação de preditores metabolômicos para o parto 
prematuro espontâneo, utilizamos amostras provenientes de mulheres de duas 
subpopulações diferentes. Apesar de termos utilizado o mesmo protocolo de 
preparo e aquisição de dados no espectrômetro de massas acoplado à 
cromatografia gasosa, as análises das respectivas subpopulações foram 
realizadas por equipes e equipamentos diferentes. Além disso, a diferenciação de 
mulheres com parto prematuro devido a ruptura prematura de membranas ou 
trabalho de parto prematuro teria sido mais adequada. Não podemos excluir que 
isso possa ter interferido nos resultados.  
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Nossa metodologia incluiu a avaliação da razão dos mesmos metabólitos 
nos dois períodos de coleta no pré-natal. Nossa hipótese era que um aumento ou 
diminuição dos metabólitos entre a décima quinta e a vigésima semanas poderiam 
estar envolvidos no dinâmico desenvolvimento do parto prematuro. Entretanto, 
nenhuma razão de nenhum metabólito foi significativamente associada ao parto 
prematuro espontâneo. Não temos conhecimento de nenhum estudo publicado na 
literatura científica que tenha feito essa avaliação “dinâmica” utilizando 
marcadores metabolômicos. Em analogia, entretanto, há avaliações utilizando 
mudanças na medida do colo uterino ao longo da gestação, utilizando-se da 
diminuição em número absoluto (em centímetros ou milímetros) ou proporcional 
da medida do colo. Uma revisão sistemática incluindo 14 estudos na meta-análise 
mostra que essas mudanças não são marcadores úteis na predição de parto 
prematuro. A sensibilidade não ultrapassa 50%. Uma abordagem integrada 
incluindo as diferentes ciências ômicas (genômica, transcriptômica, protêomica ou 
metabolômica) possivelmente seja uma alternativa promissora na avaliação do 
desenvolvimento do parto prematuro e na busca de marcadores biológicos, apesar 
de complexa e dispendiosa (46). 
O parto prematuro espontâneo e, sobretudo, terapêutico foram associados 
com maior incidência de desfechos maternos e perinatais adversos no estudo de 
coorte Preterm SAMBA. A taxa de pouco mais de 90% de cesariana nos casos de 
parto prematuro terapêutico, sendo em torno de 89% eletivas, alerta para a 
necessidade de uma reflexão sobre as indicações desse procedimento, ainda 
mais nesse grupo de mulheres – nulíparas de “baixo risco”. As décadas de 80 e 
90 foram marcadas pelo aumento das taxas de cesárea e isso ocorreu por uma 
conjuntura de fatores: modelo de assistência ao parto adotado centrado no 
médico, desvalorização dos procedimentos médicos relacionados a obstetrícia, 
“terceirização” da construção do modelo de cuidado à mulher às seguradas de 
saúde que priorizaram a valorização ao parto cesárea, acesso a parto com 
analgesia e etc. Os efeitos das políticas públicas implementadas para reduzir a 
taxa de cesárea no Brasil, como o Pacto para Redução das Taxas de Cesarianas, 
o Programa de Humanização do Parto e, mais recentemente, o Parto Adequado 
ainda possuem resultados limitados (48,49).  
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A associação de pré-eclâmpsia e fetos pequenos para idade 
gestacional/restritos com prematuridade terapêutica já haviam sido reportados 
pelo estudo EMIP (50). Complicações maternas e/ou fetais são, por conceito, 
fatores motivadores da prematuridade terapêutica. Alerta-se, contudo, para o fato 
de ambos os estudos em prematuridade (EMIP e Preterm SAMBA) terem 
demonstrados que esses recém-nascidos por prematuridade terapêutica 
apresentam com mais frequência desfechos perinatais adversos, incluindo maior 
mortalidade neonatal. Decidir pelo parto prematuro terapêutico é uma medida que 
visa melhorar os desfechos maternos e perinatais. Para isso, uma decisão 
baseada em evidência científica de que os riscos em manter a gestação superam 
os riscos relacionados à intervenção, seja porque se ocasiona prematuridade 
terapêutica ou seja porque, ainda, a grande maioria das mulheres são submetidas 
a cesariana. Não só as maternidades e outros serviços de atendimento de 
referência obstétrica devem possuir médicos e equipe multiprofissional 
adequadamente treinada e suficiente para atender casos que envolvam 
complicações obstétricas, mas o sistema de saúde deve funcionar de maneira 
apropriadamente adequada para regular os casos de maneira a evitar sobrecarga 
ou falta de vagas. O estudo da Rede de Vigilância Materna Grave, desenvolvido 
pela Unicamp em 27 serviços de obstetrícia do país em 2009-2010, mostrou que 
as demoras relacionadas ao atendimento de complicações maternas contribuem 
para desfechos maternos ainda mais graves (51). As desigualdades de renda, 
educação e acesso ao cuidado à saúde ainda são algumas das grandes barreiras 
para a mudança desse cenário  da saúde materna e perinatal no Brasil (26,52–
54). 
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6. CONCLUSÃO 
Objetivo 1: Avaliar a associação do índice de massa corpórea e ganho de peso 
gestacional com os diferentes subtipos de parto prematuro e com desfechos perinatais.  
A taxa de ganho de peso por semana durante a gestação foi associada com 
risco de parto prematuro a depender do IMC inicial e da categoria de ganho de 
peso, se excessivo ou insuficiente. Esse efeito foi diferente para os diferentes 
subtipos de parto prematuro (parto prematuro espontâneo, RPPMO e terapêutico. 
Anormalidades na taxa de ganho de peso conforme as recomendações do IOM-
2009, categorizado em insuficiente ou excessivo, estão associados com 
desfechos perinatais adversos. A taxa de ganho de peso, um fator de risco 
modificável e de fácil aferição durante o pré-natal, já controlada pelo IMC inicial, 
pode ser uma variável estratégica para ser melhor abordada na prevenção de risco 
de parto prematuro e eventos adversos em grupos de maior risco. 
 
Objetivo 2: Identificar fenótipos maternos relacionados ao parto prematuro e suas 
respectivas condições associadas, características maternas e desfechos maternos e 
perinatais. 
A análise por cluster dos partos prematuros identificou grupos de mulheres 
caracterizadas por diferentes condições. Essa abordagem por agrupamento por 
cluster demonstrou que uma parcela significativa de mulheres não possui 
nenhuma das condições pré-definidas potencialmente associadas com parto 
prematuro e confirma a associação de pré-eclâmpsia, eclampsia e síndrome 
HELLP com parto prematuro terapêutico. A investigação de outras condições 
relacionadas à prematuridade pode melhorar a identificação de mulheres com 
maior risco de parto prematuro durante o pré-natal e daquelas que terão pior 
desfecho perinatal. 
 
Objetivo 3: Realizar uma revisão narrativa sobre a aplicação da ciência ômica nos 
estudos em saúde materna e perinatal, com enfoque na metabolômica e na predição de 
complicações. 
A metabolômica parece ser uma abordagem promissora na investigação de 
marcadores de predição e na elucidação da fisiopatologia de doenças na área de 
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saúde materna e perinatal, cuja interação entre metabolismo materno, fetal, 
placentário e ambiental torna essa investigação desafiadora nas práticas de 
pesquisa tradicionais, baseadas em hipóteses. Entretanto, validações externas 
dos resultados e reprodutibilidade são os maiores desafios para que essa técnica 
seja mais amplamente empregada. 
 
Objetivo 4: Desenvolver um método padronizado para revisar sistematicamente os 
estudos em predição de prematuridade espontânea através de marcadores 
metabolômicos. 
Essa revisão sistemática verificará a disponibilidade de estudos em 
predição de parto prematuro utilizando técnicas metabolômicas, buscando 
evidência científica baseada em estudos com adequado padrão metodológico e 
que utilizaram definição do desfecho e técnicas padronizadas. 
 
Objetivo 5: Desenvolver o método e procedimentos utilizados em um estudo 
multicêntrico para investigar a predição de parto prematuro e outras complicações 
maternas e perinatais. 
A adoção de metodologia e técnicas padronizadas são fundamentais para 
o desenvolvimento do estudo que aborda marcadores biológicos para parto 
prematuro. A utilização de desfechos com definições precisas e detalhadas, da 
coleta de dados e amostras seguindo padrões internacionais de boas práticas 
clínicas, de frequente controle de qualidade e monitoramento dos dados é crucial 
para atingi os objetivos do estudo. O planejamento inicial, desenvolvendo os 
métodos e procedimentos, foi uma das partes fundamentais do estudo que 
objetiva avaliar preditores metabolômicos para parto prematuro e diversas outras 
abordagens epidemiológicas relacionadas à saúde materna e perinatal. 
 
Objetivo 6: Implementar e desenvolver um estudo para predição de parto 
prematuro e outras complicações maternas e perinatais, fornecendo subsídios 
metodológicos e descrevendo detalhes sobre os aspectos práticos dessa implementação 
e estratégias para a solução de dificuldades encontradas. 
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O planejamento, implementação e desenvolvimento de um estudo 
multicêntrico desenhado para abordar diversos desfechos maternos e perinatais 
em 5 maternidades de referência em 3 regiões diferentes no Brasil foi uma tarefa 
complexa, com grandes desafios e muitos aprendizados a todos os envolvidos. A 
organização profissionalizada da Rede e os comprometimentos institucionais de 
cada centro participante envolvido foram fundamentais para todas as etapas do 
estudo. A valorização do desenvolvimento de um estudo robusto como esse, no 
contexto da Rede Brasileira de Estudos em Saúde Reprodutiva e Perinatal, é 
fundamental para a manutenção de pessoal qualificado e de aproveitamento de 
recursos tecnológicos e científicos inestimáveis que foram construídos (como o 
biobanco, por exemplo). A experiência da Rede, através da narrativa apresentada, 
pode auxiliar no planejamento e desenvolvimento de outros estudos similares em 
contextos semelhantes.  
 
Objetivo 7: Identificar um conjunto de marcadores metabolômicos, clínicos e/ou 
sociodemográficos preditivos de parto prematuro.  
A combinação de marcadores metabolômicos coletados no sangue 
materno às 20 semanas de gestação com variáveis clínicas compuseram um 
modelo preditor com boa performance discriminatória para parto prematuro 
espontâneo, tanto para partos abaixo de 37 semanas quanto para abaixo de 34 
semanas, em mulheres nulíparas de baixo risco. A não identificação de 
marcadores metabolômicos na outra população estudada seguindo similar 
abordagem indica que os metabólitos podem ser específicos da população de 
Cork, na Irlanda. Apesar da boa performance demonstrada pelo modelo 
desenvolvido em um dos subgrupos do estudo, os achados acarretam mais 
questionamentos: Provavelmente essa é uma etapa de um processo ainda não 
concluído. Novas fases de identificação e outras de validação, utilizando outras 
coortes e populações, serão necessárias para uma contribuição consistente na 
predição e mecanismos envolvidos no parto prematuro espontâneo.  
 
Objetivo 8: Avaliar a incidência e potenciais fatores de risco associados à 
ocorrência de parto prematuro espontâneo. 
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O parto prematuro espontâneo e terapêutico são eventos comuns e sua 
identificação através de fatores de risco clínico e epidemiológicos é limitada. A 
medida do colo uterino por ultrassonografia transvaginal confirma-se como um 
marcador clínico importante. A investigação de prematuridade através de 
subgrupos fenotípicos de mulheres também se mostra uma estratégia 
potencialmente útil na identificação de grupos de maior risco, incluindo o 
rastreamento do uso de álcool. Em ambos os casos, contudo, as estratégias de 
prevenção devem ser melhor exploradas. 
 
Objetivo 9: Avaliar a ocorrência de desfechos perinatais adversos associados à 
prematuridade. 
Parto prematuro espontâneo e, sobretudo, terapêutico foram associados 
com maior incidência de desfechos adversos perinatais em mulheres nulíparas de 
baixo risco. Recém-nascidos cujos partos ocorreram em intervalos de idade 
gestacional próximas ao termo (prematuridade tardia e termo precoce) 
representam mais de um terço dos casos e apresentaram desfechos perinatais 
adversos em maior incidência que os nascidos no termo tardio. Adequado cuidado 
pré-natal e de assistência ao parto, intervenções obstétricas baseadas em 
evidência e avanços na prevenção da prematuridade devem ser prioridade na área 
de saúde materna e perinatal para melhorar os resultados perinatais relacionados 
ao parto prematuro.
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8. Anexo 1 – Formulário de coleta de dados EMIP 
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